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The nuclear receptor Ff1b has been established as the master regulator of the 
organogenesis and the function maintenance of interrenal gland in zebrafish, in 
reminiscent to its mammalian ortholog, SF-1. Despite the well defined expression 
profile, gene structure, and loss-of-function data for both Ff1b and SF-1, the molecular 
mechanisms underlying their regulatory functions and the upstream factors mediating 
their tissue-selective expression remain largely undefined. To better elucidate the 
transcriptional activity of Ff1b, the 5’ proximal promoter of cyp11a1, a putative target 
gene of Ff1b, was isolated and analyzed. The characterization of this promoter with 
regards to Ff1b transactivation ability has ascertained the conserved role of Ff1b as the 
major transcriptional regulator in the steroidogenesis pathway.  
To create an in vivo system for the functional studies of Ff1b, a transgenic 
zebrafish model was generated using a recombined BAC clone spanning 100 kb of ff1b 
locus with EGFP reporter inserted into Exon 2. The EGFP expression that faithfully 
recapitulates the endogenous ff1b expression in zebrafish embryos has proven useful for 
the lineage tracing of ff1b-expressing cells during embryonic development. The 
transgenic model has been used successfully for the fate tracing of interrenal cells from 
early stages of development following the morpholino knockdown of ff1b gene function 
and steroid inhibitor treatment using aminoglutethimide.  
 x
 In an effort to characterize the genomic organization of ff1b, ~46 kb of genomic 
sequences encompassing zebrafish ff1b locus was determined. With the exception of the 
presence of an additional Intron IV, sequence analysis of ff1b locus revealed conserved 
genomic organization compared with human and mouse SF-1 genes. Comparative 
genomics revealed that the presence of the extra intron in ff1b is likely to represent an 
ancestral feature of vertebrate FF1 genes. Using a Red/ET recombination, a novel 
genomic deletion strategy has been adopted to delete two genomic fragments at the 5’ 
flanking region and seven intronic sequences of ff1b from a recombined BAC plasmid 
that contains an EGFP reporter. When combined with transient microinjection assay 
into zebrafish embryos, an interrenal-specific enhancer is localized to Intron IV of ff1b. 
Computational analysis of Intron IV unravels cis-elements that potentially regulate the 
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1.1 The hypothalamic-pituitary-steroidogenic organ (HPS) axis 
 
In vertebrates, the endocrine system is composed of organs or glands that 
interact with one another via the release of chemical messenger called hormone into 
the blood stream. The major organs that constitute this system include the 
hypothalamus, pineal gland, pituitary gland, thyroid gland, thymus, adrenal gland, 
ovary, and testis. The endocrine system controls almost every biological process in a 
vertebrate including growth and development, metabolism, sexual and reproductive 
functions, normal tissue functions, as well as, determination of mood and behavior. 
Similar to the central nervous system (CNS), it helps us to respond properly to various 
stimulants, albeit in a much slower and adaptive manner. This is largely due to the 
difference in the nature of signaling molecules utilized in the two different but related 
systems. While the components of CNS interact with one another through rapid 
neurocrine signaling among neurons, the various organs in endocrine system integrate 
through hormones secreted into the blood stream. Although the effects of endocrine 
signaling are usually not as acute as the CNS, they often last longer. 
Within the endocrine system, the hypothalamus functions like a control centre 
as it links the nervous system to the endocrine system through the pituitary gland 
(hypophysis) and subsequently sends signals to the relevant target organs to initiate 
the appropriate responses. The hypothalamus exerts its functions mainly by secreting 
and distributing hormones to the pituitary gland through the hypophyseal portal 
system (a highly specialized capillary network). Together, the two organs form the 
hypothalamic-pituitary axis that maintains the normal physiology of a vertebrate by 
1
 regulating homeostasis, immune response, and several behavioral changes. Among 
the major target organs under the control of hypothalamic-pituitary axis are the 
adrenal cortex and gonads (testis and ovary), which represent two of the major 
steroid-producing tissues in the endocrine system. In vertebrates, these organs 
collectively form the hypothalamic-pituitary-steroidogenic (HPS) axis which 
constitutes a central part of the endocrine system. The HPS axis can be further divided 
into hypothalamic-pituitary-adrenal (HPA) and hypothalamic-pituitary-gonadal (HPG) 
axes, as each of them is regulated by different sets of chemical messengers. 
1.1.1 The HPS axis of higher vertebrates 
 
The regions of hypothalamus that are involved in the regulation of the HPS 
axis include the paraventricular nucleus (PVN), post-optic area (POA), and arcuate 
nuclei, which send neuronal projections to the external zone of the median eminence 
(ME). The pituitary consists of two portions, which are known as the anterior 
(adenohypophysis) lobe and the posterior (neurohypophysis) lobe. In mammals, the 
adenohypophysis can be further subdivided into three regions: the pars distalis, pars 
intermedia, and pars tuberalis. As for the adenohypophysis, six main specialized cell 
types are distinguishable by the types of peptide hormones they synthesize. The 
activities of these cells are regulated by hypophysiotropic factors produced by specific 
neurons in the hypothalamus. Furthermore, the adenohypophysis receives hormonal 
signals from the hypothalamus via the hypophysial portal system.   
Although the organs along the HPS axis function as an integrative system, the 
hormones that modulate the HPA and HPG axes are highly specialized. Along the 
HPA axis, corticotrophin-releasing hormone (CRH) is secreted by the PVN of 
hypothalamus in response to stress. The CRH is then delivered to the corticotrophs in 
the anterior lobe of pituitary gland to stimulate the production of POMC peptide. 
2
 POMC is eventually processed into adrenocorticotrophic hormone (ACTH) and 
secreted into the blood circulation, where it will reach ACTH receptors (melanocortin 
2 receptors, MC2R) on the surface of adrenocortical cells. The hormone stimulation 
then triggers a series of signal transductions events that involve the cyclic adenosine 
monophosphate (cAMP) second messenger system to increase the production of 
steroids in the adrenal cortex. The synthesis and release of CRH is regulated by 
cortisol in a classic negative feedback loop mechanism to inhibit further secretion of 
ACTH in the anterior pituitary and CRH in the hypothalamus (Dallman et al., 1987; 
Kretz et al., 1999).   
As for the HPG axis, secretion of gonadotropin-releasing hormone (GnRH) from 
the POA and arcuate nuclei of hypothalamus stimulates the secretion of gonadotropins 
from the gonadotropes in the pituitary gland. The two principal gonadotropins are 
luteinizing hormone (LH) and follicle stimulating hormone (FSH). By binding to the 
G-protein coupled, cAMP-dependent gonadotropin receptors on the target organ cells 
(primarily ovaries and testes), the gonadotropins elicit multiple responses that regulate 
reproductive development and function. Generally, LH stimulates the synthesis of 
androgens (mainly testosterone) in the ovary theca cells and testicular Leydig cells. 
LH also controls gamete release i.e. ovulation in females and spermiation in males as 
well as the formation of corpus luteum in females. In males, the effects of testosterone 
on genital and extragenital tissues are dominant. Not only is it required for the 
initiation and maintenance of spermatogenesis, it is also essential for the development 
and proper differentiation of the Wolffian duct. FSH, on the other hand, primarily 
modulates gamete maturation by controlling follicle development and 
spermatogenesis (Hillier, 2001; Sairam and Krishnamurthy, 2001).  
3
 Although the HPA and HPG axes are stimulated by distinctive signaling 
pathways and they eventually produce different classes of steroid hormones, there are 
evidences of interdependence between the two axes. For instance, while the adrenal 
cortex produce primarily glucocorticoids and mineralocorticoids, they also synthesize 
small amounts of androgens and they express low level of luteinizing 
hormone/chorionic gonadotropin receptors (LHCGR), a characteristic of gonad-
specific G-protein coupled receptor (Pabon et al., 1996; Couzinet et al., 2001). 
Further investigations indicate that the adrenocortical responsiveness to gonadotropins 
might represent a pathological condition in the presence of elevated gonadotropin 
levels (Bernichtein et al., 2008).   
1.1.2 The HPS axis of teleost 
 
Teleosts possess a functional equivalent of the HPS axis though they are 
generally not as well studied as the mammalian system. Due to the vast adaptive 
radiation that they have gone through, teleosts display certain degree of variation in 
the architecture of their HPS axis. A few obvious differences can be found in the 
tissue organization of the organs that constitute the HPS axis, the hormone-secreting 
cell types, as well as, the major classes of active steroids. For example, the adrenal 
equivalent in teleost is known as interrenal and the basic anatomy is very different 
from that of mammals. This aspect will be discussed further in Section 1.2.  
Generally, the teleostean and mammalian hypothalamus and pituitary are 
composed of essentially the same major components including the hypothalamus, 
adenohypophysis, and neurohypophysis. However, teleosts lack the pars tuberalis and 
their pars distalis are subdivided into a rostral and proximal portion (Bentley, 1998). 
In addition, the median eminence is absent and this is accompanied by the lack of a 
true hypothalamo-hypophysial portal system. Instead, the adenohypophysis is 
4
 extensively innervated by finger-like projections of the preoptic and hypothalamic 
neurons (Peter et al., 1990). As a result, the release of tropic hormones from the 
hypothalamus is mainly neuroglandular via direct peptidergic or aminergic 
innervation rather than neurovascular as found in tetrapods and many primitive fishes.  
In sharp contrast to the mammalian system, most of the neurosecretory cells of 
the teleostan hypothalamus are located in the POA and the nucleus lateralis tuberis 
(NLT). The NLT represents the teleostean homolog of the mammalian arcuate 
nucleus and is responsible for the secretion of CRH and GnRH as well as a few other 
hypothalamic hormones including the arginine vasotocin (AVT). A few studies show 
that there might be two types of CRH-secreting cells: one located in the POA and the 
other in the NLT (Norris, 2006). There are experimental evidences suggesting that the 
CRH in the POA is responsible for its secretion while the CRH in the NLT is 
responsible for its synthesis. Other than these differences, the HPS axis of teleost is 
regulated largely by the same hormonal pathways as the mammals. The various 
peptide hormones including the CRH, GnRH, ACTH, LH, and FSH as well as their 
cognate receptors have been identified in many teleostan species. Nevertheless, the 
major classes of steroid hormones that are produced eventually in the interrenal and 
gonads differ slightly from that of mammals and other higher vertebrates.    
1.2 The functional anatomy and embryonic morphogenesis of adrenals  
1.2.1 The adrenal glands in mammals  
 
Along the HPS axis, the adrenal glands represent one of the most important 
steroidogenic organs as the adrenal cortex produce two major classes of steroids 
(glucocorticoids and mineralocorticoids) that are indispensable to sustain life. Indeed, 
the removal of adrenals leads to fatality within just a few days, primarily due to the 
derangement in electrolyte balance, cardiac function, and inability to cope with 
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 stressors. In mammals, the adrenal glands are located on top of the kidneys. Each 
adrenal gland is compartmentalized into two regions that are distinct in histological 
structure, embryonic origin, and physiological function. The adrenal cortex forms the 
outer part of adrenal and it is a factory for steroid hormones production. The medulla 
constitutes the inner part of adrenal and it releases catecholamines (adrenaline and 
noradrenaline). 
The adrenal cortex is derived from the mesoderm germ layer (Hatano et al., 
1996). An adrenocortical cell can be easily distinguished by the large number of lipid 
droplets and smooth endoplasmic reticulum as well as the presence of tubulovesicular 
mitochondria in their cytoplasm. The adrenal cortex is further compartmentalized into 
three concentric zones, namely zona glomerulosa, zona fasciculata, and zona 
reticularis from outside to inside. Each layer differs from one another in their 
characteristic arrangement of cells and major classes of steroid hormones produced. 
The outermost zona glomerulosa secretes primarily mineralocorticoids (mainly 
aldosterone) in response to increased levels of potassium or decreased blood flow to 
the kidneys, as part of the renin-angiotensin system. By increasing re-absorption of 
sodium and water, as well as, excretion of potassium, aldosterone plays a pivotal role 
in maintaining electrolyte balance. The zona fasciculata and reticularis produce 
glucocorticoids (cortisol in humans and corticosterone in mice) and weak androgens 
(dehydroepiandrosterone, DHEA), respectively, under the stimulation of ACTH. 
Glucocorticoids exert a broad range of important physiologic effects including the 
regulation of stress response and carbohydrate metabolism as well as the modulation 
of the immune functions. Its actions are mediated by intracellular glucocorticoid 
receptors via alterations of target gene expression (Payne and Adcock, 2001; Yudt and 
Cidlowski, 2002; Schoneveld et al., 2004).  
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 The different classes of steroid hormones are synthesized from cholesterol via 
a series of biochemical reactions that are catalyzed by a battery of oxidative enzymes 
located in the mitochondria and endoplasmic reticulum. There are two major classes 
of steroidogenic enzymes, namely the steroid hydroxylases and hydroxysteroid 
dehydrogenases. Prior to the enzymatic synthesis, the free cholesterol from the 
cytoplasm need to be transported into the mitochondria by the steroidogenic acute 
regulatory protein (StAR). Within the steroidogenesis pathway (Fig. 1.1), the side-
chain cleavage enzyme CYP11A1 (also known as P450SCC) catalyzes the first rate-
limiting step by converting cholesterol into pregnenolone. Pregnenolone then serves 
as the immediate precursor for the synthesis of all other steroids. Typically, steroid 
hormones can be classified into five major classes, namely the glucocorticoids 
(mainly cortisol but species-dependent), mineralocorticoids (mainly aldosterone), 
androgens (mainly testosterone), estrogens (estrodiol and estrone), and progestagens 
(progesterone). The last three classes are collectively termed sexual or gonadal 
steroids. In humans, monkeys, hamsters, guinea pigs and fish, cortisol is the major 
glucocorticoid whereas in rodents, rabbits, birds, and snakes, corticosterone is the 
predominant glucocorticoid. 
In contrast to the adrenal cortex, the adrenal medulla is derived from the 
embryonic neural crest cells, which are of ectoderm origin (Unsicker et al., 2005). It 
is composed mainly of chromaffin cells that produce catecholamine by converting 
tyrosine into adrenaline and noradrenaline (also called epinephrine and 
norepinephrine). Although the adrenal medulla and adrenal cortex was thought to be 
functionally independent, subsequent investigations have established anatomical and 
functional links between them. For example, medullary catecholamine secretion is 
under sympathetic control and paracrine control of cortisol. Conversely, the 
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 neuropeptides and catecholamines synthesized by the adrenal medulla influence the 
steroidogenesis in adrenal cortex (Bornstein and Vaudry, 1998; Ehrhart-Bornstein et 
al., 1998; Ehrhart-Bornstein and Hilbers, 1998; Hinson et al., 1994). 
 
Figure 1.1 Biosynthesis pathways of adrenocortical and sexual steroids from 
cholesterol in tetrapods. The steroidogenic enzymes catalyzing the corresponding 
biochemical reaction are indicated with the arrow labels. The dominant glucocorticoid, 
corticosterone, in rodents, amphibian, and birds is indicated in box (taken from Bury 
and Sturm, 2007).    
 
The morphogenetic events during the embryonic development of adrenals are 
well defined in mouse and human (Bland et al., 2003; Coulter, 2005; Else and 
Hammer, 2005; Hammer et al., 2005). In mouse, the adrenal cortex and gonads arise 
from common precursor cells that originate from the coelomic epithelium of the 
intermediate mesoderm at approximately embryonic day (E) 9.0. At E10.5, the 
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 adrenal cortical precursor cells separate from the gonadal precursors. The neural crest 
cells then migrate to the growing and encapsulated adrenal cortex from E12.5 to 
E13.5, and differentiate to form islands of the catecholamine-producing chromaffin 
cells. In the fetal adrenal cortex of human and mice, there are two distinct layers 
namely the outer definitive (adult) zone and the inner fetal zone. The adrenal 
development is complete only after birth where the medullary islands coalesce to form 
a rudimentary medulla, and the fetal zone degenerates with the proliferation of 
definitive zone. 
1.2.2 The interrenal gland in teleost 
 
The teleostan equivalent of the adrenal cortex is the interrenal. The interrenal 
is embedded in the head kidney, which is located anterior to the pronephros (kidney). 
Similar to its mammalian counterpart, it is composed of two major types of cells 
namely the steroidogenic interrenal cells and the non-steroidogenic chromaffin cells 
which represent the homologs of mammalian adrenocortical and adrenomedullary 
cells respectively (Nandi, 1962; Grassi et al., 1997a; Rocha et al., 2001b). The 
structural organization of adrenocortical tissues and chromaffin tissues has been 
shown to vary greatly among evolutionarily divergent species (Fig. 1.2). In teleosts, 
the interrenal gland appears as a highly intermingled structure of steroidogenic and 
chromaffin cells.  
In the early sixties, Nandi (1962) performed detailed examination of the 
structural organisation and the distribution of interrenal and chromaffin cells of the 
interrenal gland in 129 teleost species. According to his observations, the interrenal 
gland consists of structures such as streaks, lumps or cell strands, which are located in 
proximity to the posterior cardinal veins or their branches. The interrenal gland of 
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 many teleosts has been found to be asymmetrically located at one side of the trunk 
(Nandi, 1962; Grassi et al., 1997b; Rocha et al., 2001a).  
 
 
Figure 1.2 Structural organization of chromaffin and adrenocortical tissues in 
evolutionarily divergent lineages. 
 
 
In terms of the steroidogenic capability, the interrenal glands of teleosts 
generally express similar sets of steroidogenic enzymes that catalyze cascade of 
steroid biosynthesis. One exception is the Cyp11b2 (aldosterone synthase) enzyme 
that catalyzes the final step for synthesis of aldosterone. Till date, the presence of 
mineralocorticoids in fishes remains debatable (Jiang et al., 1998; Nelson, 2003; Bury 
and Sturm, 2007; McCormick et al., 2008). In comparison to the steroidogenesis 
pathway in tetrapods, the steroidogenesis pathway in teleosts displays a few distinct 
features (Fig. 1.3). Firstly, the CYP17 enzyme catalyzes reactions that divert 
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 corticosterone to the synthesis pathway of cortisol. In addition, teleosts lack 
CYP11B2 and have cortisol as their dominant corticosteroid. 
 
 
Figure 1.3 Biosynthesis pathways of adrenocortical and sexual steroids from 
cholesterol in fish. The steroidogenic enzymes catalyzing the corresponding 
biochemical reaction are indicated with the arrow labels. The dominant glucocorticoid 
is cortisol in teleost and the bioactive 1α-hydroxycorticosterone in Chondrichtyes 
(sharks and rays), as indicated in box (taken from Bury and Sturm, 2007). 
 
1.2.3 The interrenal gland in zebrafish 
 
For zebrafish, which is the model organism used in this study, the anatomy 
and early morphogenesis of interrenal has been recently reported (Hsu et al., 2003f). 
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 Histological examination revealed the head kidney of adult zebrafish as fused bilateral 
lobes found in the anterior region of the kidney. In situ hybridization (ISH) assays 
using cyp11a1 demonstrated that the steroidogenic interrenal cells are found in both 
lobes with the right gland bigger than the left one. Further examination of the 
interrenal cells with electron microscopy revealed a multiple layered epithelial 
organization that interposed with two distinct types of chromaffin cells (adrenaline 
and noradrenaline). Similar to mammalian adrenocortical cells, a large number of 
mitochondria can be seen in the cytoplasm of interrenal cells in zebrafish. However, 
the lipid droplets, a characteristic of steroidogenic cells in mammals, are not present 
in the zebrafish interrenal cells.  
The morphogenetic movement of interrenal primordium in zebrafish has also 
been examined in detail by ISH analyses of ff1b, the earliest molecular marker for 
interrenal primordium (Chai and Chan, 2000b; Hsu et al., 2003b), as well as, that of 
steroidogenic enzymes such as cyp11a1 and 3β-hsd. The interrenal primordia first 
appeared as small and dispersed bilateral clusters ventral to the third somite at 20-22 
hours post fertilization (hpf) (Chai and Chan, 2000a; Hsu et al., 2003g; Liu, 2007). By 
~28 hpf, the primordia converged at the midline but further expansion of the interrenal 
cells placed them unevenly on both sides of the notochord again by 3 days post 
fertilization (dpf). At 3 dpf, a capsule-like structure of the interrenal gland formed but 
the epithelial structure and vascularization did not take place even at 5 dpf. 
The morphogenetic movement of interrenal primordia has been demonstrated 
to be closely associated with the pronephric primordia (Hsu et al., 2003d) and also the 
endothelium cells (Liu and Guo, 2006). In addition, midline signaling has also been 
implicated in the morphogenetic movement of interrenal primordia, as the 
convergence of bilateral interrenal cells was shown to be defective in midline 
12
 patterning mutant such as one-eyed pinhead (oep), squint (sqt), and floating head (flh) 
(Chai and Chan, 2000c; Chai et al., 2003f; Hsu et al., 2003a). Besides, the Hedgehog 
(Hh)/Gli-mediated signaling pathway, which also represents a major signaling from 
the midline, has just recently been shown to modulate the interrenal morphogenesis in 
zebrafish by mediating the gene expression of ff1b and wt1 (Bergeron et al., 2008).   
1.3 Nuclear receptors NR5A: one of the key molecular players in the HPS axis 
 
Nuclear receptors (NRs) are ligand-inducible transcription factors that regulate 
gene expression by interacting with specific DNA sequences upstream of their target 
genes and recruiting co-regulator protein complexes that modify chromatin templates 
and contact the basal transcription machinery. They represent one of the largest 
families of transcription factors, with 48 members identified in human (Robinson-
Rechavi et al., 2001). Working in concert with other proteins, they regulate a variety 
of biological processes, including growth, development, metamorphosis, 
organogenesis, reproduction, and metabolic pathways (Carson-Jurica et al., 1990; 
Mangelsdorf et al., 1995; Giguere, 1999c; Smirnov, 2002; Gronemeyer et al., 2004). 
Many of the NRs play key roles in regulating the proper development and function of 
the HPS axis, and a good proportion of NRs bind steroids as their cognate ligands. 
To date, more than 500 members of the nuclear receptor superfamily have been 
identified in animals ranging from hydra to human and a systematic classification 
dividing NRs into seven major groups have been established (Nuclear Receptors 
Nomenclature Committee, 1999; Germain et al., 2006). Considering the physiological 
importance of NRs, several publicly available online databases, including the Nuclear 
Receptor Signaling Atlas (NURSA; www.nursa.org) and the Nuclear Receptor 
database (NURBASE; http://www.ens-lyon.fr/LBMC/laudet/nurebase/nurebase.html) 
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 have been established (Duarte et al., 2002; Ruau et al., 2004; Margolis et al., 2005; 
Lanz et al., 2006). 
The NR5 sub-family of NRs, which is commonly known as Fushi-tarazu factor 
1 (Ftz-F1), represents one of the most ancestral NR groups with essential functions in 
both invertebrates and vertebrates (Laudet and Adelmant, 1995; Laudet, 1997; Escriva 
et al., 2004). The Ftz-F1 gene was initially identified in Drosophila as an activator 
that binds specifically to regulatory sequences of the segmentation gene, fushi tarazu 
(Ueda et al., 1990; Lavorgna et al., 1991). Members of the NR5 receptors have been 
reported from more than 40 species of invertebrate and vertebrate. The extensive 
distribution of FF1s and the highly conserved structure among the family members 
imply that members of this subfamily have critical function that might be conserved 
across the various phyla. As a key subject in this study, the FF1 genes may be 
classified into two major subgroups namely the NR5A1 (SF-1/Ad4BP) and NR5A2 
(LRH/FTF) based on sequence similarity and expression domains. 
Members of FF1 sub-family share a typical structural organization with other 
members of NR superfamily (www.nursa.org). An FF1 receptor is composed of four 
functionally interacting domains (Fig. 1.4) which include: an Activating function 1 
(AF1) domain at the N-terminus, a highly conserved DNA binding domain (DBD) 
that harbors a DNA-binding motif composed of two zinc fingers, a structurally 
conserved ligand-binding domain (LBD) and a highly variable hinge domain 
separating the DBD and the LBD (Giguere, 1999b; Li et al., 2003). The AF1 domain 
of NR5A members is relatively short as compared to other subfamilies of NRs. The 
NR5A members are also characterized by the presense of a conserved and unique Ftz-
F1 box near the C-terminal region of their DBD (Pick et al., 2006). The Ftz-F1 box is 
known to stabilize the binding of NR5 receptors to their target DNA sequences by 
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 interacting with nucleotides flanking the core recognition element (Wilson et al., 
1993a; Li et al., 1999). Furthermore, the N-terminal LBD region in LRH-1 and SF-1, 
encompasses helices H1 to H3 of LBD, and is highly conserved in FF1 members and 
shares no sequence similarity with other receptor subfamilies (Giguere, 1999a). 
 
Figure 1.4 Structure/function domains in NR5A nuclear receptors. NR5A sub-
family of nuclear receptors share structure/function domains with a typical nuclear 
receptor, which contains a variable N-terminal region (AF1), a conserved DNA 
binding domain (DBD), a variable hinge region, and a conserved ligand binding 
domain (LBD) with a conserved AF1 motif at its C-terminus. 
  
1.3.1 NR5A1 (SF-1/Ad4BP) and NR5A2 (LRH-1/FTF) 
 
NR5A1, which is commonly known as Steroidogenic factor-1 (SF-1), was first 
identified as a transcription factor with limited tissue distribution and recognized a 
conserved regulatory motif in the proximal promoter regions of genes encoding the 
cytochrome P450 steroid hydroxylases in mouse and bovine (Lala et al., 1992; 
Morohashi et al., 1992; Honda et al., 1993). In human, the SF-1 gene is located on 
chromosome 9q33 and the gene product is a nuclear protein of approximately 54 kDa. 
SF-1 binds to target gene promoters as a monomer and recognizes variations of the 
DNA sequence PyCAAGGTCA (Rice et al., 1991; Wilson et al., 1993b), which will 
be referred to as FF1 response element (FRE) throughout the thesis. SF-1 displays 
high sequence homology to the drosophila Ftz-F1 receptor, which regulates the 
expression of fushi tarazu homeotic gene (Lavorgna et al., 1993). In mouse, the Sf-1 
locus also encodes three other transcripts that give rise to embryonic long terminal 
repeat-binding protein ELP1, ELP2, and ELP3 by alternative promoter usage and 
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 differential splicing. However, subsequent studies demonstrated that SF-1 is the key 
factor that exerts a regulatory function in the HPS axis (Luo et al., 1995b; Ninomiya 
et al., 1995b; Kotomura et al., 1997).   
Consistent with its role in the transcriptional activation of steroidogenic enzyme 
genes, Sf-1 expression is restricted to a subset of endocrine tissues including the 
gonads, adrenal cortex, ventromedial hypothalamus, and the pituitary gonadotropes 
(Ikeda et al., 1994; Ingraham et al., 1994a; Morohashi et al., 1994; Ikeda et al., 1995b; 
Hammer and Ingraham, 1999). Interestingly, Sf-1 is only weakly expressed in the 
placenta, although it is the major site of steroid production during pregnancy (Ikeda et 
al., 1993; Sadovsky et al., 1995c; Ramayya et al., 1997b), and placental development 
and steroid production was unaffected in Sf-1 knockout mice (Sadovsky et al., 1995b). 
It was subsequently demonstrated that regulatory roles of SF-1 in inducing 
sterodogenic enzyme expression can be carried out by AP2 instead in the palcenta 
(Ben Zimra et al., 2002). In addition to the conventional steroidogenic tissues, Sf-1 
expression has also been detected in the skin (Patel et al., 2001) and spleen (Ramayya 
et al., 1997a; Morohashi et al., 1999a). Nevertheless, the physiological importance of 
its expression in these tissues has not been closely examined.   
The liver receptor homologue 1 (LRH-1; NR5A2) or α-fetoprotein transcription 
factor (FTF) is the other member of the mammalian FF1 receptors. The expression of 
LRH-1 is abundant in the liver and intestine where it regulates genes encoding key 
enzymes in bile acids synthesis such as CYP7A and CYP8B1 (Castillo-Olivares and 
Gil, 2000b) as well as genes involved in cholesterol transport (Luo et al., 2001a; 
Schoonjans et al., 2002a). Intriguingly, LRH-1 regulates its target genes by binding to 
the same DNA response element, the FRE, as SF-1 (Lu et al., 2000).   
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 It was conventionally assumed that SF-1 expression is exclusive to endocrine 
tissues and LRH-1 expression is exclusive to endoderm-derived tissues such as liver 
and intestine until the subsequent discovery of LRH-1 expression in the ovaries of 
humans and rodents. The high level of LRH-1 expression has been shown to be 
important in regulating the promoter activity of the steroid hydroxylase genes 
(Falender et al., 2003c; Sirianni et al., 2002b). However, LRH-1 is expressed to a 
much lesser extent in the adrenal cortex of human (Wang et al., 2001). The high level 
of LRH-1 expression in the ovaries implies a functional redundancy to SF-1. 
Nevertheless, in instances where SF-1 and LRH-1 are coexpressed, it can be 
extremely difficult to decipher the specificity of the target genes regulated by these 
two receptors because both of them bind FRE with equal affinities. For example, 
while SF-1 was assumed to regulate CYP19 encoding the aromatase enzyme that 
converts androgen to estrogen (Fitzpatrick and Richards, 1993), expression patterns of 
these two receptors during follicular maturation in rat showed LRH-1, and not SF-1, 
as the major regulator of ovarian aromatase (Liu et al., 2003b). 
1.3.2 NR5A subfamily members in zebrafish 
 
In zebrafish, genes that belong to the FF1 family have been cloned and they 
have been established as orthologues of mammalian SF-1 and LRH-1. To date, four 
Ff1s have been identified in zebrafish, namely Ff1a (Liu et al., 1997), Ff1b (Chai and 
Chan, 2000f), Ff1c (Xia, 2003), and Ff1d (Kuo et al., 2005g). During early embryonic 
development, only ff1a and ff1b are expressed. At 26 hpf, ff1a (nr5a2) shows a 
broader tissue expression pattern where its transcripts can be detected in the 
hypothalamus and trigeminal ganglion in the head region, and in the spinal neurons, 
somites and endodermal cells in the trunk (von Hofsten et al., 2001a; Kuo et al., 2005f; 
Sheela et al., 2005). In adult, ff1a is expressed in the brain, spinal cord, mandibular 
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 arch and digestive organs. Ff1a is a close homologue of LRH-1 by sequence 
homology and functional analyses (Lin et al., 2000; Liu et al., 2000; von Hofsten et al., 
2001b). On the other hand, ff1b (nr5a1a) has a more restricted expression profile in 
the ventromedial hypothalamus (VMH), interrenal gland, and gonads from embryonic 
development till adult stage (Chai and Chan, 2000d). Furthermore, Ff1b is found to 
play an essential role in the initiation of the interrenal primordium and its subsequent 
development and acquisition of steroidogenic capacity (Chai et al., 2003e; Hsu et al., 
2004).  
In contrast, ff1c is expressed only after the completion of embryonic 
development at 4 dpf and its expression in the adult fishes is ubiquitous, 
predominantly in the intestine, liver, ovary, muscle, and heart (Xia, 2003; Kuo et al., 
2005e). The ff1d transcript is present throughout all stages of embryonic development, 
mainly in anterior and dorsal neural tissues in the head and trunk, including and VMH 
and pituitary (Kuo et al., 2005d; von Hofsten et al., 2005d). In addition, ff1d has been 
reported to be expressed transiently in the interrenal at ~30 hpf (von Hofsten et al., 
2005c). In adult fishes, ff1d shows the highest level of expression in testis and with 
much lower expression in the brain, ovary, muscle, and heart (Kuo et al., 2005c; von 
Hofsten et al., 2005b). Although functional data of ff1c and ff1d genes are not 
available currently, the differential expression patterns of the four ff1 genes indicate 
that they may have distinctive functions.    
Both the DBD and LBD domains are highly conserved for all four zebrafish ff1 
genes, and they transactivate the basal promoter containing a consensus FRE (Liu et 
al., 2003d). The study of the four zebrafish ff1 genes by phylogenetic analysis, genetic 
mapping, and comparative genomics have defined the evolutionary relationships 
among the four isoforms, as well as to tetrapod FF1s (Kuo et al., 2005b). Notably, the 
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 orthology of ff1a to NR5A2 is very apparent with data from phylogenetic analyses, 
chromosomal mapping and expression patterns. These findings suggest that the 
zebrafish ff1a and human NR5A2 are derived from a single gene in their last common 
ancestor.  
In contrast with ff1a, the evolutionary relationship of zebrafish ff1b and ff1d to 
tetrapod NR5A1 and NR5A2 are less clear in phylogenetic analysis. Nevertheless, the 
relationship of the two genes as gene duplicates are apparent, in that they are sisters in 
a phylogeny tree and they are localized on paralogous chromosomes compared with 
the genome of a related species that did not undergo whole-genome duplication 
(Amores et al., 1998b; Postlethwait et al., 1998; Taylor et al., 2003; Jaillon et al., 2004; 
Naruse et al., 2004). The tight association of ff1b and ff1d genes to an NR6A1 co-
orthologue as in humans indicates that the tandem duplication occurred before the 
divergence of human and zebrafish lineages.  
The zebrafish ff1c is grouped into the third set of ff1 genes, which include only 
teleostan representatives from pufferfish (Kuo et al., 2005a). The ff1c genes may thus 
come from genome-amplification events that occurred before the tetrapod/teleost 
divergence but was subsequently lost in the tetrapod lineage. This phenomenon where 
an ancient paralogue is retained in the fish lineage but was lost in the human lineage 
has been reported previously (Amores et al., 1998a). Genetic mapping has also 
revealed the conserved syntenies of the four ff1 genes with notch paralogues in 
comparison to human NR5A paralogues. These chromosome segments conserved 
between the zebrafish and human genomes indicate a common ancestral origin. Most 
likely, the two NR5A groups arose before the divergence of mammalian and teleost 
lineages through a genome-amplification event.     
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 1.4 NR5A1: the main player in development and function of HPS axis 
 
Since its discovery in 1992, SF-1 (NR5A1) has emerged as a NR that is 
pivotal for the proper development and function of steroidogenic tissues. Consistent 
with this role, SF-1 is expressed in all organs along the HPS axis and it modulates the 
development and maintenance of these organs at multiple levels along the HPS axis. 
In embryonic stem (ES) cells, stable expression of SF-1 is sufficient to alter cell 
morphology, permit cAMP and retinoic acid-induced expression of the endogenous 
CYP11A1 gene, and consequently promote steroidogenesis (Crawford et al., 1997b). 
This indicates that SF-1 is the master regulator in the specification and determination 
of steroidegenic lineage. Great insights into the endogenous function of SF-1 in 
embryonic development have been gained from SF-1 knockout (KO) mice studies. A 
few attempts of tissue-specific KO studies reported recently have provided important 
clues to SF-1 function in the VMH, pituitary, and gonads. On top of that, its functions 
in sex determination pathway and the maintenance of adrenal functions have long 
been established after nearly one and half decade of extensive research.    
1.4.1 SF-1 in embryonic development: insights from knockout mice  
 
Targeted disruption of Sf-1 in mice was reported by three independent groups of 
researchers and they revealed the critical role of SF-1 in adrenal and gonadal 
development (Luo et al., 1994a; Sadovsky et al., 1995a; Shinoda et al., 1995d). The 
SF-1 knockout (KO) mice exhibited adrenal and gonadal agenesis, male-to-female sex 
reversal of the internal and external genitalia regardless of genetic sex, impaired 
gonadotrope function, and ablation of VMH. In a separate study, the spleen of SF-1 
KO mice was shown to be smaller with obvious defects in the splancnic 
vascularization and erythropoiesis (Morohashi et al., 1999b) although the precise 
function of SF-1 in the spleen has remained undefined till date. 
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 The SF-1 KO pups completely lack adrenals and die shortly after birth 
presumably due to the lack of corticosteroids, as the mice can be maintained by 
administration of exogenous corticosteroids (Luo et al., 1995a). This observation 
implies the critical role of SF-1 not only in adrenal development but also in the 
biosynthesis of steroid hormones. It is important to note that the mesenchymal, 
adrenocortical, and gonadal precursor cells in these KO mice form at the correct time 
and place but undergo programmed cell death thereafter, indicating that SF-1 is not 
required for the initial specification of adrenogonadal primordia but is essential for 
their subsequent maintenance and differentiation. The complete lack of gonads and 
sex reversal phenomenon following the loss of SF-1 clearly indicate that it is involved 
not only in the organogenesis of gonads but also in the sex determination pathway. 
The molecular mechanisms underlying the complete regression of the adrenal and 
gonadal primordia remain largely unknown until now. 
Contrary to the complete agenesis of adrenals and gonads, some of the 
dorsomedial region of VMH neurons persisted in SF-1 KO pups although they display 
severe defects. For instance, the VMH of SF-1 KO mice did not form discrete nucleus 
and further immuno-reactivity assays have revealed the markedly altered organization 
of the major cell types of VMH (Ikeda et al., 1995a; Shinoda et al., 1995c). Although 
the characteristic structures of VMH are present at E17, they progressively regress 
thereafter. A closer examination of these KO mice showed that the normal exclusion 
of GABA from the developing VMH did not take place (Dellovade et al., 2000a). 
Moreover, cells expressing neuropeptide Y, estrogen receptor α, and galanin 
displayed altered cell distribution, and so as the Islet-1- and Nkx2.1-expressing cells 
(Dellovade et al., 2000b; Davis et al., 2004b).  
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 As the expression of SF-1 is restricted to only a sub-domain (gonadotrope) of 
pituitary, the pituitary gland develops normally. In the absence of SF-1, gonadotropes 
were formed but functionally impaired and they failed to express LHβ, FSHβ, and 
GnRH-R (Ingraham et al., 1994b; Shinoda et al., 1995b). Although SF-1 is not the 
sole determinant in the embryonic development of VMH and pituitary, it is important 
in shaping their normal architecture and function.  
Although the global gene disruption of SF-1 has unraveled its crucial roles in 
embryonic development, the early postnatal death of KO pups has hindered further 
characterization of SF-1 functions. To partially solve this problem, SF-1+/- 
heterozygous KO has been generated. The mice display adrenal and gonadal 
hypoplasia but no major defect in the VMH and pituitary (Bland et al., 2000). As a 
result, the mice are unable to respond properly to stress stimulant, as measured by the 
levels of corticosteroid produced when they are subjected to inflammatory stress, food 
deprivation, and immobilization. The haploinsufficiency of SF-1 also revealed the 
dosage-sensitive effect of SF-1 action.   
1.4.2 Tissue-specific knockouts of SF-1 
 
With the advances in DNA engineering particularly the establishment of the 
Cre-loxP recombination system (Sauer and Henderson, 1988; Sauer and Henderson, 
1989; Orban et al., 1992), tissue-specific knockouts of SF-1 are made possible. Using 
a transgene containing the Cre recombinase driven by the gonadotrope-specific 
promoter of αGSU gene, a loxP-modified SF-1 locus was selectively disrupted in the 
gonadotrope cells in pituitary (Zhao et al., 2001a; Zhao et al., 2001b). The resultant 
mice never mature sexually, and the testes and ovaries displayed severe hypoplasia 
although the VMH and adrenals appeared to be largely intact. The markedly decrease 
level of LH and FSH indicate that the absence of gonadotropins in global SF-1 KO 
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 mice is of pituitary origin and not the secondary effect resulted from defect in GnRH 
production of VMH.    
Using a similar strategy, SF-1 was selectively inactivated in the Leydig cells 
and granulosa cells with the allele of the anti-Müllerian hormone type 2 receptor 
knocked-in by a Cre-mediated strategy (Jeyasuria et al., 2004). In these mice, the 
adrenals develop and function normally, albeit at smaller size. In contrast, histological 
abnormalities were obvious in the testes from prenatal stages and spermatogenesis 
was impaired. Although female mice produced ovaries that were indistinguishable to 
the wild-type during embryogenesis and at birth, adult females were sterile, 
characterized by the absence of corpora lutea and the presence of hemorrhagic cysts in 
reminiscent of estrogen receptor alpha and aromatase KO mice. 
The ablation of SF-1 specifically in the central nervous system (CNS) using a 
nestin-Cre/loxP recombination strategy has also been reported (Davis et al., 2004a; 
Kim et al., 2008; Zhao et al., 2008). In these mice, SF-1 expression was largely 
unaffected in the anterior pituitary, adrenals, and gonads; and the structural defects in 
VMH were largely similar to that of global SF-1 KO. Interestingly, these mice 
showed increased anxiety-like behavior, unravelling a regulatory role of SF-1 in a 
complex behavioral phenotype. In addition, novel target genes [Brain-derived 
neurotrophic factor (BDNF), corticotropin-releasing hormone receptor 2 (Crhr2), 
urocortin 3 (Ucn3), and cannabinoid-1 receptor (CB1R)] of SF-1 that potentially play 
a role in anxiety behaviour and energy homeostasis have been identified. 
1.4.3 SF-1 in sex determination 
 
In eutherian mammals, the basic principle underlying sex determination is the 
chromosomal genetic sex, which is determined at the time of fertilization by the 
presence or absence of the Y chromosome. This genetic determinant, however, needs 
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 to be executed through the highly coordinated gene regulatory network along the HPG 
axis. SF-1 appears to be involved at all three levels of these events. SF-1 is expressed 
in the VMH nucleus (Shinoda et al., 1995a) where it is regulated by GnRH 
(Haisenleder et al., 1996). In pituitary gonadotrope, SF-1 has been shown to regulate 
the gene expression of nitric oxide synthase, which mediates the gonadotropin release 
and sexual behaviour (Wei et al., 2002a). In the bipotential gonad, SF-1 expression 
was maintained together with the activation of a Y chromosome-located gene, SRY, 
along the testis determination and differentiation pathway but its expression was 
repressed by the dosage-sensitive sex reversal-adrenal hypoplasia congenita critical 
region on the X chromosome (DAX-1) just after the onset of ovarian differentiation 
(Tremblay and Viger, 2001b). The expression of SF-1 was restored in females at a 
later stage of embryogenesis.  Besides DAX-1, SF-1 (in concert with SOX9, GATA-4 
and WT1), was also able to stimulate MIS promoter activity in male gonadogenesis 
(De Santa et al., 1998c; Nachtigal et al., 1998a; Tremblay and Viger, 1999a; De Santa 
et al., 2000).   
1.4.4 Ff1b as the earliest molecular marker and master regulator of interrenal 
development in zebrafish 
 
Among the four ff1 genes in zebrafish, ff1b shows the strongest homology to 
mammalian SF-1 in terms of protein sequence, expression pattern, and functional 
properties. Ff1b is the earliest known molecular marker for the zebrafish interrenal 
gland and it is also expressed in the VMH from early developmental stage (Chai and 
Chan, 2000e). Double in situ hybridization for ff1b and the steroidogenic markers, 
cyp11a and 3β-hsd, showed that the expression of ff1b preceded the onset of 
steroidogenic identity by nearly 2 hr during the ontogeny of the interrenal (Chai et al., 
2003d). Furthermore, ff1b and wt1 seem to be co-expressed in the interrenal 
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 primordium in a restricted time frame (Hsu et al., 2003h), and wt1 may also 
participate in the interrenal development mediated by Ff1b (Hsu et al., 2003e). 
Importantly, the disruption of ff1b gene function in vivo by antisense 
morpholino (MO) knockdown resulted in late larval morphological phenotype that 
suggests an impaired interrenal function (Chai et al., 2003c). The resultant morphants 
could be subdivided into four classes A to D according to the severity of phenotype 
(Fig. 1.5). When the ff1b gene function was knocked down by MO, the expression of 
cyp11a1 and the enzymatic activity of 3β-Hsd were markedly reduced. A recent study 
that reported the isolation of DAX-1 in zebrafish has also demonstrated that ff1b 
knockdown abolished the expression of DAX-1 and that DAX-1 probably functions 
downstream of Ff1b in a regulatory cascade governing the proper development and 
function of interrenal gland (Zhao et al., 2006b). This observation implicates a direct 
involvement of ff1b in zebrafish interrenal development, which is highly reminiscent 
to the results obtained in mouse SF-1 knockout studies. This similarity observed 
between the two systems suggests a conserved regulatory program for adrenocortical 
development in evolutionarily divergent species.   
1.4.5 Zebrafish Ff1s in sex determination 
 
In contrast to mammals, the sex determination in zebrafish is a delicate process, 
which in many cases can be influenced by environmental factors. The mechanisms 
underlying zebrafish sex determination and differentiation are largely uncharacterized. 
By far, neither sex linked genes nor sex chromosomes have been identified in 
zebrafish. A number of genes have been linked to the process of sex determination or 
differentiation in zebrafish based on their orthology to mammalian counterparts and 
Ff1s are certainly one of them (von Hofsten and Olsson, 2005). Particularly, ff1d has 

















ovary and testis, and it has been proposed as a promising candidate in regulating sex 
determination pathway in zebrafish (von Hofsten et al., 2005a).  
 
Figure 1.5 Morphological phenotypes of 7 dpf larvae microinjected with 11.25 
μM ff1bMO per embryo (from Chai at el., 2003). (A) Wild-type, (B) Class A, (C) 
Class B, (D) Class C, and (E) Class D morphants. Classification was based on the 
severity of morphant phenotypes, mainly on the severity of subcutaneous edema. 
Arrowheads in (D) and (E) indicate blood island formation. 
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 In line with the observations from mammals, gene dosage effects may be an 
influential factor involved in zebrafish sex determination. Based on their homology to 
mammalian orthologs and the expression profiles in the gonads, allelic variants and 
dosage effects of autosomal genes, the ff1 genes, sox9, wt1, amh, dmrt1 and gata4 
have been proposed to be involved in determining sex and directing gonad 
development in zebrafish (von Hofsten and Olsson, 2005). The recent isolation of 
DAX-1 homolog in zebrafish opens up the possibility of its involvement in the sex 
determination pathway (Zhao et al., 2006a). Nevertheless, the molecular interactions 
among the above factors remain to be characterized. 
1.5 Transcriptional Regulation of SF-1 
 
The highly selective expression of SF-1 along the HPS axis indicates its tight 
transcriptional regulation. However, the molecular mechanism underlying the tissue-
specific expression of SF-1 is still not well understood. The first decade of research 
merely identified a number of cis-elements at the 5’ flanking promoter region of SF-1 
that modulate its basal transcription in transient transfection assays. Only in the last 
five years, the rapid advances in DNA engineering accelerated the study of regulatory 
elements that are responsible for the tissue-selective expression of SF-1. These studies 
made use of large DNA inserts, contained within yeast artificial chromosome (YAC) 
or bacterial artificial chromosome (BAC), spanning the entire genomic locus of SF-1 
in combination with in vivo transgenic mice studies. The identification of several 
tissue-specific enhancers within the mouse Sf-1 locus highlights the high level of 
complexity in SF-1 transcriptional regulation. Despite the successful identification of 
putative cis-elements and the accompanying trans-acting factors that could account 
for the tissue-specific expression of SF-1, the definition of the upstream regulators 
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 that restrict adult expression, and signaling pathways that control SF-1 expression in 
the HPS axis during embryonic development are still lacking.  
1.5.1 Cis-elements at the 5’ proximal promoter 
 
The mapping of regulatory elements governing SF-1 expression was possible 
once the genomic sequences were made available (Ninomiya et al., 1995a; Wong et 
al., 1996), and it began with the study of its 5’ flanking promoter. Transient 
transfection studies using cell lines have identified a number of cis-elements that are 
required for SF-1 expression. Notably, a 90 bp 5’ promoter fragment spanning an E-
box, a Sp1 (Splicing factor 1) site, and a CAT box is capable of activating reporter 
gene in testis and adrenocortical cells (Scherrer et al., 2002; Woodson et al., 1997b). 
The E-box that binds the ubiquitous USF factor has been shown to be essential for the 
transcriptional activation of SF-1 promoter in several heterologous cell lines (Nomura 
et al., 1995; Woodson et al., 1997a; Harris and Mellon, 1998b; Oba et al., 2000a). In 
addition, SOX9, a tissue-specific transcription factor, has also been implicated in 
inducing the expression of SF-1 in Sertoli and Y1 cells (Shen and Ingraham, 2002), 
while GATA-4 has been shown to moderately activate SF-1 expression in Sertoli cells 
(Tremblay and Viger, 2001a).  
Despite the seemingly successful identification of putative cis-elements in the 
5’ promoter of SF-1 using in vitro transient transfection studies, subsequent in vivo 
transgenic mouse studies revealed that tissue-specific expression of SF-1 cannot be 
established with these genomic information (Stallings et al., 2002b; Wilhelm and 
Englert, 2002c; Zubair et al., 2002). For instance, while a 674-bp 5’ promoter of 
mouse SF-1 could restrict lacZ expression to the gonads, the regulatory elements 
required to fully recapitulate the endogenous expression of SF-1 are missing (Wilhelm 
and Englert, 2002b). Furthermore, a 50 kb 5’ flanking region of mouse SF-1 from a 
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 BAC plasmid could direct the expression of EGFP reporter gene to most SF-1-
expressing tissues but not the pituitary (Stallings et al., 2002a). By far, the most 
successful transgenic mouse study has come from an effort that utilized genomic 
locus of rat Sf-1 gene spanning 153 kb, as the resultant transgene fully recapitulates 
the endogenous expression of Sf-1 in mouse and the transgene was able to rescue SF-1 
KO mice (Karpova et al., 2005c). 
DNase I hypersensitivity mapping has also identified several potential 
regulatory regions within the Sf-1 locus. One such domain surrounds the FRE in 
Intron I where the chromatin adopts an open structure in Y1 and adrenal cells, but is 
closed in liver, 3T3, and ECA2 cells (Ninomiya et al., 1996b; Nomura et al., 1996b). 
The second region is located 3’ to Exon 7 of SF-1. Interestingly, a recent study 
identified three DNase I hypersensitive sites within the intergenic region between the 
mouse Sf-1 gene and its upstream neighbor, germ cell nuclear factor (Gcnf) (Ishihara 
and Morohashi, 2005). Further dissection showed that one of the sites binds an 
insulator protein, CTCF, while the others are likely to be associated with nuclear 
matrix. These hypersensitive sites that are associated with CTCF and nuclear matrix 
were suggested to define an insulating boundary of histone acetylation between the 
two genes, and contribute to their distinct expression patterns in different tissues.        
1.5.2 Auto-regulation of SF-1 gene expression 
 
SF-1 has been proposed to autoregulate its own expression in rat and human 
through the FRE located in the first intron (Nomura et al., 1996d; Oba et al., 2000c). 
In transient transfection studies, mutation of this FRE decreased reporter gene activity 
in Y1 adrenocortical cells and the FRE was responsive to SF-1 overexpression in CV-
1 cells (Nomura et al., 1996c). Furthermore, open chromatin structure surrounding the 
FRE has been revealed by DNase I hypersensitivity mapping (Ninomiya et al., 1996a; 
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 Nomura et al., 1996a). Nonetheless, other investigations indicate that the FRE does 
not enhance transcription of SF-1 and the autoregulation of SF-1 might be species-
dependent (Harris and Mellon, 1998a; Oba et al., 2000b). A more recent study has 
identified two highly conserved FREs within a fetal adrenal enhancer (FAdE) located 
in intron IV of mouse and human SF-1 gene (Zubair et al., 2006e). The two FREs 
were established to be essential to maintain an autoregulatory loop that is necessary 
for the maintenance of SF-1 expression in the fetal adrenal.     
1.5.3 KO mice with downregulated SF-1 expression 
 
Gene KO studies have been helpful in the identification of potential upstream 
regulator of SF-1 transcription on the basis that the loss of these genes is accompanied 
by downregulation or disappearance of Sf-1 expression. One such example is the 
Wilm’s tumor 1 (WT1) KO mice where SF-1 expression failed to initiate at all in the 
gonads (Wilhelm and Englert, 2002a). Similarly, the LIM homeobox protein Lhx-9 
has been proposed to regulate Sf-1 expression as Lhx-9 KO mice did not develop 
gonads and had markedly reduced Sf-1 expression in their urogenital ridges (Birk et 
al., 2000). Besides WT1 and Lhx-9, the pre-B-cell transcription factor 1 (Pbx1) has 
also been implicated in the regulation of Sf-1 expression due to the differentiation 
defects in adrenal and urogenital that are associated with minimal Sf-1 expression in 
Pbx-/- mice (Schnabel et al., 2003). The Pbx1-dependent regulation of SF-1 expression 
in the mouse fetal adrenal has indeed been demonstrated recently (Zubair et al., 
2006d).   
1.5.4 Localization of tissue-specific regulatory DNA elements in intronic 
regions 
 
A DNA fragment containing 153 kb of genomic sequences spanning the rat 
SF-1 locus has successfully recapitulated the endogenous expression of Sf-1  in 
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 transgenic mouse and the same region has been shown to rescue SF-1 KO mice 
(Karpova et al., 2005a; Karpova et al., 2005b). Using computational analysis based on 
evolutionarily conserved regions and observations from transgenic mouse studies, 
they have predicted potential regulatory elements for Sf-1 expressing tissues.  
Following this report, another laboratory has reported four additional 
transgenic mouse studies using long genomic regions spanning Sf-1 locus to locate 
tissue-specific enhancers of SF-1 and all all them have delivered exciting findings 
(Shima et al., 2005c; Zubair et al., 2006c; Shima et al., 2008a; Zubair et al., 2008). By 
determining the lacZ reporter expression driven by overlapping genomic fragments 
spanning the mouse Sf-1 locus in transgenic mice, Shima et al. (2005) successfully 
mapped a VMH-specific enhancer (VMHE) to Intron VI. A highly conserved 
equivalent of VMHE was also found in the human SF-1 gene. By further deletion, a 
503-bp core enhancer element has been identified (Shima et al., 2005b).  
Using the same experimental approach as outlined in Shima et al. (2005), 
Zubair et al. (2006) successfully localized the fetal adrenal enhancer (FAdE) to Intron 
IV of mouse and human SF-1 gene. The 648-bp core FAdE was able to induce lacZ 
expression in the fetal adrenal gland with the hsp68 basal promoter but the expression 
disappeared along with the regression of fetal adrenals. In the same study, a two-step 
regulation of SF-1 gene activation in the fetal adrenal has been proposed. The initial 
step involves the initiation of SF-1 transcription in the fetal adrenal by a Hox-Pbx-
Prep1 complex and the continued expression of SF-1 is then maintained via an 
autoregulatory loop (Zubair et al., 2006b). Subsequently, the FAdE has been 
successfully used in lineage tracing of fetal adrenal cells during different stages of 
embryonic development (Ref, Zubair 2008). By monitoring transgene expression in 
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 transgenic mouse, a direct link between the fetal zone and adult zone of adrenal cortex 
has been established.              
An intronic enhancer for pituitary-specific expression of SF-1 has been 
recently  localized to Intron VI of mouse Sf-1 gene (Shima et al., 2008b). This 
enhancer functionally recapitulated the endogenous expression of SF-1 in the fetal 
Rathke's pouch right up to the adult pituitary gonadotrope. Similar to the FAdE and 
VMHE, the pituitary-specific enhancer consists of several elements conserved among 
animal species and mutational analyses confirmed the significance of these elements 
for the enhancer function. One of these elements was able to interact with pituitary 
homeobox 2 (Pitx2) in vitro and in vivo, indicating that Pitx2 regulates SF-1 gene 
transcription in the pituitary gonadotrope by interacting with the gonadotrope-specific 
enhancer. 
1.6 Target genes of SF-1 
 
SF-1 binds the extended consensus site of GTCAAGGTCA as a monomer. In 
all binding sites studied so far, the guanines are absolutely required and the two 
alanines preceding them are very highly conserved. For the remaining nucleotides, 
variations from the consensus are normally negligible (Busygina et al., 2005). As 
expected, SF-1 target genes can be found in all SF-1-expressing tissues. Generally, 
SF-1 target genes can be separated into those expressed in steroidogenic cells and 
non-steroidogenic cells [see Val et al. (2003) for an extensive review of SF-1 target 
genes]. Several studies have also highlighted the possible role of SF-1 in regulating a 
set of target genes that are actively involved in the signaling pathways modulating cell 
proliferation and/or apoptosis. 
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 1.6.1 Steroidogenic targets of SF-1 
 
The steroidogenic target genes of SF-1 encompass those that are 
transcriptionally modulated by SF-1 in the adrenals and gonads. Since its isolation in 
1992, genes encoding steroidogenic enzymes represent the most dominant and well 
studied set of SF-1 target genes. Indeed, SF-1 has been shown to participate in the 
transcriptional regulation of all steroidogenic enzymes in the adrenal cortex and 
gonads with the exception of CYP11B2 (Bassett et al., 2002). In any case, SF-1 is 
required to activate the basal transcription of the target promoter and it seems to 
participate in the cAMP responsiveness of some of those target genes. The location of 
FREs in these promoter often overlap with that of the cAMP response elements 
(CREs) although SF-1 might not participate in cAMP responsiveness of all 
steroidogenic enzyme genes. Among the steroidogenic enzymes, CYP11A1 represents 
the most well characterized member in terms of SF-1 regulation as it catalyzes the 
first rate-limiting biochemical step in the steroidogenesis pathway. Two FREs mapped 
in the human CYP11A1 promoter have been implicated in both the basal transcription 
and hormone sensitivity of CYP11A1 gene (Hu et al., 2001; Guo et al., 2007c). In 
addition, SF-1 has been shown to regulate the cAMP-dependent transcription of 
CYP11A1 promoter in cooperation with AP-1 (Guo et al., 2007b; Lan et al., 2007).  
Besides steroidogenic enzymes, SF-1 also controls the expression of genes 
encoding proteins that are involved in cholesterol transport and synthesis. These 
include the sterol carrier protein 2, SCP2 (Pfeifer et al., 1993); the sterol acute 
regulatory protein, StAR (Stocco, 2000); and the HMG-CoA synthase (Mascaro et al., 
2000). Notably, a new class of genes encoding proteins that protect the steroidogenic 
cells against toxic by-products of steroidogenesis is emerging and SF-1 has also been 
implicated in their gene expression. These include the aldose reductase akr1-b7 
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 (Aigueperse et al., 2001; Martinez et al., 2002; Val et al., 2002; Martinez et al., 2003) 
and the superoxide-dismutase 2 SOD2 (Chinn et al., 2002). The last subset of SF-1 
target genes related to steroidogenesis are those encode for receptors of ACTH 
(Marchal et al., 1998; Naville et al., 1998; Naville et al., 1999; Winnay and Hammer, 
2006; Lichtenauer et al., 2007a) and FSH (Heckert, 2001; Levallet et al., 2001), which 
regulate the hormone stimulated steroidogenesis of adrenals and gonads.  
The other subset of SF-1 target genes covers those that are mostly expressed 
specifically in the gonads, and are involved in proper reproductive function and sexual 
determination and differentiation. They include DAX-1 (Burris et al., 1995; Kawabe 
et al., 1999), Mullerian inhibiting substance receptor (De Santa et al., 1998d), anti-
Mullerian hormone gene (MIS) (De Santa et al., 1998b), small heterodimer partner 
(SHP) (Lee et al., 1999), scavenger receptor, class B, type 1 (SRB1) (Cao et al., 1997), 
insulin like 3 (Koskimies et al., 2002a), prolactin receptor (Hu et al., 1997), α-inhibin 
(Ito et al., 2000; Gummow et al., 2003b) and sex determining region Y (SRY) (De 
Santa et al., 2001b).   
1.6.2 Non-steroidogenic targets of SF-1 
 
The non-steroidogenic target genes of SF-1 mainly reside in the hypothalamus 
and pituitary. In SF-1 KO mice, the GnRH receptor and gonadotropins were not 
detected and SF-1 has been subsequently shown to regulate the gene promoter of 
GnRH receptor (Duval et al., 1997; Ngan et al., 1999; Pincas et al., 2001), αGSU (a 
common subunit of LH and FSH) (Fowkes et al., 2003), LHβ (Halvorson et al., 1996; 
Halvorson et al., 1998), as well as FSHβ (Jacobs et al., 2003b). In addition, SF-1 has 
also been demonstrated to regulate several hypothalamic genes that play important 
roles in the CNS. They include the N-methyl D-aspartate (NMDA) receptor, a non-
specific cation channel that directly contributes to excitatory synaptic transmission 
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 (Pieri et al., 1999); the neuronal nitric oxide (NO) synthase that modulates the 
secretion of GnRH (Wei et al., 2002b); and oxytocin that acts as a neurotransmitter 
and involved in female reproduction (Wehrenberg et al., 1994).  
1.6.3 Beyond reproductive function and steroidogenesis: SF-1 in cell 
proliferation and apoptosis?  
 
Several observations have highlighted that target genes activated by SF-1 
should extend beyond the broad classes that have been discussed. For instance, the 
presence of adrenal and gonadal anlage and their subsequent regression by apoptosis 
in SF-1 KO mice clearly indicate a role of SF-1 in cell proliferation or apoptosis (Luo 
et al., 1994b). SF-1 has also been demonstrated to modulate the proliferation rate of 
rat ovarian surface epithelial cells (Nash et al., 1998). A recent study demonstrated 
that increased dosage of SF-1 triggered cell proliferation and cancer development of 
adrenocortical cells (Doghman et al., 2007). Importantly, the transcriptional 
regulating protein of 132 kDa (TreP-132), which is expressed in steroidogenic tissues 
and known to acts as a coregulator of SF-1 (Gizard et al., 2002b), has been 
demonstrated to control cell proliferation by regulating the expression of cyclin-
dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1 (Gizard et al., 2005).  
1.7 LRH-1: diverse functions in development, metabolism, and steroidogenesis 
 
The expression domain of LRH-1 (NR5A2) is slightly broader than that of SF-
1. LRH-1 is expressed since early developmental stage and it is absolutely required 
for proper endoderm development. It is dominantly expressed in endoderm-derived 
tissues including liver, intestine, and exocrine pancreas. Its transcripts can also been 
detected in the ovary, adrenal, and testis but the expression seems to be species-
dependent. The molecular mechanisms by which LRH-1 regulates the cholesterol and 
bile acid homeostatic pathways are well characterized while its function in ovarian 
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 steroidogenesis is emerging just recently [for review, see (Fayard et al., 2004b; Lee 
and Moore, 2008)].   
1.7.1 LRH-1 in endoderm development 
 
Lrh-1 is abundantly expressed in mouse embryonic stem cells (Gu et al., 
2005c; Gao et al., 2006) and its expression can be detected as early as preimplantation 
stage (Pare et al., 2001a; Pare et al., 2004a; Gu et al., 2005b). Homozygous disruption 
of Lrh-1 gene in mice is embryonic lethal and the developing embryos do not survive 
beyond E7.0, the gastrulation stage (Pare et al., 2004b; Gu et al., 2005a; Labelle-
Dumais et al., 2006b). In LRH-1 KO mice, the primitive streak morphogenesis and 
mesoderm formation are severely impaired although the anterior-posterior 
specification is unaffected (Labelle-Dumais et al., 2006a). LRH-1 is actively involved 
in the transcriptional cascade governing the proper endoderm differentiation and 
hepatic determination. Its expression is tightly regulated by early endodermal markers 
including GATA4, GATA6, and HNF4, as well as by other developmental 
transcription factors from the basic helix-loop-helix, homeodomain, and NR families 
(Pare et al., 2001b; Annicotte et al., 2003a). On the other hand, LRH-1 has been 
shown to regulate the expression of a number of liver-specific genes including 
Forkhead box a2 (Foxa2), hepatocyte nuclear factor 1α (HNF1α), HNF3β,  and HNF4 
(Rausa et al., 1999; Pare et al., 2001c). Furthermore, it has been implicated as a 
downstream target of pancreatic and duodenal homeobox 1 (Pdx1), which is a 
homeobox factor that is essential for pancreatic development (Annicotte et al., 2003b). 
These findings collectively indicate that LRH-1 is acting downstream of transcription 
factors that are important for early endoderm specification but upstream of genes 
involved in the development of hepatopancreatic lineages.  
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 1.7.2 LRH-1 in cholesterol reverse transport and bile acid homeostasis 
 
Besides serving as the precursor for steroidogenesis, cholesterol also mediates 
other important cellular functions including membrane biogenesis as well as the 
biosynthesis of bile acids. LRH-1 participates in reverse cholesterol transport from 
peripheral tissues to the liver by mediating the transcription regulation of cholesteryl-
ester-transfer protein (CETP) and scavenger receptor class B type I (SR-BI). LRH-1 
potentiates the cholesterol-induced expression of CETP in concert with oxysteroid-
activated NRs Liver X Receptor (LXR) α and LXRβ (Luo et al., 2001b). Besides, 
LRH-1 binds FREs present in the murine and human SR-BI promoters and the 
expression of SR-BI is found to be reduced in LRH1+/- mice (Schoonjans et al., 
2002b).  
LRH-1 also participates in the regulation of the bile acid (BA) synthesis 
pathway in concert with several other NRs. Briefly, LRH-1 regulate the expression of 
cholesterol 7α-hydroxylase (CYP7A1) and sterol 12α-hydroxylase (CYP8B1) in 
cooperation with LXRα, Farnesoid X receptor (FXR) and SHP (Castillo-Olivares and 
Gil, 2000a; Goodwin et al., 2000; Lu et al., 2000b; Yang et al., 2002; Castillo-
Olivares et al., 2004). In addition, LRH-1 also regulates the expression of several 
genes involved in lipoprotein assembly and lipid re-absorption including the 
pancreatic enzyme carboxyl ester lipase (CEL) (Fayard et al., 2003), ileal apical 
sodium-dependent BA transporter (ASBT) (Chen et al., 2003), and enterocytic 
multidrug-resistance protein 3 (MRP3) (Inokuchi et al., 2001).        
1.7.3 Emerging roles of LRH-1 in steroidogenesis 
 
Following the discovery of its abundant expression in the ovary in several 
species studied, it is now clear that LRH-1 modulates steroidogenesis cooperatively 
with SF-1 in the ovary (Boerboom et al., 2000b; Sirianni et al., 2002a; Falender et al., 
37
 2003a; Hinshelwood et al., 2003b; Liu et al., 2003a). LRH-1 expression is restricted 
to the corpus luteal cells and follicular granulosa cells in all stages of development, 
whereas SF-1 expression is primarily found in the theca and interstitial cells. Besides 
differential expression in distinct ovarian cell types, the two NRs are differentially 
regulated by estradiol, FSH, and LH during the estrous cycle (Boerboom et al., 2000a; 
Falender et al., 2003b). LRH-1 has been demonstrated to regulate the expression of 
SR-BI and CYP19 in the granulosa cells (Hinshelwood et al., 2003a; Liu et al., 2003c; 
Schoonjans et al., 2002c). Moreover, LRH-1, rather than SF-1, regulates the 
expression of 3β-hydroxysteroid dehydrogenase type II (HSD3B2) in the human 
corpus luteum, which primarily produces progesterone (Peng et al., 2003). These 
observations suggest that LRH-1 may play a more important role in female sexual 
function compared to SF-1, whose role is more dominant in male sexual 
determination (Fayard et al., 2004a). The ovarian expression of LRH-1 in a stage-
specific manner also raises the possibility that LRH-1 may have specific roles in 
modulating luteal and follicular functions.  
An overexpression study of SF-1 and LRH-1 demonstrated that they exert 
qualitatively similar actions to stimulate the production of estrogen and progesterone 
in rat granulosa cells (Saxena et al., 2007). Since the binding specificity for FRE by 
SF-1 and LRH-1 is similar, they could potentially activate the same target genes if 
their expression domains overlap. Indeed, it has been reported that molecular 
switching between SF-1 and LRH-1 exist if they are co-expressed in the same cell. 
Hormonal stimulation of GRMO2 granulosa cell lines with forskolin resulted in a 
dynamic switching of SF-1 and LRH-1 at the inhibin α-subunit gene promoter such 
that SF-1 is replaced by LRH-1 (Weck and Mayo, 2006). 
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 1.8 Modulation of transcriptional activity of NR5A receptors 
It is now recognized that the activity of NRs can be modulated by at least three 
distinct mechanisms. Firstly, conformational changes of NRs can be induced by 
binding of a small lipophilic ligand or interacting partner in heterodimer complexes. 
Secondly, NRs activity can be modified by covalent modification, usually in the form 
of phosphorylation, and they are regulated by signaling events or during the cell cycle. 
Lastly, the transcriptional activities of NRs are dependent on protein-protein 
interactions, generally through contacts with other transcription factors and 
coregulators, including NRs themselves. All three mechanisms can either work 
individually or in concert with each other to exert NR function.  
1.8.1 Identification of physiological ligands 
 
For ligand-dependent receptors, hormone binding induces conformational 
changes that include a critical repositioning of the C-terminal helix H12 within the 
AF2 region (Nolte et al., 1998). Like other NRs, LRH-1 and SF-1 possess an intact 
and functional AF2 region (Galarneau et al., 1996; Ito et al., 1997). Intriguingly, both 
NRs are thought to be constitutively active as they are able to activate reporter 
constructs in the apparent absence of exogenous ligand in most cell lines. The 
proposal of oxysterols as a physiological ligand of SF-1 was largely controversial 
because these steroids fail to alter the activity of SF-1 in most cellular contexts, or 
elicit conformational changes predicted upon ligand binding (Lala et al., 1997; Mellon 
and Bair, 1998; Desclozeaux et al., 2002). Thus, SF-1 and LRH-1 remained as orphan 
NR until the high-resolution structures of both receptors are solved.  
The X-ray crystallography structure of the mouse LRH-1 LBD was first 
reported by Sablin et al. (2003). The structure revealed a fold that resembled that of 
the known agonist-bound LBD structure with a large but empty ligand-binding pocket 
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 as result of the tight packing of bulky hydrophobic residues, which is indicative that 
LRH-1 could remain constitutively active in the absence of a ligand (Sablin et al., 
2003). In opposition to this, a subsequent attempt to solve the X-ray structure of LRH-
1 and SF-1 LBD from mouse and human revealed that phosphotidyl inositol second 
messengers were the cognate ligands and that ligand binding was necessary to achieve 
maximal NR activity (Krylova et al., 2005). According to their evolutionary analysis 
of structure-function relationships across the NR5A subfamily, ligand binding 
represents the ancestral state of NR5A receptors and was probably diminished or 
altered uniquely in the rodent LRH-1 lineage. Intriguingly, a third study published on 
the X-ray crystal structure of human SF-1 and LRH-1 LBD demonstrated that the 
ligand-binding pocket of both NRs could use a wide range of phospholipid molecules 
as ligands (Wang et al., 2005). Obviously, the dependency of the two NRs on their 
potential ligands in vivo remain to be tested with more transient transfections and 
biochemical assays. 
1.8.2 Covalent modifications that modulate the activities of NR5A receptors 
 
The study of post-translational modifications of SF-1 revealed several 
signaling pathways that potentially regulate its transcriptional activity. SF-1 was first 
found to be phosphorylated in ovary granulosa cells following FSH stimulation 
(Carlone and Richards, 1997). The protein kinase A (PKA), which has been 
implicated in the stimulation of many SF-1 target genes expression, was able to 
phosphorylate the LBD and N-terminal region of SF-1 (De Santa et al., 2001a; Zhang 
and Mellon, 1996). In another study, SF-1 was shown to be phosphorylated at Ser-203 
in AF1 domain by the extracellular signal-regulated kinase 2 (ERK2) in the 
ras/MAPK signaling pathway (Hammer et al., 1999). More importantly, mutation of 
Ser-203 to an alanine residue markedly decreased the activation potential of SF-1 by 
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 50%.  Besides, phosphorylation of Ser-203 enhances the recruitment of cofactors 
TIF2 and SMRT, and stabilized the structure of LBD in SF-1. Phosphorylation of 
LRH-1 at serine 238 and 243 has also been reported and it led to the stimulation of its 
transactivation activity (Lee et al., 2006).  
Besides phosphorylation, SF-1 has been shown to be acetylated in vivo by the 
acetylase GCN5 and this modification stimulates its transcriptional activity (Jacob et 
al., 2001). Lastly, SF-1 is known to be covalently modified by small ubiquitin-like 
modifier 1 (SUMO). The SUMOylation of SF-1 was first identified by its protein-
protein association with components of SUMOylation pathway and SF-1 can be 
SUMOylated at Lys-119 and Lys-194 in vitro (Komatsu et al., 2004). Subsequent 
investigations reveal that SUMOylation modification of SF-1 protein primarily 
represseed its transcriptional activity on its target genes (Lee et al., 2005; Campbell et 
al., 2008; Yang et al., 2008).  
1.8.3 Protein-protein interactions with coregulators 
 
To achieve transcriptional activation of target genes, DNA-bound NRs were 
originally believed to directly recruit general transcription factors (GTFs) to the 
preinitiation complex. Subsequent research revealed, however, that most NR regulated 
transcription events require intermediary factors, the so-called coregulators, which 
often constitute subunits of larger multiprotein complexes that act at several functional 
levels including chromatin remodeling, enzymatic modification of histone tails, or 
modulation of the preinitiation complex via interactions with RNA polymerase II and 
GTFs.  
Most NR coregulators can be further subdivided into coactivators and 
corepressors, respectively, depending on whether they mediate transcriptional 
activation or repression. Many of the NR-coregulator interactions occur through the 
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 LXXLL motif of NRs (Jepsen and Rosenfeld, 2002; Savkur and Burris, 2004). 
Furthermore, it has become clear that coactivation or corepression is not necessarily 
an intrinsic feature of a given coregulator but can depend on the target gene and cell-
type specific context, i.e. some coregulators can function either as a coactivator or a 
corepressor in a context-dependent manner (Nagy and Schwabe, 2004; Kishimoto et 
al., 2006; O'Malley et al., 2008; Wolf et al., 2008).  
Similar to many other NRs, SF-1 interacts with a wide range of coregulators to 
modulate the transcription of its target genes. The known interactors characterized so 
far include steroid receptor coactivator 1, SRC1 (Crawford et al., 1997a; Ito et al., 
1998), coactivator TIF2 and p/CIP (Borud et al., 2002), corepressor RIP140 
(Sugawara et al., 2001), DAX1 (Hanley et al., 2001; Koskimies et al., 2002b), 
androgen receptor (Jorgensen and Nilson, 2001), hMBF1 (Kabe et al., 1999), β-
catenin (Gummow et al., 2003a; Mizusaki et al., 2003), Sp1 (Sugawara et al., 2000), 
Ptx1 (Tremblay et al., 1999), Egr-1 (Tremblay and Drouin, 1999), CREB binding 
protein (Monte et al., 1998), TreP-132 (Gizard et al., 2002a), paired-like 
homeodomain transcription factor 1 (Tremblay et al., 1998b), pituitary specific 
transcription factor 1 (Tremblay et al., 1998a), nuclear factor Y (Jacobs et al., 2003a), 
estrogen receptor alpha (Drean et al., 1996), nuclear receptor co-repressor 2 
(Crawford et al., 1998), CCAAT/enhancer binding protein (Reinhart et al., 1999), 
dead box polypeptide 20, 103KD (Ou et al., 2001), Zip67 (Borud et al., 2003), 
GATA4 (Tremblay and Viger, 1999b), small nuclear RING finger protein (Curtin et 
al., 2004), AP1 (Guo et al., 2007a), and Foxl2 (Wang et al., 2007). In the sex 
determination pathway, SF-1 has been shown to regulate the gene expression of the 
MIS gene in physical association with WT1 and SRY-related HMG box 9 (SOX9) (De 
Santa et al., 1998a; Nachtigal et al., 1998b; Gurates et al., 2002; Gurates et al., 2003). 
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 Furthermore, Pbx1 together with SF-1 have been shown to act synergistically on Mcr-
2 promoter (ACTH receptor) to modulate adrenocortical growth as well as 
steroidogenesis (Lichtenauer et al., 2007b). 
The transcriptional activity of LRH-1 has also been shown to be mediated by 
interactions with a wide range of coregulator although the list of interactors is not as 
extensive as SF-1. The small heterodimer protein (SHP) (Lu et al., 2000a; Lee and 
Moore, 2002; Li et al., 2005), prospero-related homeobox factor (Prox1) (Qin et al., 
2004), silencing mediator for retinoic acid receptor and thyroid hormone receptor 
(SMRT) (Xu et al., 2003) and sterol regulatory element-binding protein (SREBP) 
(Kanayama et al., 2007) have been implicated as transcriptional corepressor of LRH-1. 
In addition, steroid receptor coactivator 1 (SRC-1) (Xu et al., 2004) and β-catenin 
(Botrugno et al., 2004) have both been reported to interact with LRH-1 and 
potentiates its transcriptional activity. Following the discovery of LRH-1 expression 
in the ovary, several coregulators that mediate LRH-1 transcriptional activity at the 
gene promoter of steroidogenic enzymes have been identified. These include the 
peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1α) and 
retinoid X receptor (RXR) (Safi et al., 2005) as well as PIASy, the shortest member of 
the protein inhibitor of activated STAT family (Hsieh et al., 2008). A recent study 
showed that the LXXLL-related motifs in DAX-1, which is well documented as the 
coregulator of SF-1, have target specificity for both SF-1 and LRH-1 (Suzuki et al., 
2003).  
For zebrafish Ff1s, Prox1 has been implicated as a novel corepressor of Ff1b 
and both of them work in conjunction to regulate the development of the zebrafish 
interrenal primordium (Liu et al., 2003e). It is postulated that Prox1 can form a 
repressor complex with Ff1b, which subsequently regulates the target genes in the 
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 interrenal development. Just recently, antisense morpholino knockdown of wt1 in 
zebrafish showed that Wt1 plays an important role in the development of both 
pronephric and interrenal primordia in coordination with Ff1b (Hsu et al., 2003c). 
Therefore, Wt1 might be a potential coregulator that can physically interact with Ff1s 
in modulation of their activities. In addition, the transcriptional intermediary factor 2 
(TIF2), which belongs to the p160 coactivators family, has been shown to interact 
strongly with Ff1b and Ff1c (Tan et al., 2005). As zebrafish Ff1s share a high 
homology to their mammalian homologues, the list of coregulators that mediate their 
transcriptional activity will continue to grow. 
1.9 Aims of this study 
 
The focus of the present study was on ff1b, which is the most well studied 
member among the four zebrafish ff1 genes isolated. As a follow-up to previous 
studies carried out in our laboratory that explored the cloning, genomic organization, 
expression pattern, and loss-of-function studies in relation to ff1b, this research project 
was initiated with the long-term objective to understand the regulatory mechanisms 
governing the expression and transcriptional activity of ff1b in the organogenesis and 
maintenance of mature zebrafish interrenal gland.  
While Ff1b functions as a master regulator gene in the specification of 
interrenal primodium (Chai et al., 2003b), nevertheless, the upstream cis-acting 
elements and their corresponding trans- factors that modulate the expression and 
transcriptional activity of Ff1b, have not been defined. Furthermore, unanswered 
questions remained concerning the downstream effectors of Ff1b, particularly as the 
target genes that are activated by Ff1b for steroidogenesis and maintenance of 
endocrine function maintenance are likely to be different from that for organogenesis. 
For the later, many of these downstream gene targets are likely to encompass classes 
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 of genes that are involved in apoptosis, cell proliferation, vascularization, and 
restriction of expansion domain for organogenesis. 
While the relevance of SF-1 KO mice studies cannot be questioned, they have 
nevertheless also highlighted the difficulty of using a mammalian system to study the 
in vivo gene functions. Even with the development of tissue-specific KO approach, 
the investigation of adrenal organogenesis in mammalian system remains a great 
challenge due to its in utero development. In this regard, the zebrafish model 
complements the mammalian system perfectly in that it allows discoveries that are 
otherwise not possible, especially if they required direct embryonic manipulation or 
when combined with both forward and reverse genetic approaches, which are well 
established in zebrafish model. In the last decade, zebrafish has emerged as a popular 
model organism for a wide spectrum of endocrinology studies (McGonnell and 
Fowkes, 2006). The zebrafish endocrine system is sufficiently similar in comparison 
to human and mouse, thereby allowing the experimental findings to be broadly 
applicable among these vertebrate models. Besides, the transparency and rapid 
development of zebrafish embryos enable live imaging and developmental study of 
endocrine organs, as well as embryonic and molecular micromanipulation. 
Furthermore, injections of DNA, RNA, and morpholino oligo, cell transplantation, 
and many other molecular and histochemical techniques are well established in 
zebrafish (Westerfield, 2000). The wide variety of both forward and reverse genetic 
approaches can be readily employed to decipher gene function. As a vertebrate, 
zebrafish displays many experimental advantages of invertebrate models including the 
ease of maintainance under laboratory conditions, large number of offsprings (a few 
hundred eggs weekly), external fertilization, short development and generation time, 
just to mention a few.  
45
 While the overall endocrine function of Ff1b is conserved with mammalian 
SF-1, subtle differences still exist and some of these differences have indeed 
highlighted the advantages of zebrafish model in comparison to mammalian models. 
For instance, the knockdown of ff1b gene function in zebrafish is not embryonic lethal 
(Chai et al., 2003a), probably due to the maternal store or alternate site of 
corticosteroids synthesis. Thus, ff1b morphants of zebrafish can be easily subjected to 
a wide range of experimental manipulations, including direct treatment with chemical 
or corticosteroids, co-injection of overexpression constructs, as well as, imaging 
analyses from early stages of embryonic development. With the established role of 
Ff1b as a master regulator of interrenal development, it is now plausible to generate a 
faithful transgenic marker using ff1b gene. Obviously, a fluorescent lineage tracer of 
ff1b in zebrafish is likely to provide a higher level of versatility and convenience than 
that of SF-1 in the mouse model, mainly due to the possibility of live imaging in 
zebrafish embryos.     
In this research project, three major lines of research that have been 
undertaken will eventually lead us to achieving the long-term goal of deciphering ff1b 
gene functions in the morphogenesis of the interrenal gland. Despite the well defined 
central role of Ff1b in interrenal development, the supporting evidence of its in vivo 
function as a transcription factor is still lacking.The first objective is directed at the 
establishment of Ff1b as a bona fide transcription factor and we will use the 5’ 
promoter of cyp11a1, a putative target gene of Ff1b, to study this aspect. The 
establishment of the association of Ff1b with the cyp11a1 promoter would aid to 
generate an endogenous target gene promoter for the detailed study of Ff1b 
transcriptional activity.  
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 For the second objective, we aim to establish a stable transgenic zebrafish line 
that will allow lineage tracing of ff1b-expressing cells, particularly those in the 
interrenal gland, using EGFP as the fluorescent marker. The resultant transgenic line 
would create an in vivo model for the visualization of ff1b-expressing cells throughout 
the developmental process, thereby enabling a much more detailed and close 
examination of the morphogenetic events that are taking place during the 
organogenesis of the interrenal gland. Furthermore, the stable transgenic zebrafish 
will allow the isolation of pure populations of ff1b-expressing cells for a variety of 
cellular and molecular analyses to identify the upstream regulators, interacting 
partners, and downstream target genes of Ff1b.  
The third objective is the identification of cis-regulatory elements that control 
the tissue-specific expression of ff1b in zebrafish, particularly that in the interrenal 
gland. Although tissue-specific enhancers, such as VMHE and FAdE, are conserved 
between mouse and human (Shima et al., 2005a; Shima et al., 2008c; Zubair et al., 
2006a), sequences that share sufficient homology to these enhancers could not be 
mapped in zebrafish ff1b through  biocomputational analysis and comparison. The 
close examination of ff1b locus and the identification of tissue-specific enhancers for 
ff1b would aid to unravel the commonalities and disparities between the 
transcriptional regulation of ff1b and SF-1. This would be useful in defining the 
evolutionary mechanisms that have taken place to shape the current gene function of 
ff1b and SF-1, and probably also other FF1 genes. This requires the sequencing of a 
major portion of the ff1b genomic locus to fully establish the sequence information. 
Subsequently, a recombination-based deletion study of the ff1b locus, in combination 
with transient transgenesis, in zebrafish embryos has been adopted to identify 
enhancer elements that are responsible for the tissue-specific expression of ff1b. 
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 CHAPTER 2 
Materials and Methods 
 
 
2.1 Purification of plasmids from bacterial culture 
Small-scale purification of plasmids < 20 kb in size intended for cloning, 
sequencing, and clone screening was carried out from 2 - 3 ml of DH10B or DH5α E. 
coli bacterial culture. The isolation of plasmid DNA was performed with the 
QIAprep® Spin Column (QIAGEN GmbH, Germany) or with the spin column from 
High-Speed Plasmid Mini Kit (Geneaid, Taiwan).  
Large-scale purification of plasmids < 20 kb in size and bacterial artificial 
chromosome (BAC) plasmids from bacteria intended for microinjection or 
transfection experiments was carried out using QIAGEN Plasmid Endofree 
Midi/Maxi Kit with the following modifications for BAC DNA. For the purification 
of BAC DNA, at least 400 ml of bacteria culture was used and the resulting lysate was 
treated as two Maxiprep reactions and passed through either one QIAGEN-tip 500 or 
two QIAGEN-tip 100. Elution buffer was pre-heated to 65°C when purifying BAC 
DNA and the final DNA pellet was dissolved overnight at 4°C in TE buffer, after 
which the DNA was stored at 4°C. 
2.2 Subcloning techniques 
All general subcloning and DNA manipulation techniques including restriction 
endonucleases digestions, ligations, and PCR amplification of DNA fragments were 
performed according to protocols described in Sambook and Russel  (2000) as well as 
the corresponding manufacturer’s manual. The enzymes used were mostly purchased 
from New England Biolabs Inc (MA, USA), Promega Corp. (WI, USA), Roche 
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 (Switzerland), and Invitrogen (CA, USA). The DNA fragments generated by PCR or 
restriction digestion were purified using QIAquick PCR Purification Kit (QIAGEN) 
or gel-purified using QIAquick Gel Extraction Kit (QIAGEN).  
2.3 Site-directed mutagenesis 
Mutagenesis on the desirable site in a plasmid DNA was generated using the 
Quickchange® XL Site-directed Mutagenesis Kit (Stratagene, CA, USA). Briefly, the 
pairs of mutagenic primers were designed following the guidelines described in the 
manufacturer’s manual and complementary oligonucleotide primers were ordered 
from 1stBASE (Singapore) or Research Biolabs (Singapore). Mutant strands were 
synthesized from the parental plasmid by PCR amplification using the complementary 
mutagenic oligonucleotides. Reactions were set up in a final volume of 50 µl and 
contained 1X Pfu reaction buffer, 10 ng of template DNA, 125 ng of the each 
oligonucleotide primers, 0.2 mM of each dNTPs, 3 µl of Quickchange Solution (to 
facilitate replication of large plasmids), and 1 µl of PfuTurbo DNA polymerase (2.5 
U/ µl).  
Following PCR amplification, 1 µl of Dpn I restriction enzyme was added 
directly into the PCR reaction mixture and the resulting mixture was incubated at 
37°C to digest the non-mutated, methylated parental DNA strands. Two microlitre of 
this final reaction mixture was transformed into 50 µl of home-made electrocompetent 
cells of DH10B (transformation efficiency ~109 cfu/μg). Half or all of the transformed 
cell mixture was then plated onto LB plates with appropriate antibiotics selection and 
the LB plates were incubated overnight at 37 °C to obtain single colonies. To screen 
for the successfully mutagenized construct, plasmids were subsequently isolated from 
8 – 10 colonies and sent for sequencing to identify the correctly mutagenized clone. 
The efficiency of mutagenesis is normally 20 – 50 %. 
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 2.4 Genome walking for the isolation of putative promoter regions of zebrafish 
steroidogenic genes 
 
The putative promoter regions of the zebrafish steroidogenic genes including 
cyp11a1, star, cyp17, and 3β-hsd were isolated by a modified genome walking 
method (Siebert et al., 1995). Briefly, 2 μg of zebrafish genomic DNA was separately 
digested with five different restriction enzymes that leave 3’ overhangs, namely BstXI, 
NsiI, PstI, SacI and SphI. Following purification by phenol: chloroform: isoamyl 
(25:24:1, PCI) extraction, each pool of digested DNA fragments was subjected to 
homopolymeric dC-tailing in 40 μl reactions containing 0.2 mM dCTP, 10 mM Tris-
Cl (pH 8.4), 25 mM KCl and 1.25 mM MgCl2 and 38.4 U of TdT for 1 h at 37°C. 
Only “ 3’ overhang cutters” were used as TdT tends to extend more readily from 3’ 
overhangs than from 5’ overhangs or flushed double-stranded DNA ends. The poly 
(dC) tail serves as a priming site for the anchored adapter primer, ANC1 (5’-
GAGGTCGACGGGIIGGGIIGGGIIGH-3’), which contains doublets of deoxyinosine 
residues (I) to prevent the formation of strong G-C clamps when anealed to the poly 
(dC) stretch.  
Hemi-nested PCR was performed with aliquots of each pool of DNA fragment 
using the Expand™ Long Template PCR System (Roche) with ANC1 and gene-
specific primers (Table 2.1). One μl (~40 ng) of genomic DNA was used for primary 
PCR. An initial denaturation step at 94°C for 2 min was followed by an extension at 
68°C for 15 min to generate the second strand of template DNA. Cycling conditions 
for primary PCR were: 25 cycles of 94°C for 20 sec, annealing for 30 sec, 68°C for 8 
min followed by a final extension at 68°C for 10 min. From 25 µl of primary 
amplified product, 1 µl was used as template for secondary PCR. Cycling parameters 
for secondary PCR were essentially the same as for primary PCR except that initial 
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 denaturation was reduced to 1 min. The annealing temperature during cycling was set 
according to the calculated Tm of the gene-specific primer used. Amplified fragments 
were checked and identified by gel electrophoresis of the PCR product. The distinct 
bands on gel were then cloned into pGEM-T vector and sequenced to identify clones 
that contain the 5’ flanking region of the four genes aforementioned. The promoter 
fragments carrying the putative 5’ promoter sequences were subsequently cloned into 
pEGFP-1 and pGL3Basic vector for transient expression studies in cell lines and 
zebrafish embryos. 
Table 2.1 Primers designed for the isolation of 5’ flanking promoter of the following 
steroidogenic genes by genome walking. 
cyp11a1 zfP450SCCr2 5’ CCATAATTCGGTGGACATTCCTG 3’ 
 zfP450SCCr3 5’ TGAAGGCAAGGACACTGAGCAG 3’ 
star zfStARr3 5'- CTGTCATATTTCTCATGTGTCTG -3' 
 zfStARr4 5'- GTCTGTAAGAAATGCCAGCACAC -3' 
cyp17 zfP450C17r2 5’ ATCTCCTTCGCATGATGGTGG 3’ 
 zfP450C17r3 5’ CACCAGGCTCAGCAGACTCC 3’ 
3β-hsd zf3bHSDr1 5’ TGATGGCGTCACGTGTTGTCG 3’ 
 zf3bHSDr2 5’ GATTCGAGACAATGCGGTGTC 3’ 
 
 
2.5 Bioinformatic analysis of transcription factor binding sites 
Genomic sequences were searched for putative transcription factor binding 
sites using the MatInspector program (Cartharius et al., 2005) at the online genomatix 
server http://www.genomatix.de/. Analyses of sequences were performed against the 
MatInspector library of transcription factor binding sites (TFBSs) weight matrices 
(version 6.0 or 7.1). Matrix group selected includes general core promoter elements 
and vertebrates. Matrix filter was set to include all tissue associations. Only binding 
sites that showed a matrix similarity score of > 0.90 were considered significant. A 
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 perfect match to the matrix was assigned 1.00 (each sequence position corresponds to 
the highest conserved nucleotide at that position in the matrix). Putative 
transcriptional cis-elements that might play a regulatory role were then presented as a 
schematic diagram.  
2.6 Preparation of electrocompetent bacterial cells 
 
DH10B strain of E. coli bacterial cells were inoculated into 10 ml of LB media 
alone or supplemented with the necessary antibiotics for plasmid and/or BAC 
selection. Culture was grown at 37 °C with vigorous shaking at 250 rpm overnight 
until OD600 reaches 1.2 – 1.8 the next morning. For bacterial cells harboring the 
pRed/ET plasmid, culture was grown at 30°C. The overnight culture was then diluted 
with ~200 ml of fresh LB media (pre-warmed to room temperature, RT) so that the 
OD600 of the fresh culture reads ~0.1. The fresh culture was incubated at 37°C or 30°C 
with vigorous shaking for 2 – 3 h until OD600 reaches 0.35 – 0.45.  The growth of 
culture was monitored for OD600 with spectrophotometer at every 30 min. In the case 
where the bacterial cells will be used for homologous recombination, 8 ml of 10% L-
arabinose was added to the culture at the beginning of incubation and the temperature 
was adjusted from 30°C to 37°C when OD600 reaches ~0.2. The final culture at log 
phase (OD600 = 0.35-0.45) was then chilled in ice water bath for 20-30 min with 
occasional swirling.  
The chilled culture was centrifuged at 5,000 rpm for 15 min at 4°C to harvest 
bacterial cells. The cell pellet was subsequently rinsed with 200 ml of ice-cold sterile 
MQ water followed by 100 ml and 20 ml of ice-cold 10% glycerol. The cell pellet was 
thoroughly resuspended in the rinsing solution by pipetting up and down prior to 
every centrifugation using serological pipette. Following the final wash with 10 % 
glycerol, the bacterial pellet was resuspended in 500 μl of 10 % glycerol by gentle 
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 swirling. The OD600 of bacterial cell suspension was measured at 1:100 dilution using 
spectrophotometer. Each 1.0 OD600 corresponds to 2.5 X 108 cells/ml. The bacterial 
cell suspension was then adjusted to a final concentration of 2 to 3 X 1010 cells/ml and 
aliquoted (50 μl each) into sterile and pre-chilled microfuge tubes. Finally, the cells 
were snap-freezed in liquid nitrogen and stored at -80°C until use. 
2.7 Transformation of E. coli bacteria 
Supercoiled plasmid DNA was transformed into E. coli bacteria by chemical 
method. For each transformation, 100 μl of thawed DH10B or DH5α competent cells 
was added into a microfuge tube containing ~10 ng of plasmid DNA and mixed by 
tapping. The mixture was left on ice for 20 – 30 min after which heat shock treatment 
was performed for 5 min at 37°C. The tube was immediately placed back on ice, 
followed by the addition of 1 ml of LB media. The bacterial culture was then 
incubated at 37°C for 1 h with shaking at 200 rpm for recovery of the competent cells. 
The appropriate amount (~50 μl) of transformation mix was then plated onto selective 
LB agar plates with antibiotics and incubated for 16 – 20 hr at 37°C. 
Electroporation was adopted for transformation of linear DNA fragments (for 
homologous recombination), BAC plasmids, mutagenized and freshly ligated plasmid 
DNA into E. coli bacteria. DH10B electrocompetent cells was thawed on ice and 
mixed with 1 – 3 μl of DNA construct to be transformed. The mixture was left on ice 
for 2 – 3 min while the Gene Pulser (Bio-Rad) was set to a capacitance of 25 μFarad, 
pulse controller to 200 ohms, and voltage to 1.8 kV. The mixture was then transferred 
from microfuge tube to a fresh pre-chilled 0.1 cm cuvette (Bio-Rad) and pulsed in the 
electroporation chamber so that the time constant reads 4 – 5 msec. Cells were 
allowed to recover in 1 ml of LB or SOC at 37°C with gentle shaking at 200 rpm for 
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 45 – 70 min. The appropriate amount (usually 100 μl) of transformation mix was then 
plated onto selective LB agar plates with antibiotics and incubated for 16-20 h at 37°C. 
2.8 Red/ET homologous recombination 
Red/ET recombination, also referred to as λ-mediated recombination, relies on 
homologous recombination in vivo in E. coli bacteria. The recombineering process is 
catalyzed by a pair of phage-derived proteins RecE and RecT that have been placed 
under L-arabinose induction and require a temperature shift from 30°C to 37°C for 
homologous recombination to take place (Zhang et al., 1998). In the presence of the 
recombination proteins, homologous recombination between a linear DNA molecule 
(e.g. a PCR product) and a circular DNA (plasmid, BAC, or E. coli chromosome) can 
occur with as little as 42 bp homologous sequence. This exchange of genetic material 
between two DNA molecules in a precise, specific, and accurate manner has opened 
up a wide range of modifications (insertions, deletions, point mutations, fragment 
exchanges) of DNA molecules of any size and at any chosen position. In this study, 
various BAC constructs were modified by DNA engineering based on homologous 
recombination. The desired modifications were introduced using the Counter-
Selection BAC Modification kit from Gene Bridges (Dresden, Germany).  
2.8.1 Insertion of an EGFP-Kanr cassette into ff1bBAC2 
An EGFP-Kanr was designed to be inserted into nucleotide 338 within codon 
25 in Exon 2 of ff1b so that the resultant EGFP expression was regulated by the 
endogenous ff1b locus. The EGFP-Kanr donor fragment was generated by PCR 
amplification with primers ff1bEx2EGFPKan/4170F (5'-ACGGTGATGGACTTCA 
GAGC-3') and ff1bEx2EGFPKan/6457R (5'-ACTGATGTGAGTATTCGCAGC-3') 
from pUC18Ff1bEx2EGFPKan (-NotI) containing genomic sequences of ff1b 
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 flanking the EGFP-Kanr selectable marker (Fig. 2.1). The original Not I restriction site 
located between EGFP and Kanr coding sequences was removed by restriction 
digestion with Not I followed by Klenow fill-in and ligation. The removal of the 
internal Not I site was necessary to enable the release of the whole genomic insert 
emcompassing ff1b locus from the pBeloBAC-11 vector backbone for stable 
transgenesis studies following successful recombination. The size of this DNA donor 
fragment (2288 bp) was checked by gel electrophoresis. This linear DNA fragment 
was subsequently purified through Qiagen gel extraction column and DNA 
concentration was measured by Nanodrop spectrophotometer.   
 
Figure 2.1 Schematic diagram representing pUC18Ff1bEx2EGFPKan (-NotI) as 
template for PCR amplification of donor fragment ff1bEx2EGFPKan. Positions 
of primers used to generate the donor fragment were indicated by black arrows. Sizes 
of ff1b genomic sequences flanking the insertion site in Exon 2 were indicated by Ex2 
5’ and 3’.   
 
 
Concurrently, bacterial cells were prepared to undergo homologous 
recombination with the above donor fragment. The BACff1b2 plasmid carrying ~100 
kb of zebrafish genomic sequence encompassing ff1b locus (Chai, 2002) was first 
transformed into DH10B electrocompetent cells by electroporation (Section 2.6). The 
pRed/ET plasmid, which encodes the phage-derived proteins RecE and RecT that 
catalyze homologous recombination, was then transformed into the bacterial cells 
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 harboring the BAC plasmid by a modified electroporation protocol in the manual 
(Genebridges). Briefly, bacteria containing the BACff1b2 plasmid was grown in 1 ml 
of LB medium supplemented with chloramphenicol (15 μg/ml) in a 1.5 ml 
microcentrifuge tube at 37°C with 16 hr vigorous shaking (1000 rpm) using a table-
top thermomixer (Eppendorf). The next day, a microcentrifuge tube containing fresh 
1.4 ml LB medium supplemented with chloamphenicol were set up with 30 μl of 
overnight culture. This diluted culture was then grown for 2 – 3 h at 37°C with 
shaking at 1000 rpm in a table-top thermo-mixer (Eppendorf). Cells were then 
centrifuged for 30 sec at 11,000 rpm in a chilled microfuge benchtop centrifuge at 2°C. 
The cell pellet was washed twice with 1 ml of chilled sterile MQ water after which the 
final pellet was resuspended in ~30 μl of water remaining in the microcentrifuge tube. 
The cell suspension was mixed with 1 μl (20 ng) of pRed/ET plasmid on ice and 
electroporation was carried out as described in Section 2.6. Transformed bacteria were 
grown on LB agar plates supplemented with chloramphenicol (15 μg/ml) and 
tetracycline (3 μg/ml) selecting for BACff1b2 and pRed/ET plasmid, respectively at 
30°C. Incubation was carried out in dark as tetracycline is light sensitive. Furthermore, 
as pRed/ET is a derivative of a termo-sensitive pSC101 replicon(Miller et al., 1995), 
the incubation temperature was maintained at 30°C.    
Following the transformation of pRed/ET plasmid, the bacteria were now 
ready to undergo homologous recombination with the linear donor Ex2EGFPKan 
fragment. The bacteria were made electro-competent as described in section 2.11 prior 
to electroporation. Subsequently, 150 – 250 ng of Ex2EGFPKan donor fragment was 
electroporated into 50 μl of electrocompetent DH10B cells (3x1010cells/ml) 
containing BACff1b2 and pRed/ET plasmids. The transformation mixture was plated 
onto LB agar plates supplemented with chloramphenicol (15 μg/ml) and kanamycin 
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 (15 μg/ml) to select for bacterial cells that had the EGFP-Kan cassette successfully 
inserted into the BACff1b2 plasmid by homologous recombination. To screen for the 
successfully recombined clones, 10 – 20 colonies were subjected to colony PCR using 
primers spanning the insertion junction (one primer within the Kan CDS and the other 
located ~100 bp 3’ to the donor fragment).  
Subsequently, large-scale BAC plasmid isolation was carried out using 
QIAGEN Plasmid Endofree Maxi Kit (Section 2.1) from bacterial clone that showed 
positive results in colony PCR screening. The insertion was verified by DNA 
sequencing and the BACff1b2 that had the EGFP-Kanr cassette successfully inserted 
into Exon 2 was named pBACff1bEx2EGFPKan.  
2.8.2 Truncations of specific genomic regions from pBACff1bEx2EGFPAmp by 
counter-selection strategy 
 
When it was not desirable to leave a selectable marker (e.g. kanamycin) at the 
recombination site, i.e. truncation of specific genomic sequences from the above 
recombined BAC plasmid, a two-step recombineering strategy termed counter-
selection was employed. To begin, PCR product containing rpsL-neo counter 
selection cassette flanked by homology arms targeting the site to be truncated were 
electroporated into the L-arabinose-induced bacteria (Fig. 2.2). This selection cassette 
was inserted into the BAC at the first recombination step and the resulting recombined 
plasmid can be retrieved by kanamycin resistance selection. In the second step, the 
induced cells were electroporated with PCR product containing a non-selectable 
marker i.e. only the right and left homology arms from the first step. As the E. coli 
DH10B strain carries a mutation in the rpsL gene, it is streptomycin-resistant. The 
removal of rpsL-neo cassette together with the replacement of non-selectable DNA 
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 can be identified by streptomycin resistance selection, as the rpsL gene renders the 
bacteria streptomycin sensitivity in the first step of recombination. 
 
                       
 
Figure 2.2 Schematic representation of modification of BAC-of-interest by 
homologous recombination based on counter-selection method. The pRed/ET 
plasmid is first transformed into the E. coli host that carries the BAC to be modified. 
The expression of genes mediating Red/ET recombination is induced by adding L-
arabinose and a temperature shift from 30°C to 37 °C. Following induction, PCR 
product containing rpsL-neo counter selection cassette flanked by homology arms are 
electroporated into the bacteria. This selection cassette is inserted into the BAC at the 
first recombination step and can be retrieved by kanamycin resistance selection. In the 
second step, the induced cells are electroporated with PCR product containing the 
non-selectable marker (non-sm), which can either be just an oligonucleotide harboring 
the right and the left homology arms of the selection cassette and a point mutation 
(control reaction) or a gene flanked by homology arms. The removal of rpsL-neo 
cassette together with the replacement of non-selectable DNA can be identified by 
streptomycin resistance selection, as the rpsL gene renders the bacteria streptomycin 
sensitivity after the first step of recombination.   
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2.8.2.1 Replacement of Kan resistant gene with an Amp resistant gene 
 
As the pBACff1bEx2EGFPKan BAC palsmid (Section 2.8.1) carries a 
kanamycin resistance gene, it is not suitable to be used in counter-selection scheme, 
which requires a kanamycin selection to identify successful recombination in the first 
step. Therefore, a replacement of the kanamycin resistance gene with ampicilin 
resistance gene was carried out by Red/ET recombination by a protocol that is 
essentially the same as that described in Section 2.8.1. 
The β-lactase (Amp) gene flanked by right and left homology arms targeting 
the immediate 60 bp upstream and downstream of kanamycin CDS in 
pBBff1bEx2EGFPKan was generated by PCR amplification using the Advantage2 





with sequences in italic denoting priming sites in β-lactase (Amp) gene. The resulting 
recombined BAC plasmid, with the ampicilin resistance gene replacing the original 
kanamycin resistance gene, was named pBACff1bEx2EGFPAmp. The BAC plasmid 
was now ready to go through any modification by the two-step counter selection 
method.  
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 2.8.2.2 Truncations of specific genomic regions from pBACff1bEx2EGFPAmp 
 
To carry out the first step of recombination, various rpsL-neo fragments 
carrying homology arms (60 bp for each side) targeting sites to be truncated in 
pBACff1bEx2EGFPAmp were generated by PCR amplification using the long PCR 
primers listed in Table 2.2. All long primers (80 bp) were synthesized by Sigma-
Proligo (Singapore). These linear DNA fragments (~1.4 kb) generated by PCR were 
gel-purified and ~150 – 250 ng of DNA was electroporated into electrocompetent 
DH10B bacteria carrying the pBACff1bEx2EGFPAmp and pRed/ET plasmids. 
Bacterial cells that had the rpsL-neo selectable marker inserted into the target sites, in 
replacement of the genomic region that had been truncated, were identified by 
kanamycin selection. Bacterial clones that had successfully undergone homologous 
recombination were verified by colony PCR screening. Ten to 20 bacterial colonies 
were selected and individually lysed in PCR water by heating at 95°C for 10 min. The 
resultant lysate was used as DNA template in PCR reactions with primers spanning 
the insertion site. The forward primer (RpsLneo843F: 5’CCGAGAAAGTATCCATC 
ATGG 3’ lied within the neo CDS and the reverse primer was designed to be located 
~100 – 150 bp downstream of rpsL-neo donor fragment. Sequences of reverse primers 
that were used to check for successful integration of rpsL-neo cassette at targeted 
genomic regions are listed in Table 2.4. 
To complete the second step of recombination, long primers (120 bp) spanning 
just the right and left homology arms (Table 2.3) of the first set of primers (for rpsL-
neo amplification) were synthesized and annealed. Annealing was done by heating 
both forward and reverse oligonucleotides (1:1 mixture) to 100ºC for 5 min and 
cooling the mixture down in an insulated box left at RT overnight.  
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Table 2.2 Long primers used in the first recombination step of counter-selection to 






name Primer sequence (80 bp each, 5’ to 3’) 
5’10kb 5’10kb RpsLneoF 
ATACCATATTTGCAAGATTAATGACCTACAACAATGAAGGTGG
AAATGAAGGCCAGTCGCGGCCTGGTGATGATGGCGGGATCG  
 5’10kb RpsLneoR 
TTAATCATTACTGACCCTGCTGAAAAATCCAGCTTAAACCAGC
CTAGGATGGTTAGCTGGTCAGAAGAACTCGTCAAGAAGGCG  
5’20kb 5’20kb RpsLneoF 
ATACCATATTTGCAAGATTAATGACCTACAACAATGAAGGTGG
AAATGAAGGCCAGTCGCGGCCTGGTGATGATGGCGGGATCG’ 
 5’20kb RpsLneoR 
TTCATTCCGCTGTGGCGACCCCAGATTAATAAAGGGACTAAGC
CGACAAGAAAATGAATGTCAGAAGAACTCGTCAAGAAGGCG  
Intron I Int1Del RpsLneoF 
AACATCTCTAGCCTTATTATTTTAATACGCATCATTTTAGTGTG
ACACTTTAATATTGAGGGCCTGGTGATGATGGCGGGATCG  
 Int1Del RpsLneoR 
ATCTCCACACACCGGGCAAAGCTCCTCCAAATCCTCATCTGCT
CTGAAGTCCATCACCGTTCAGAAGAACTCGTCAAGAAGGCG  
Intron II Int2Del RpsLneoF 
TTGGTTGTAACACTGGCAGAGCATTACGCTAGCGGCTTTCTGA
CCTGCGAAAGTTGTAAGGGCCTGGTGATGATGGCGGGATCG’ 
 Int2Del RpsLneoR 
GTCCTGGTTCTGTGTGCACGTGTATCTCTTGTTATTCTGAACTG
TCCTCTTGAAAAAACCTCAGAAGAACTCGTCAAGAAGGCG  
Intron III Int3Del RpsLneoF 
GGAAAAGATGTCCGTTCTGCCGCTTCCAGAAGTGTCTGAGTGT
CGGCATGAGACTTGAGGGGCCTGGTGATGATGGCGGGATCG’ 
 Int3Del RpsLneoR 
CTCGCTTGTACATTGGGCCAAACTTATTTCTTCCACCTCTCATC
CGGTCTGCACGCACAGTCAGAAGAACTCGTCAAGAAGGCG  
Intron IV Int4Del RpsLneoF 
CCGCCGCTGGTGCTGGAGCTGCAGAGCTGCGACCCAGATGAG
GAGCAGGTATGAAGCAAAGGCCTGGTGATGATGGCGGGATCG  
 Int4Del RpsLneoR 
CTCCAGCTTTCCTCTGCCGCTCTGCTCCTGGTGGAGATACGCGC
AGATCTTTCCTCTCACTCAGAAGAACTCGTCAAGAAGGCG  
Intron V Int5Del RpsLneoF 
GACGCTCTTCTCTATCGTGGAGTGGGCGAGAAGCTGTGTCTTC
TTCAAGGAACTAAAGGTGGCCTGGTGATGATGGCGGGATCG  
 Int5Del RpsLneoR 
ATGTGATCCAGAAGCAGCAGCTCGCTCCAGCAGTTATGCAGCA
GACGCATCTGATCGCCCTCAGAAGAACTCGTCAAGAAGGCG  
Intron VI Int6Del RpsLneoF 
ATCTGCAGACAGGTGCATCATGGGAGAGACGGCAGCCTGCTG
CTCATCACAGGACAGGAGGGCCTGGTGATGATGGCGGGATCG  













# Oligonucleotide sequences in italic denote primer sequence that annealed to the 
rpsL-neo DNA template during PCR amplification.  
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 Table 2.3 Long primers used in the second recombination step of counter-selection to 





















































































 Table 2.4 Primer sequences used to check for successful recombination in two-step 
counter selection to delete specific genomic regions. 
Region to be 
deleted Primer name 
Length 
(bp) Primer sequences (5’ to 3’) 
5’10kb 5’10kbChkF 21 GACCTACAACAATGAAGGTGG 
 5’10kbChkR 23 GCGCTTTTACAATGTAGATTGTG 
5’20kb 5’20kb ChkF 21 GACCTACAACAATGAAGGTGG 
 5’20kb ChkR 23 AGACGCTCAGATATTTCCCAGAG
Intron I Int1DelChkF 21 CACGTCCATATAGGAGGCTTG 
 Int1DelChkR 21 AGCGTAATGATAACCGGACAC 
Intron II Int2DelChkF 20 CACGACATTCAACCTACCCC 
 Int2DelChkR 21 TCCTCTGAGTTTTGTCGATGC 
Intron III Int3DelChkF 21 GCATCGACAAAACTCAGAGGA 
 Int3DelChkR 20 GAGCCGTAATTCTGCAGAGC 
Intron IV Int4DelChkF 20 CAGTGTCCCCATAAACCCTG 
 Int4DelChkR 22 GAGCCGTACCTTTAGTTCCTTG 
Intron V Int5DelChkF 20 CTTCAGCCTGCTGTGTGTCA 
 Int5DelChkR 20 CATGATGCACCTGTCTGCAG 
Intron VI Int6DelChkF 20 CTGCAGACAGGTGCATCATG 
 Int6DelChkR 21 GGATGAGGAACTTCAGACAGG 
Intron VII Int7DelChkF 20 CAGGTGGACAGCAGAGAGAT 
 Int7DelChkR 20 TCTCGATCAGCAGGTTGTTG 
 
The annealed oligonucleotides were subsequently used as the donor DNA 
fragment in the second step of counter-selection where ~150 – 250 ng of annealed 
oligonucleotides were electroporated into electrocompetent bacteria harboring the 
respective recombined BAC plasmid constructs from the first recombination and 
pRed/ET plasmid. For instance, annealed Int1DelF and Int1DelR primers were 
electroporated into bacterial cells containing pBACff1bEx2EGFPAmp plasmid 
having ff1b Intron I replaced by the rpsL-neo selectable marker in the first 
recombination step of counter-selection. As an example, Intron I was eventually 
truncated without leaving a selectable marker when the rpsL-neo cassette was 
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 replaced by the Int1Del oligonucleotides in the second recombination step. Bacterial 
cells that had successfully undergone this second step of recombination could be 
retrieved by streptomycin (50 μg/ml) selection. Positive clones were confirmed by 
colony PCR as described for the first recombination step. The reverse primers used to 
screen for positive clones were essentially the same as the first recombination step 
while the forward primers were as listed in Table 2.4. 
2.9 Tissue culture 
The mouse Y1 adrenocortical cells obtained from the American Type Culture 
Collection (ATCC) were maintained in Ham’s F12K medium supplemented with 10% 
horse serum (HS) and 2.5% fetal bovine serum (FBS). Chinese hamster ovary cells 
(CHO-K1; ATCC) were maintained in Ham’s F12K medium supplemented with 10% 
FBS. The mouse LβT2 gonadotrope cells (a kind gift from Dr. P. Mellon, UCSD) 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% FBS, 2 mM L-glutamine, and 1 mM sodium pyruvate. The mouse MA-10 
Leydig tumor cells (a kind gift from Dr. Martin Lee, Department of Physiology, NUS) 
were maintained in Waymouth’s medium supplemented with 15% HS and 25 mM 
Hepes (pH 7.4). The human 293T kidney cells were maintained RPMI medium 
supplemented with 10% FBS. The human HepG2 hepatoma cells were maintained in 
DMEM supplemented with 10 % FBS.  
All cell lines were maintained at 37ºC in 5% CO2 with penicillin (100 U/ml) 
and streptomycin (100 µg/ml) added into the culture media. All basal media were 
purchased from Gibco, Invitrogen. Cells were routinely grown to 80-90% confluency 
prior to seeding for transfections or passages. For passages, media was removed from 
monolayer cells and cells were washed once with 1X PBS. Monolayer cells were then 
treated with 2 – 3 ml of 0.25 % trypsin-EDTA at RT for 3 min after which 8 – 9 ml of 
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 media (with serum) was added to inhibit trypsin. Cells were routinely passaged at a 
ratio of 1:4 to 1:6.   
2.10 Transient transfection 
On the day before transfection, cells were seeded in 24-well tissue culture plates 
at a density of 0.8 – 1.5 x 105 cells per well so that cells were 60-80 % confluent by 
the time of transfection. All transfections were carried out using Fugene 6 transfection 
reagent (Roche, Switzerland) except for MA-10 cells, which were transfected using 
Lipofectamine 2000 transfection reagent (Invitrogen) following the manufacturer’s 
protocol with optimization of plsmid: transfection reagent ration. When Fugene 6 
transfection reagent was used, 0.4 µg of each luciferase reporter plasmid, 2 ng of 
pRL-SV40 (as a transfection efficiency control), and 0.6 µl of Fugene 6 transfection 
reagent were added into each well. When Lipofectamine 2000 was used, 0.8 µg of 
each luciferase reporter plasmid, 2 ng of pRL-SV40, and 4 μl of Lipofectamine 2000 
transfection reagent were added into each well. Cells were harvested at 24 h following 
transfection and lysed in 1× passive lysis buffer provided in the Dual Luciferase 
reporter assay system (Promega) for dual-luciferase assay. 
2.11 Dual-Luciferase assay 
The dual-luciferase assay was carried out using reagents and experimental 
protocol provided by the manufacturer of Dual-Luciferase Reporter Assay System 
(Promega). For transfected cells, media was removed and cells were washed with 1X 
PBS, after which 100 μl of 1X passive lysis buffer was added into each well of 24-
well tissue culture plate. The cells were left to lyse at RT for 15 min with gentle 
shaking (~50 rpm) and the lysed cells were kept on ice thereafter until luciferase 
measurement was completed. For microinjected embryos, 50 embryos were 
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 dechorionated manually and homogenized in 100 μl of 1X passive lysis buffer by 
pippeting up and down until no big clumps of tissues were visible. Lysis was left to 
proceed on ice for 10 – 15 min and the samples were kept on ice until luciferase 
measurement is completed.  
The LAR II and Stop & Glo® reagents required for the dual-luciferase assay 
were warmed up to RT at least 30 min before measurement. To start measuring 
luciferase activity, 20 μl of homogenate from transfected cells or microinjected 
zebrafish embryos was transferred into a borosilicate glass tube (12 x 75 mm; Fisher-
Scientific) that fits perfectly into the measurement chamber of the Lumat LB9507 
luminometer (Berthold, Australia). One hundred μl of LARII mixture was added into 
the homogenate and firefly luciferase activity was assayed over a 10 sec measurement 
period. The glass tube was quickly taken out from the luminometer and 100 μl of Stop 
& Glo® after which the Renilla luciferase activity was measured. The firefly 
luciferase activity of a particular luciferase construct was normalized by the Renilla 
luciferase activity conferred by the pRL-SV40 construct. Data are presented as the 
mean ± SD (standard deviation) of the average of four independent transfections, 
which were repeated at least once to ascertain the reproducibility of the data. 
2.12 Immunoblot detection of biotin-labeled Ff1b produced by coupled in vitro 
transcription and translation 
 
Ff1b protein was produced in vitro using the TNT® T7 quick coupled 
transcription/translation system (Promega) for electrophoretic mobility shift assay.  
To verify the identity of the Ff1b protein (~50 kDa) produced by this method, the 
translated proteins were biotinylated, separated on PAGE gel, and subsequently 
detected by chemi-luminescence using the Transcend™ Non-Radioactive Translation 
Detection System (Promega).  
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 To set up the in vitro transcription/translation reaction, 40 μl of TNT® quick 
master mix, 1 μl of methionine (1 mM),  1 μl of TranscendTM biotin-lysyl-tRNA, and 
1 μl of DNA template pCDNA3.1ff1b (1 μg/μl) were mixed thoroughly in a PCR tube. 
Reaction volume was adjusted to a final volume of 50 μl with sterile MQ water after 
which incubation was carried out in a PCR machine at 30ºC for 90 min. A negative 
control reaction was set up by replacing the pCDNA3.1ff1b template with empty 
pCDNA3.1 vector. After incubation, a 1 μl aliquot was removed and mixed with 11 μl 
1X SDS sample buffer and the mixture was heated at 70ºC for 15 min to denature the 
proteins. The denatured samples were subjected to SDS-PAGE in a 10% PAGE gel 
after which the gel was equilibrated in Towbin transfer buffer (2.5 mM Tris, 19.2 M 
glycine, 0.1% SDS, 20% methanol) for 20 min at RT. Concurrently, PVDF membrane 
(Bio-Rad) was activated by submerging in methanol for 2 – 3 sec and equilibrated in 
Towbin transfer buffer for 20 min at RT.   
Proteins were transferred to a PVDF membrane using the Trans-blot Semy-dry 
apparatus (Bio-Rad) at 15 V for 20 min. Blocking was carried out by incubating the 
membrane in 1X Tris-buffered Saline with Tween-20 (TBST; 150 mM NaCl, 0.1% 
Tween-20, 10 mM Tris-Cl, pH7.4) with gentle shaking (~50 rpm) for 1 hr at RT. 
After blocking, the PVDF membrane was incubated in 1:7500 dilution of 
Streptavidin-Horse Radish Peroxidase (Streptavidin-HRP; Pierce, IL, USA) with 
gentle shaking for 1 hr at RT. This was followed by 3 x 5 min washes with 1X TBST 
and another 3 x 5 min washes with sterile MQ water. The membrane was immersed in 
substrate solution, which is composed of stable peroxide buffer and luminol/enhancer 
solution (SuperSignal West Pico Chemiluminescent substrate, Pierce) for 1 – 2 min. 
Finally, chemiluminescence from the biotin-labeled Ff1b protein was detected by 
exposing the PVDF membrane to Fuji X-ray film for 1 min in dark. 
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 2.13 Electro-mobility shift assays (EMSA) 
Electrophoretic mobility shift assays (EMSA) were performed using the 
LightShift Chemiluminescent EMSA kit (Pierce). Oligonucleotides containing the 
putative cyp11a1 distal (FREd) and proximal (FREp) FREs and the mutated versions 
of each FRE (Table 2.3) was synthesized and labeled with biotin using the biotin 3’ 
end DNA labeling kit (Pierce). Core regconition sequences of FREs are underlined 
and mutated residues were highlighted in bold. For each labeling reaction, 50 nmol of 
single-stranded oligonucleotides was labeled at their 3’ end with biotin-11-UTP. The 
labeled oligonucleotides were subjected to chloroform extraction and complementary 
oligonucleotides at equal amount were annealed. Annealing was done by heating each 
pair of oligonucleotides to 100ºC in water bath in a 2 L beaker for 5 min and cooling 
down to RT slowly in an insulated box overnight. 
 
Table 2.5 Ftz-f1 response elements (FREs) mapped in the zebrafish cyp11a1 
promoter analyzed by electrophoretic mobility shift assay. 
 zsccFREdF  5'-GTTGACCTTGGGAAAAGTAAATG-3' 
Distal FRE 
 zsccFREdR  5'-CATTTACTTTTCCCAAGGTCAAC-3' 
zsccFREdMutF  5'-GTTGACCTCGGTGAAAGTAAATG-3' Mutated distal 
FRE zsccFREdMutR  5'-CATTTACTTTCACCGAGGTCAAC-3' 
 zsccFREpF  5'-GTAGTTCATTGTCCTTGACCTGTG-3' 
Proximal FRE 
 zsccFREpR  5'-CACAGGTCAAGGACAATGAACTAC-3' 
zsccFREpMutF  5'-GTAGTTCATTCACCGTGACCTGTG-3' Mutated 
proximal FRE zsccFREpMutR  5'-CACAGGTCACGGTGAATGAACTAC-3' 
# Core recognition sequences of FREs are underlined and mutated residues were 
highlighted in bold. 
 
Ff1b protein was produced by in vitro transcription and translation from 
pcDNA3.1ff1b (Liu et al., 2003) using the TNT® T7 quick coupled 
transcription/translation system (Promega). The identity of Ff1b protein produced by 
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 this method was verified as described in Section 2.12. For each binding reaction, 8 µl 
of the in vitro translated mixture of Ff1b was mixed with 1 µg of Poly dI·dC and 20 
fmol of the corresponding biotin-labeled DNA probes in 1x binding buffer (10 mM 
Tris, pH7.5; 100 mM KCl; 1 mM DTT) with a total reaction volume of 20 µl. 
Reactions were carried out at 25ºC for 20 min. Unbound labeled DNA was separated 
from protein-DNA complexes by electrophoresis at 100 V in a 5 % acrylamide-0.5% 
Tris-bovate-EDTA (TBE) gel for approximately 45 min, transferred onto a zeta-probe 
membrane (Bio-Rad) by electroblotting, and UV cross-linked. Chemi-luminescence 
from the biotin-labeled DNA bands was detected by exposing the zeta-probe 
membrane (Bio-Rad) to Fuji X-ray film for 3 – 5 sec in dark. 
2.14 Development of Ff1b polyclonal antibodies 
A polyclonal antibody for Ff1b was raised against amino acid residues 234-
248 (CAYLHQEQSGRGKLE) of Ff1b protein, which corresponds to the N-terminus 
of ligand binding domain (Fig. 2.3) by Biogenes (Gmbh). This epitope was selected 
based on the likelihood of antigenicity based on computational analysis using the 
program Antheprot (Release 5). This peptide sequence was compared to the other Ff1 
proteins of zebrafish and a BLAST search was performed against the NCBI protein 
database to ensure that cross-reactivity to other zebrafish proteins is minimal. 
 
 
Figure 2.3 Location of epitope chosen for the generation of Ff1b polyclonal 
antibody. An epitope spanning 15 amino acid residues of Ff1b at the N-terminal 
region of ligand binding domain was chosen for the generation of custom-raised 
polyclonal antibody in rabbit. The residues are highlighted in purple and the 
alignment with the other three Ff1 isoforms at the corresponding region is shown. 
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 The 15-residues peptide was synthesized by Biogenes and the resultant peptide 
was conjugated to the carrier protein LPH to ensure the immunogenicity of the 
peptide. According to the immunization protocol of Biogenes, pre-immune serum was 
collected from two rabbits (#1659 and #1660) on day 0. Immunization of the rabbits 
was carried out over a period of two months on day 7, 14, 28, and 56. Bleeding of the 
immunized rabbits was performed on day 35 and 63 and the polyclonal antibodies 
produced were delivered as crude antiserum. The reactivity of the antibody produced 
was tested by Western blot and a clear band corresponding to the size of Ff1b (~50 
kDa) was detected in ovary protein extract from an adult zebrafish female. The 
antiserum produced from rabbit #1660 gave rise to a stronger band as compared to 
that from rabbit #1659, and thus, the #1660 antiserum of Ff1b was subsequently used 
for chromatin immunoprecipitation (ChIP) assays.   
2.15 Chromatin Immunoprecipitation (ChIP) 
ChIP assays were carried out using the ChIP assay kit (Upstate). For every 
ChIP assay, ~1 X 106 of cells was needed and this was estimated to be ~25 mg of 
ovary tissues by a cell count using hemocytometer. To begin, ovary tissues were 
freshly extracted from a zebrafish female adult and ~25 mg was placed into each 1.5 
ml microcentrifuge tube for each ChIP assay. The ovary tissue was briefly 
homogenized in 1X PBS using a telfon pestle that was fitted to the 1.5ml 
microcentrifuge tube until no big clump of tissue was visible. The homogenate was 
subsequently treated with 1% formaldehyde for 15 min on a nutator at RT. Following 
the cross-linking of DNA/protein, cells were pelleted by centrifugation at 2000 rpm 
for 4 min at 4ºC. The cell pellet was then washed twice with chilled 1 x PBS 
supplemented with a cocktail of protease inhibitor (1 mM PMSF, 1 μg/ml aprotinin, 
and 1 μg/ml pepstatin A). The washed cell pellet was resuspended in 200 μl of SDS 
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 Lysis Buffer (1% SDS, 10 mM EDTA, 50 M Tris, pH 8.1) followed by 10 min 
incubation on ice. Lysate was subjected to sonication to shear DNA to length between 
200 and 800 bp. Using a Vibra Cell sonicator VC505 equipped with a 3 mm tip and 
set to 20% of the maximum amplitude (100 V), 14 x 10-sec pulses, separated by a 4 
min interval, were shown to be the optimal condition for this amount of ovary lysate.  
 Sonicated samples were centrifuged for 10 min at 13,000 rpm in a 1.5 ml 
microcentrifuge tube at 4ºC, and the supernatant was transferred (~200 μl each) into a 
new 2 ml tube. One tenth of the sonicated supernatant was kept at -20°C and used as 
positive control for PCR analysis later on. The remaining cell supernatant was then 
diluted 10-fold with ChIP Dilution Buffer (0.01 % SDS, 1.1 % Triton X-100, 1.2 mM 
EDTA, 167 mM NaCl, 16.7 mM Tris-HCl, pH 8.1). 
To reduce non-specific background, the diluted cell supernatant was pre-
cleared with 75 μl of Protein A agarose/salmon sperm DNA (50% slurry) for 30 min 
at 4°C on a nutator. The 50% slurry of Protein A agarose/salmon sperm DNA was 
provided by the ChIP assay kit as 1.5 ml packed beads containing 600 μg of sonicated 
salmon sperm DNA, 1.5 mg of BSA and ~4.5 mg of recombinant protein A 
resuspended in TE buffer, pH 8.0, containing 0.05 % of sodium azide to a final volum 
of 3 ml. Agarose was pelleted by centrifugation at 1,000 rpm at 4°C for 1 min after 
which the supernatant was transferred to a fresh 2 ml tube. Twenty μl of 
immunoprecipitating antibody (Ff1b antiserum) was added into each tube and 
incubated overnight at 4°C on a nutator. As a negative control, immunoprecipitation 
was always performed with the same amount of pre-immune serum in parallel.  
The next day, 60 μl of protein A agarose/salmon sperm DNA (50% slurry) was 
added into each tube and incubated for 1 hr at 4°C on a nutator. Agarose was pelleted 
by centrifugation at 1,000 rpm at 4°C for 1 min. The supernatant was carefully 
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 removed and discarded. The agarose beads were then washed with 1 ml of each of the 
following buffers sequentially (provided as part of the ChIP assay kit). Each washing 
was carried out for 4 min at 4°C with shaking on a nutator.   
i) Low Salt Immune Complex Wash Buffer (0.1% SDS, 1% Triton X-100, 2 
mM EDTA, 150 mM NaCl, 20 mM Tris-HCl; pH 8.1) 
 
ii) High Salt Immune Complex Wash buffer (0.1 % SDS, 1% Triton X-100, 2 
mM EDTA,  500 mM NaCl, 20 mM Tris-HCl; pH 8.1) 
 
iii) LiCl Immune Complex Wash Buffer (0.25 M LiCl, 1% IGEPAL-CA630, 
1% deoxycholic acid sodium salt, 1 mM EDTA, 10 mM Tris; pH 8.1) 
 
iv) TE Buffer (1 mM EDTA, 10 mM Tris-HCl; pH 8.0), twice 
 
The histone complexes were eluted from antiserum by adding 250 μl of elution 
buffer into each tube. Elution buffer was prepared fresh by mixing an equal volume of 
2% SDS with 0.2 M NaHCO3. Samples were tapped briefly and incubated at RT for 
15 min on a nutator with gentle shaking. The agarose beads were spun down as above 
and the eluates were transferred and pooled into a new 1.5 ml microcentrifuge tube for 
each sample. Elution was repeated one more time to produce ~500 μl of eluates in 
total for each ChIP sample. To reverse cross linking, 20 μl of 5M NaCl was added 
into each eluate and heated at 65°C in a heat block for 4 h. Cross linking reversal was 
also done on input samples where 1 μl of 5 M NaCl was added for each 20 μl of input 
sample. If necessary, samples were stored at -20°C. 
Following the cross-linking reversal, 10 μl of 0.5 M EDTA, 20 μl of 1 M Trsi-
HCl (pH 6.5), and 2 μl of 10 mg/ml Proteinase K were added to each eluate and 
incubated for 1 hr at 45°C in a heat block. DNA was then recovered by PCI extraction 
using heavy phase lock gel (1.5 ml, Eppendorf) and ethanol precipitation. Briefly, 
equal volume of eluate and PCI (25:24:1) solution (~500 μl each) was mixed in each 
of the 1.5 ml phase lock gel tube with vigorous shaking for ~1 min. The mixtures 
were then spun at 13,000 rpm, RT, for 5 min to separate the organic and aqueous 
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 phases. The upper aqueous phase was transferred into a fresh 2 ml microcentrifuge 
tube. One μl of glycogen (Roche, 20 mg/ml) was added into each ChIPed sample or 
0.3 μl for the input sample prior to ethanol precipitation to increase the visibility of 
the small DNA pellet. Subsequently, 2.5 volume (1250 μl) of chilled absolute ethano 
was added and DNA was allowed to precipitate at -20 °C for 2 hr to overnight. 
Precipitated DNA was then spun down at 14,000 rpm, 15 min at 4°C. The visible 
DNA pellet was then washed with 1 ml of chilled 70% ethanol and the final pellet was 
air-dried for about 10 min at RT, and resuspended in 20 μl of MQ water. 
The immunoprecipitated DNA samples were analyzed for enrichment in the 
genomic region of interest by PCR analyses. Standard PCR reactions were set up 
using Promega GoTaq® polymerase system with primers targeting FREd and FREp 
regions within cyp11a1 promoter. As negative control, a pair of primers targeting the 
keratin8 promoter region, where FRE is absent, was included. About 3 – 5 μl of DNA 
was used for each 20 μl PCR reaction. Cycling parameters were 95 °C for 5 min and 
30 cycles of 95°C for 30 sec, 56°C for 30 sec, 72°C for 1 min followed by a final 
elongation step at 72°C for 10 min. Ten μl of each PCR product was checked using 
1.2% TAE gel with the 100 bp DNA ladder to determine the sizes of amplicon. 
2.16 General maintenance of zebrafish 
Fish stocks were maintained in the S2-L2 aquarium facility of the Department 
of Biological Sciences, National University of Singapore. Embryos were obtained by 
natural spawning and cultured in egg water medium at 28.5°C (Westerfield, 2000). 
Egg water is composed of instant ocean sea salt (60 μg/ml) and methylene blue (30 
μg/ml). Staging of embryos was carried out according to Kimmel et al., (1995). 
Embryos meant for histological analysis were treated with 0.03% phenylthiourea 
(Sigma, MO, USA) from ~10 hpf, to inhibit melanin pigment formation (Karlsson et 
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 al., 2001). Feeding was initiated for larva at 4 – 5 dpf with larval diet (Aquatic Eco-
systems Inc, FL, USA). At about 8 – 10 dpf, artemia feeding was initiated. Up to 50 
larvae were maintained in a 1 L tank until they were 3 – 4 weeks old. The juvenile 
fishes were eventually transferred and maintained in 2.5 L tanks in the AHAB 
aquarium system. No more than 25 adult fishes were kept in one 2.5 L tank at a time.  
2.17 Generation of the ff1bEx2EGFP stable transgenic zebrafish line 
The ff1bEx2EGFP transgenic line was generated using DNA insert released 
from BAC plasmid pBACff1bEx2EGFPKan by Not I digestion. This insert 
encompasses ~100 kb of zebrafish genomic sequences including the ff1b locus (~25 
kb) with the EGFP-Kanr cassette inserted into Exon 2 of ff1b by homologous 
recombination (Section 2.8.1). To generate a linear DNA fragment from 
pBACff1bEx2EGFPKan, 20 – 30 μg of BAC plasmid was digested by Not I 
restriction enzyme at 37°C overnight. The digested DNA was purified by PCI 
extraction using heavy phase lock gel (1.5 ml, Eppendorf) and ethanol precipitation. 
Briefly, equal volume of phenol: chloroform: isoamyl (25: 24: 1) was added into the 
overnight digestion mixture in a 1.5 ml microcentrifuge tube containing 300 μl of 
phase lock gel. The tube was sealed with parafilm and shaked on a rocking platform at 
RT for 30 min. The aqueous and organic phase was separated by centrifugation at 
13,000 rpm for 5 min at RT. The upper phase was transferred to a fresh 1.5 ml tube 
and DNA was precipitated with an equal volume of isopropanol. The mixture was 
inverted for about 10 times to thoroughly mix and immediately centrifuged at 13,000 
rpm for 15 min at 4°C. The DNA pellet was washed twice with 70 % ice-cold ethanol 
and the DNA pellet was finally resuspended in an appropriate volume of 1X TE 
buffer (~50 μl).  
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 For microinjection, the purified pBACff1bEx2EGFPKan/NotI fragment was 
diluted to a final concentration of 50 ng/μl in 1x Danieau’s buffer containing 0.05% 
phenol red. About 4.6 nl of this injection solution was microinjected into the animal 
pole of wild-type zebrafish embryos at one-cell stage. At 36 to 48 hpf, injected 
embryos were screened for GFP fluorescence. Only those embryos carrying strong 
GFP signal in ff1b-expressing tissues (interrenal and VMH) were selected and 
maintained to adulthood. When fishes reached adult stage (3-4 months), they were 
inter-bred to screen for positive founder that could give rise to progeny showing GFP 
expression at the above tissues. F1 progeny was grown up to adulthood and out-
crossed with wild-type zebrafish to produce F2 progeny. The F2 progeny and 
subsequent generations were in-crossed among siblings to produce the next 
generation.   
2.18 Microinjection of DNA constructs and morpholinos 
Micropipettes were prepared from 3.5-inches borosilicate glass capillaries with 
an internal diameter of 0.5 mm (WPI, Florida, USA) on a Model PC-10 Micropipette 
puller (Narishige, Tokyo, Japan). Pulled capillaries were cut manually with sterile 
blade under 40X magnification of a Bausch & Lomb dissection microscope at an 
angle of ~45° to produce slanted and sharp tips. Cut capillaries were back-filled with 
mineral oil (Sigma) using a 10 ml syringe fitted with an 18.5 gauge needle. Capillaries 
were placed horizontally upon two rows of blue tack plastic adhesive in 140 mm petri 
dishes for storage prior to use.  
Freshly laid embryos were collected in egg water and transferred onto a 90 mm 
petri dish containing 1.5% agarose with trenches for fitting embryos using a pasteur 
pipette (Westerfield, 2000). Excess water surrounding the embryos was removed by 
aspiration although a small amount of water must be retained to keep the embryos 
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 moist. Microinjection was performed using a Nanoliter 2000 injector (WPI, Florida, 
USA) equipped with a micromanipulator to enable rapid fine insertion and withdrawal 
of the micropipettes during the process of microinjection. The polished borosilicate 
glass capillary was fixed onto the pistol of Nanoliter 2000 injector. Excess mineral oil 
was removed by wiping with paper towel. Mineral oil in the capillary was emptied by 
pushing the ‘Empty’ button until the stainless steel needle in the pistol reached 1/3 of 
the capillary to ensure proper fixation of capillary. The injection solution containing 
DNA or morpholino was back-filled into the capillary by placing the tip of capillary 
into 2 – 3 µl injection solution and pushing the ‘Fill’ button at the same time. After 
microinjection, embryos were cultured in egg water at 28.5°C.  
DNA constructs were microinjected at a concentration of 50 ng/µl in 1X  
Danieu’s buffer (58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM Ca[NO3]2)  
and 0.25% phenol red. About 450 pg (4.6 nl) was delivered by direct injection into the 
animal pole of one-cell stage embryos. For all DNA constructs and morpholinos, the 
injection solution was stored at 4°C for up to a week, after which fresh injection 
solution must be prepared. 
Morpholinos were designed and synthesized by Genetools LLC (OR, USA). A 
stock solution of 2 mM was prepared by dissolving the lyophilized powder in MQ 
water and stored at -80°C. The required injection concentration was diluted from the 
stock solution into 1X Danieau’s buffer containing 0.05% phenol red. Morpholino 
solutions were delivered into the yolk directly underlying the blastodisc. 
Microinjected embryos were maintained in egg water in 100 mm petri dish and no 
more than 100 embryos were allowed in one dish. At about 5 to 6 hours after 
microinjection, dead embryos were removed and egg water was changed every 3 to 4 
days or whenever they turned turbid. At ~30 hpf, morpholino-microinjected embryos 
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 were checked under microscope for non-specific toxic effects including reduction of 
the head and eyes, an amorphous appearance of cells in the body, downward curving 
body axis and edema of the pericardial and yolk sac. Only embryos that showed 
normal phenotype at this stage were allowed to develop further for subsequent 
molecular or histological analyses.  
2.19 Microscopic imaging of EGFP expression in zebrafish embryos and larvae 
EGFP expression in live embryos and larvae (transgenic or plasmid-injected) 
was monitored for UV epifluorescence with a Zeiss Axiovert 25 inverted microscope. 
Embryos or larvae were anaesthetized in 0.001% 2-phenoxyethanol after which they 
were transferred to concave borosilicate glass slides or optical chambers covered with 
borosilicate cover slip of 0.15 mm thickness. To strictly prevent the embryos or larvae 
from moving around, they were embedded in 1.5% agarose at different orientations on 
a concave glass slide prior to microscopic analyses. The fixed embryos or larvae were 
manipulated to different orientations the same way for microscopic analyses.   
Epifluorescence pictures were captured using the Zeiss Axiovert 200M 
microscope with imaging software AxioVision (version 4.3). The illumination of 
EGFP fluorescence was achieved through excitation from a high pressure mercury 
lamp (50-watt, Zeiss) using filter sets 38 of Zeiss (BP 470/40, FT 495, BP 525/50). 
Images were captured with exposure time set automatically. Exposure time normally 
falls into the range of 500 msec to 1 sec and manual adjustment was made whenever 
necessary to achieve the optimal fluorescence. 
 Confocal images were taken using Olympus IX70 microscope equipped with 
FluoView300 imaging software using 488 nm excitation and 510-550 nm band-pass 
filters. Images were captured in Kalman mode (2X) with PMT voltage set to 600 to 
700 V. Gain and Offset were always set as 1.0 to achieve the lowest background noise. 
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 Three dimensional images were always consolidated from serial optical sections, 
which were taken at ~2 or 3 µm intervals using a 10X or 20X Plan-Neofluar objective 
lenses. Raw image collection and processing were performed using the Olympus 
FluoView software (version 1.7a).  
2.20 Cryostat sectioning of transgenic ff1bEx2EGFP zebrafish embryos 
Samples were prepared for cryostat sectioning essentially as described in 
Chapter 8 of the Zebrafish Book (Westerfield, 2000). Sections of 20 µm thickness 
were collected on a Leica CM1900 Cryostat (Leica, Germany). Images of cryo-
sections were captured using the Zeiss Axiovert 200M equipped with imaging 
software AxioVision (version 4.3) or using confocal microscope (Olympus IX70) 
equipped with Olympus FV300 imaging software. 
2.21 Isolation of genomic DNA from zebrafish larvae 
Zebrafish larvae were kept in egg water at 28°C until 7 dpf. Genomic DNA was 
prepared from a single larva (transgenic or wild-type). Each larva was transferred into 
a 1.5 ml microcentrifuge tube and rinsed with 1 ml of sterile MQ water and as much 
as liquid was removed before the addition of 100 μl of gDNA extraction buffer (10 
mM Tris pH8.2, 10 mM EDTA, 200 mM NaCl, 0.5% SDS). Proteinase K and RNase 
A were freshly added into the extraction buffer to a final concentration of 200 μg/ml 
and 100 μg/ml respectively. Samples were incubated in a 55°C incubator with gentle 
shaking for 5 hr after which DNA was precipitated with 0.1 volume of 3 M sodium 
acetate (pH 5.2) and 2.5 volume of ice-cold absolute ethanol. Samples were mixed 
well and incubated at RT for 15 minutes before they were centrifuged at 13,000 rpm 
for 5 minutes. The supernatant was then removed and DNA pellet was rinsed with 
70% ethanol once and centrifuged again. The final DNA pellet was allowed to air dry 
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 after which it was dissolved in 50 μl of 10 mM Tris-HCl buffer. Integrity and quantity 
of the purified DNA was assessed on 0.7% agarose gel and by Nanodrop 
spectrophotometer measurement. About 2 – 3 μl of DNA was used as template in each 
PCR reaction for the detection of transgene or endogenous gene by PCR amplification 
using Promega GoTaq® polymerase.    
2.22 Treatment of zebrafish embryos with aminoglutethimide (AG) 
Crystalline aminoglutethimide (Sigma) was first dissoved in 0.2 N HCl to a 
concentration of 0.2M and then diluted to 1 mM in egg water. The volume of 1M 
HEPES (pH 7.9) required to adjust the 1 mM aminoglutethimide solution to pH 7.4 
was determined as 50 μl for every 30 ml of egg water(Chan and Tan, 1988), and equal 
amount of HEPES was added to other embryos cultures in the same experiment to 
control for any effects that may be caused by HEPES. The final concentration of 
HEPES added was 2.5 nM and did not produce any observable defects in embryos. 
Embryos were treated from 8 hpf onwards till 10 dpf and aminoglutethimide was 
renewed at 5 dpf. For every treatment, about 100 embryos or larvae were maintained 
in 120 ml of egg water in a 250 ml beaker. 
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 CHAPTER 3 
 






Zebrafish ff1b displays remarkable homology to mammalian SF-1 at many 
levels including gene and protein structure, expression profile and gene function (Chai 
and Chan, 2000; Chai, 2002; Chai et al., 2003). Morpholino knockdown of ff1b gene 
function led to the ablation of steroidogenic interrenal cells, as characterized by the 
downregulation of cyp11a1 transcripts and 3β-Hsd enzymatic activity (Chai et al., 
2003; Hsu et al., 2003). Furthermore, ff1b morphants displayed late morphological 
defects that were indicative of diminished osmoregulation, which was most likely 
attributed to corticosteroids deficiency (Chai et al., 2003). This is highly reminiscent 
to the findings from Sf-1 knockout studies in mice where the pups lacked adrenal 
development and died shortly after birth due to glucocorticoid and mineralocorticoid 
deficiency (Luo et al., 1994; Sadovsky et al., 1995; Shinoda et al., 1995). These 
findings point to the conserved roles of Ff1b in the transcriptional regulation of genes 
encoding key steroidogenic enzymes involved in the steroid biosynthesis pathway.  
In mammals, SF-1 has long been established as a key transcriptional regulator 
of genes encoding steroidogenic enzymes. Indeed, SF-1 was initially identified based 
on its ability to bind and activate the gene promoter of steroidogenic enzymes 
CYP11A1, CYP11B1, and CYP21 (Morohashi et al., 1992; Rice et al., 1991). As 
discussed in Section 1.7, SF-1 participates in regulating the expression of almost all 
adrenal and testicular steroidogenic genes including the steroid acute regulatory 
protein StAR, hydroxysteroid dehydrogenases (HSD3B and HSD11B), and those 
encoding P450 cytochrome enzymes in the P450 family (CYP11A1, CYP11B1, 
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 CYP17 and CYP21). In most of these studies, the transcriptional regulatory effect of 
SF-1 on steroidogenic genes was demonstrated by transient transfection studies and a 
majority of them focus on CYP11A1 gene promoter, which is by far the best 
characterized gene promoter regulated by SF-1, especially with regard to its 
responsiveness to cAMP induction (Ahlgren et al., 1999; Chen and Guo, 2000; Guo et 
al., 1994; Guo et al., 2007a; Lan et al., 2007; Pestell et al., 1993; Sher et al., 2007; 
Watanabe et al., 1994). This is not surprising because CYP11A1 encodes the very first 
enzyme that catalyses the first, rate-limiting step in steroidogenesis and is known to 
be highly conserved throughout vertebrate evolution (Norris, 2006). 
In view of the apparent conservation of the major steroidogenic pathway between 
mammals and teleosts (Hsu et al., 2006; Hu et al., 2001a), it is reasonable to postulate 
that Ff1b is responsible for regulating the steroid hydroxylases in zebrafish. The effect 
of Ff1b transcriptional activity on the putative target promoter of steroidogenic genes, 
however, had not been dissected before this study was conducted. The isolation of 
gene promoters that are responsive to Ff1b transcriptional activity would aid our 
understanding of how Ff1b regulate its target genes and also in ascertaining its 
functional analogy to its mammalian counterpart, SF-1, in the regulation of 
steroidogenesis. 
On this basis, we isolated the 5’ upstream flanking sequence of several zebrafish 
steroidogenic genes, namely cyp11a1, star, cyp17, and 3β-hsd, which could 
potentially be regulated by Ff1b. By computational analysis, cis-acting regulatory 
elements that could potentially regulate the expression of these genes were identified. 
Importantly, putative FREs have been mapped at the promoter of cyp11a1, cyp17, and 
star. Transgenesis studies in zebrafish embryos and transient transfection studies in 
Y1 cells established the 1.7 kb zebrafish cyp11a1 promoter as a functional promoter 
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 and it was subsequently used to dissect the regulatory functions of FREs and Ff1b. 
The functions of the two FRE mapped in the cyp11a1 promoter were examined 
closely by a series of deletion and mutagenesis studies in Y1 cells. Subsequent 
characterization by EMSA and ChIP assay demonstrated that Ff1b bound both FREs, 
and the binding to the distal FRE seemed to be stronger than that of proximal FRE. 
These combined approaches have established Ff1b as the central regulator of the basal 
transcriptional activity of the 1.7 kb cyp11a1 promoter. These data present the first 
experimental evidence showing the transcriptional regulatory effect of Ff1b on the 
expression of steroidogenic enzymes, and thus, steroidogenesis in zebrafish.  
 
3.2 The isolation and analyses of gene promoters potentially regulated by Ff1b  
 
As the zebrafish genome database was not yet available back when this study 
was initiated, the 5’ promoter region of cyp11a1 was isolated by a modified genome 
walking method. Gene-specific primers were also designed to isolate the 5’ upstream 
promoter of three other steroidogenic enzyme genes, namely cyp17, star, and 3β-hsd. 
The transcriptional regulation of these four genes was expected to be highly important, 
as they encode enzymes sitting on the top of steroidogenesis pathway. They are 
abundantly expressed in all steroidogenic tissues and their expression levels are likely 
to be higher than those enzymes catalyzing the peripheral reactions in the same 
pathway because they are required for the synthesis of all classes of steroid hormones 
(Payne and Hales, 2004; Sewer et al., 2007). The 5’ upstream promoter fragments of 
these steroidogenic genes at various lengths were cloned into pGEM-T vector and 
sequenced, after which the sequences were computationally analyzed for transcription 
factor binding sites (TFBSs). Subsequently, the transcriptional activities of these 
promoter fragments were assessed experimentally in zebrafish embryos and Y1 
adrenocortical cell line.  
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3.2.1 In silico identification of Ftz-F1 response elements in the 5’ putative 
promoter of steroidogenic enzyme genes 
 
Sequencing data of the four putative 5’ promoters for cyp11a1, cyp17, star, 
and 3β-hsd showed that the isolated sequences span 1735, 2676, 1262, and 1233 bp, 
respectively. The sequences were subsequently compared to the zebrafish genome 
database at Ensembl Genome browser (http://www.ensembl.org/Danio_rerio/Info/ 
Index), which became available online as this study was ongoing. The genomic 
sequences of the above four genes were mapped to the 5’ promoter of gene entry 
ENSDARG00000002347, ENSDARG00000006137, ENSDARG00000033566, and 
ENSDARG00000019747, respectively, at the Ensembl database.  
The 5’ upstream putative promoter sequences (upstream of the predicted 
transcription start site, TSS +1) were then analyzed bioinformatically for TFBS using 
the Genomatix MatInspector server online at http://www.genomatix.de/ (Cartharius et 
al., 2005). The resulting matches for TFBSs were saved in Microsoft Excel format 
and analyzed manually for binding sites that are potentially relevant to the regulation 
of steroidogenic genes. Only TFBSs that showed a matrix similarity score of >0.90 
were considered significant. A perfect match to the matrix would be assigned a score 
of 1.00 (each sequence position corresponds to the highest conserved nucleotide at 
that position in the matrix). 
When screening the TFBSs predicted by MatInspector, attention was paid 
particularly to binding sites predicted for Vertebrate Steroidogenic Factor, which 
include LRH-1 and SF-1, with consensus sequence CAAGgtca, where nucleotide in 
capital letters denotes the core sequence used by MatInspector. It has been shown 
previously that Ff1b binds to the same consensus site as SF-1 and LRH-1 (Liu et al., 
2003) and these binding sites are termed Ftz-F1 response element (FRE) throughout 
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 this study. Besides FRE, cis-elements that have previously been implicated in the 
transcriptional regulation of steroidogenic genes including cAMP responsive element 
(CRE) and binding sites for Sp1, AP-1, and Nuclear Factor-1 (NF-1) have also been 
highlighted (Chou et al., 1996; Guo et al., 2003; Watanabe et al., 1994). In addition, 
binding sites of transcription factors or coregulators that have been previously shown 
to interact physically with SF-1 in mediating its transcriptional activity such as SOX 
factors, GATA factors, WT1 were highlighted (De Santa et al., 1998; Nachtigal et al., 
1998; Shi et al., 2008; Tremblay and Viger, 1999). These matches were manually 
translated into schematic diagram that shows the relative positions of each cis-element 
drawn to scale (Fig 3.1).  
Notably, at least one FRE (except for 3β-hsd) was predicted in each of the four 
promoters analyzed (Fig. 3.1). For cyp11a1 and cyp17, two putative FREs were 
mapped at locations proximal (within 100 bp) and distal (-1500 to -1000 bp) to the 
predicted TSS. The star promoter contains only one FRE at -661 to -648 while the 3β-
hsd promoter contains no FRE. In all four promoters, binding sites for GATA factors, 
SOX factors, WT1, Sp1, and AP-1 that could potentially interact with Ff1b to 
modulate its transcriptional activity were identified at several locations. Among these 
factors, Sp1 and AP-1 have been implicated in the transcriptional activation of human 
CYP11A1 promoter (Guo et al., 2007b). In addition, three CREs were predicted in all 
four promoters indicating that they could potentially respond to cAMP, which serves 
as an important messenger in modulating the regulation of steroid synthesis. Lastly, 
motifs for NF-1, which has been implicated in the transcriptional regulation of human 
steroidogenic genes (Chou et al., 1996), were also identified in the putative promoter 
regions of cyp17 and 3β-hsd.  
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Figure 3.1 Identification of cis-elements that could potentially regulate the expression of zebrafish steroidogenic genes, including 
cyp11a1, star, cyp17, and 3β-hsd. The 5’ promoter sequences of the above four zebrafish genes spanning 1735, 2676, 1262, and 1233 bp 
respectively were extracted from Ensembl genome browser in silico. Binding sites of the transcription factors indicated were predicted using the 
web-based MatInspector program. Only binding sites for transcription factors that have previously been implicated in the transcriptional 
regulation of steroidogenic gene promoter or in SF-1 transcriptional activity were shown. The location of TATA boxes predicted in proximity to 
the predicted transcription start site +1 were shown in asterisk (*).  
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 Taken together, in silico analysis of the putative gene promoters of cyp11a1, 
star, cyp17, and 3β-hsd revealed important cis – acting elements that could potentially 
regulate their expression. The cyp11a1 and cyp17 promoter stand out among the four 
promoters, as both of them possess two FREs providing a promising site of regulation 
for Ff1b. 
 
3.2.2 Assessment of promoter activity by transient transgenesis in zebrafish 
embryos 
 
To determine whether these promoters could drive the expression of EGFP 
reporter gene specifically to steroidogenic tissues, the promoter regions of cyp11a1, 
star, cyp17, and 3β-hsd were subcloned from pGEM-T vector into pEGFP-1 vector. 
The resulting EGFP expression constructs were then microinjected into zebrafish 
embryos at 1-2 cell stage and the embryos were monitored for EGFP expression at 
early developmental stages from 32 hpf to 3 dpf. Observation from the microinjection 
experiment is summarized in Table 3.1.  
 
Table 3.1 The 1.7 kb cyp11a1 promoter drives tissue-specific expression in zebrafish 
embryos. 
Gene Source of genomic library 
Length of putative 
promoter isolated 
Site of EGFP expression in 
zebrafish embryos 
cyp11a1 Sph I 1735 bp Interrenal and genital ridge 
star Nsi I 1262 bp No expression 
cyp17 Sph I 2676 bp No expression 
3β-hsd Sph I 1233 bp No expression 
 
Out of the four promoters studied, only the 1.7 kb promoter of cyp11a1 
specifically expressed EGFP in the interrenal and genital ridge from ~32 hpf onwards 
(Fig. 3.2). The percentage of fluorescent embryos was, however, only ~10-15% (n = 
358) indicating that the promoter activity is not at its full complement. Nevertheless, 
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 the 5’ putative promoter of cyp11a1 stands out as the best target promoter candidate for 
characterization in relation to Ff1b transcriptional activity, as it drives the expression of 
EGFP reporter genes specifically to the tissues (interrenal and genital ridge) where 
Ff1b is endogenously expressed. This met our original intention to study the gene 





Figure 3.2 The 1.7 kb zebrafish cyp11a1 promoter targets EGFP specifically to the 
steroidogenic tissues, the interrenal and genital ridge, at early stages of 
development. The 1.7 kb zebrafish cyp11a1 promoter was cloned into pEGFP-1 vector 
and microinjected into zebrafish embryos at 1-2 cell stage. Injected embryos were 
monitored for EGFP expression from 32 hpf onwards until 3 dpf. Scale bar, 100 µm. 







3.2.3 Assessment of promoter activity by transient transfections in Y1 
adrenocortical cells 
 
Following the initial assessment of promoter activity in zebrafish embryos, the 
promoter fragments were concomitantly cloned into pGL3Basic luciferase reporter 
vector for transient expression studies in Y1 adrenocortical cells, which endogenously 
express SF-1 (Rainey et al., 2004). These plasmids containing the corresponding 
promoter fragments upstream to the luciferase reporter gene were transiently 
transfected into Y1 cells after which cells were harvested for dual-luciferase assay. In 
agreement with the observations from microinjection experiment, only the 1.7 kb 
cyp11a1 promoter was able to activate the luciferase reporter to a level that was ~12-
fold of the promoterless pGL3Basic vector (Fig. 3.3). It is intriguing that the other three 
gene promoters were not functional in Y1 cells despite the fact that two out of three 
promoter possess at least one FRE. This might be due to the presence of repressor 
element or the absence of crucial cis-elements that are required to activate transcription 
from the three promoter. Collectively, the transient transgenesis in zebrafish embryos 
and transient transfection studies in Y1 demonstrated the functionality of the 1.7 kb 
cyp11a1 promoter of zebrafish. Subsequent molecular characterization with regard to 
Ff1b transcriptional activity focused on this 5’ promoter region of cyp11a1.  
 
3.3 Comparison of cis-elements in the 1.7 kb promoter of zebrafish cyp11a1 to its 
counterpart in other species 
 
The 1.7 kb putative promoter sequence of cyp11a1 matches database location 
158,905-160637, Contig AL929050.6 of chromosome 25 at the Ensembl genome 
browser of zebrafish (Zv 7, 2007). When 2 kb of zebrafish cyp11a1 5’ flanking 
sequence was compared to the green spotted pufferfish Tetraodon nigroviridis, mouse, 
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 and human cyp11a1, with regard to the cis-elements predicted by MatInspector, 
conserved modules of binding sites for transcription factors SF-1, GATA factors, AP-1, 





Figure 3.3 Evaluation of promoter activity of zebrafish cyp11a1, star, cyp17, and 
3β-hsd in Y1 adrenocortical cells. The four putative promoters were cloned upstream 
to luciferase in pGL3Basic vector and transfected into Y1 adrenocortical cells. Renilla 
luciferase expression vector, pRL-SV40, was co-transfected for normalization of 
transfection efficiency. Data are expressed as fold activation above the normalized 
luciferase activity measured from cells transfected with promoterless pGL3Basic vector 
(adjusted to 1-fold) in one representative experiment, and represent the mean of 













Figure 3.4 Conservation of cis-elements predicted in the 5’ flanking promoter 
region of zebrafish cyp11a1 in comparison to the equivalent 2 kb region in the 
gene promoter of Tetraodon, human, and mouse. Binding sites of the transcription 
factors indicated were predicted using the web-based MatInspector program. Only 
binding sites for transcription factors that have previously been implicated in the 
transcriptional regulation of CYP11A1 promoter or in SF-1 transcriptional activity were 
shown. The conserved elements are indicated by different shapes in different colours. 
The location of TATA boxes identified in proximity to the transcription start site +1 are 
indicated by asterisk (*).  
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 At least two cAMP response element (CRE) were identified in the 5’ promoter 
of all species. There are at least two FREs within the 5’ promoter region and the 
location of these binding sites is highly conserved across zebrafish, human, and mouse. 
In this study, two putative FREs that have been predicted within the 1.7 kb promoter 
are designated proximal FRE (FREp) at -68/-56 bp and distal FRE (FREd) at -1484/-
1472 bp relative to the predicted TSS +1. Two TATA boxes have been identified 
upstream (-116/-100) and downstream (-43/-27) to the FREp but the actual TSS has yet 
to be determined experimentally. Collectively, the in silico comparison of the of 
zebrafish cyp11a1 promoter to human, mouse, and tetraodon pufferfish revealed highly 
conserved cis-elements that are likely to play a role in modulating their expression. 
Most importantly, locations of FREs mapped are highly conserved across different 
species indicating their crucial roles in mediating the regulation of the cyp11a1 gene. 
 
 
3.4 Activity of the zebrafish 1.7 kb cyp11a1 promoter in comparison to its human 
counterparts   
 
Considering the high degree of conservation between the human and zebrafish 
cyp11a1 promoter, we wanted to find out whether the two promoters exhibit similar 
niche of activity. The human promoter has been well characterized in terms of the 
functional importance of the two FREs and the minimal length required to recapitulate 
the endogenous CYP11A1 expression (Guo et al., 1994; Hu et al., 2001b). In a 
transgenic mouse study, it has been reported that the 4.4-, 2.3-, and 1.7 kb promoter of 
human CYP11A1 could drive lacZ reporter expression specifically to the adrenal and 
gonads (Hu et al., 1999; Hu et al., 2001b). It would be interesting to look at the activity 
of the 1.7 kb human promoter in comparison to the zebrafish promoter by trangenesis 
studies in zebrafish embryos and different mammalian cell lines of steroidogenic and 
non-steroidogenic origins.  
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 3.4.1 Assessment of promoter activity and responsiveness to ff1b overexpression in 
zebrafish embryos 
 
The human CYP11A1 promoter spanning 4.4-, 2.3-, and 1.7 kb (kind gift from 
Prof. B.C. Chung, Academia Sinicia, Taiwan) that have been shown previously to drive 
tissue-specific expression of lacZ in transgenic mice were cloned into pEGFP-1 vector 
and microinjected into zebrafish embryos. Since the zebrafish and human promoters 
contain highly conserved cis-regulatory elements, it is reasonable to hypothesize that 
they would display similar level and niche of activity. To our surprise, none of the 
human promoter fragments were able to target EGFP expression specifically to 
steroidogenic tissues in zebrafish embryos. Observation for tissue-specific EGFP 
expression was initiated from 24 hpf onwards until 10 dpf and no trace of EGFP 
expression was seen at all. 
To quantify the promoter activity and to evaluate their responsiveness to ff1b 
overexpression in zebrafish, the above promoter fragments were cloned into 
pGL3Basic vector and the resulting human or zebrafish cyp11a1-luc reporter plasmids 
were microinjected into zebrafish embryos for transactivation assay as described 
previously (Liu et al., 2003). While the microinjection of various cyp11a1-luc plasmids 
measured the intrinsic promoter activity, the co-injection of these promoter constructs 
with overexpression plasmid of ff1b measured their responsiveness to Ff1b 
transcriptional activity. Since ff1b is not expressed maternally and its zygotic 
expression initiates only after 20 hpf, zebrafish embryos provide a good in vivo context 
for evaluating the effects of Ff1b transcriptional activity on these promoter. In all 
microinjection experiments, plasmid pRL-SV40 was co-injected to allow for 
normalization of luciferase activity. The embryos were harvested and homogenized for 
luciferase assay at 14 hpf.  
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Figure 3.5 Overexpression of ff1b potentiates the transcriptional activity of 
zebrafish cyp11a1 promoter. Embryos at one- to two-cell stage were injected with the 
promoterless pGL3Basic (pGL3B) or plasmids containing human CYP11A1 promoter 
spanning 4.4-, 2.3-, and 1.7 kb (Hs4.4, Hs2.3, and Hs1.7) or the 1.7 kb zebrafish 
cyp11a1 promoter (Dr1.7) with (closed bar) or without (open bar) the overexpression of 
ff1b from pCDNAff1b plasmid. pRL-CMV was included as a normalization control for 
firefly luciferase activity. Embryos (n = 25) were harvested at 14 hpf, and dual-
luciferase assays were performed. Data are expressed as normalized luciferase activity 
measured from one representative microinjection experiment ± SEM (n = 4). 
 
 
In accordance with the observation from EGFP construct injection, the three 
fragments of human CYP11A1 promoter (4.4-, 2.3-, and 1.7 kb) were unable to activate 
luciferase reporter gene in zebrafish embryos even with the concomitant 
overexpression of ff1b (Fig. 3.5). On the other hand, the 1.7 kb promoter of zebrafish 
cyp11a1 was activated to a level that was 5.6-fold (13.24 RLU) as compared to that of 
empty pGL3Basic vector (2.36 RLU). When the ff1b overexpression plasmid 
pcDNA3.1ff1b was co-injected, the promoter activity was enhanced to ~20-fold above 
the basal level or 3.6-fold of the luciferase activity measured from cyp11a1-luc alone. 
These data provided the first in vivo evidence of Ff1b potentiating the transcriptional 
activation of the zebrafish cyp11a1 promoter. The above findings collectively indicate 
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 that the 1.7 kb cyp11a1 promoter of zebrafish and human display distinct functional 
discrepancy despite the mapping of highly conserved cis-elements within the two 
promoter. 
 
3.4.2 Promoter activity of the human and zebrafish 1.7 kb cyp11a1 promoter in 
steroidogenic and non-steroidogenic mammalian cell lines 
 
To assess the role of this 1.7 kb putative promoter of zebrafish cyp11a1 in cell 
lineage selectivity, we evaluated the expression of luciferase reporter gene directed by 
this promoter in comparison to its human equivalent in different lineages of cell lines in 
vitro. These include steroidogenic cell lines, Y1 (adrenocortical cells), MA-10 (testis 
Leydig cells), and CHO-K1 (Chinese hamster ovary), as well as non-steroidogenic cell 
lines, 293T (embryonic kidney cells), LβT2 (pituitary gonadotrope cells), and HepG2 
(liver carcinoma cells). The 1.7 kb human promoter was expected to be active in some 
of these cell lines, especially those of human or rodent origin and steroidogenic 
including Y1, MA-10, and CHO-K1, which express SF-1 endogenously.  
As shown earlier, the 1.7 kb promoter of zebrafish cyp11a1 was able to activate 
the luciferase reporter gene by 12-fold in Y1 cells (Fig. 3.3). The human 1.7 kb 
promoter was activated to a higher level, ~21-fold of basal level, in Y1 cells (Fig. 3.6). 
In CHO-K1 and MA-10 cells, the luciferase activity was increased by 4.5-fold and 6.7-
fold for zebrafish promoter (Dr 1.7 kb) while the human 1.7 kb promoter (Hs 1.7 kb) 
again to a higher level (18.5-fold and 7.8-fold). Similarly in LβT2 cells, the zebrafish 
and human 1.7 kb promoter activated the luciferase reporter to 3.5-fold and 11.3-fold of 
basal level, respectively. Both promoters were, however, not active in HepG2 liver 
carcinoma cells. Intriguingly, the luciferase activity was activated to 18-fold by 
zebrafish promoter and to 11.6-fold by human promoter in the non-steroidogenic 293T 




Figure 3.6 Promoter activity of the 1.7 kb cyp11a1 promoter of zebrafish and 
human in different lineages of cell lines. The 1.7 kb cyp11a1 promoter of zebrafish 
(Dr 1.7 kb) or human (Hs 1.7 kb) was cloned upstream to luciferase in pGL3-Basic 
vector and transfected into Y1 adrenocortical cells, MA-10 Leydig cells, CHO-K1 
ovary cells, LβT2 gonadotrope cells, HepG2 hepatoma cells, and 293T embryonic 
kidney cells. Renilla luciferase expression vector, pRL-SV40, was co-transfected for 
normalization of transfection efficiency. Data are expressed as fold activation above the 
normalized luciferase activity measured from cells transfected with promoterless 
pGL3Basic vector (adjusted to 1-fold) from one representative experiment, and 




In summary, the above findings indicate that the 1.7 kb promoter of both the 
human and zebrafish cyp11a1 contains regulatory elements controlling the activation of 
cyp11a1 gene in different lineages of mammalian cells. Despite the demonstration of its 
transcriptional activity in transgenic mouse previously, the human CYP11A1 promoter 
was inactive in zebrafish embryos, highlighting the possible functional difference 







3.5 Truncation analysis of the 1.7 kb zebrafish cyp11a1 promoter 
 
The subsequent transient transfection studies on the zebrafish promoter were 
performed in Y1 adrenocortical cells, as adrenal cortex represents one of the major 
tissues where cyp11a1 is endogenously expressed and, thus, should provide the best 
cellular niche for the investigation of cyp11a1 promoter activity. To determine the 
minimal length of the zebrafish cyp11a1 promoter required for its basal activity and to 
look at the effect of deleting the distal FRE in this promoter, the promoter 
characterization began with a series of truncations on the original 1.7 kb promoter of 
zebrafish cyp11a1. Various 5’ truncated fragments of the 1.7 kb promoter were 
generated by PCR and cloned into pGL3Basic vector for the assessment of their 
promoter activity. Truncation of the zebrafish cyp11a1 promoter to 1 kb did not affect 
the reporter gene activity significantly (Fig. 3.7). Even when the distal binding site of 
Ff1b was deleted in both the 1.5 kb and 1 kb promoter fragment, the luciferase activity 
derived from them was comparable to that of the original 1.7 kb fragment. The 
luciferase activity was reduced to ~45% of 1.7 kb fragment when the promoter was 
truncated down to 500 bp. Nevertheless, residual luciferase activity indicates that the 
500 bp promoter was still functional, probably due to the presence of an intact binding 
site of Ff1b proximally to the start codon. Taken together, these results indicate that 1 
kb of the cyp11a1 promoter is sufficient to drive the basal promoter activity and that 
the distal FRE is dispensable for basal promoter activity.  
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Figure 3.7 The distal FRE is dispensable for the basal promoter activity of 
zebrafish 1.7 kb cyp11a1 promoter. The 1.7 kb promoter of cyp11a1 and various 
truncated versions were cloned into pGL3Basic and transfected into Y1 cells for 
quantification of promoter activity. The relative positions and nucleotide sequences of 
distal FRE (FREd) and proximal FRE (FREp) are indicated. Renilla luciferase 
expression vector, pRL-SV40, was co-transfected for normalization of transfection 
efficiency. Data are expressed as normalized luciferase activity in relative light unit 
from one representative experiment, and represent the mean of luciferase activity ± 
SEM (n = 4). 
 
3.6 Mutagenesis of the two FREs in the 1.7 kb zebrafish cyp11a1 promoter  
 
 To further explore the function of the two FREs in the 1.7 kb cyp11a1 
promoter, the FREd and FREp were mutagenized either individually or both together 
by site-directed mutagenesis. The mutagenesis was introduced in reminiscent of that 
reported for FREs in human CYP11A1 promoter where it has been demonstrated to 
markedly reduce SF-1 binding and CYP11A1 promoter activity (Hsu et al., 2004; Hu et 
al., 2001b). For the zebrafish cyp11a1 promoter, the third nucleotide (T) within the 
core recognition sequences was mutagenized into C and two nucleotides downstream to 
the core recognition sequences (GA) were mutagenized into TG (Fig. 3.8). As for 
FREp, two nucleotides upstream to the core recognition sequences (GT) were 
mutagenized into CA and the second nucleotide (T) within the core recognition 




Figure 3.8 The proximal FRE is crucial for the activation of the 1.7 kb cyp11a1 
promoter. The two FREs are mutagenized individually or simultaneously in 
pGL3Basic plasmid and the resulting plasmids were transfected into Y1 cells for 
assessment of promoter activity. The relative positions and nucleotide sequences of 
distal FRE (FREd) and proximal FRE (FREp) are indicated with core motif underlined. 
Mutated residues are indicated in lower case. Renilla luciferase expression vector, pRL-
SV40, was co-transfected for normalization of transfection efficiency. Data are 
expressed as normalized luciferase activity in relative light unit from one representative 




Transient transfections into Y1 cells showed that mutagenesis in the FREp 
alone reduced the luciferase activity from 12-fold to 3-fold of basal level while the 
mutagenesis in FREd alone marginally reduced the luciferase activity from 12-fold to 
10.5-fold (Fig. 3.8). The double mutation in both FREp and FREd rendered the 
cyp11a1 promoter completely inactive. The intact FREd or other TFBSs present in the 
FREp mutant may partially compensate the function of FREp. These results 
demonstrate that the proximal and distal FREs do not have the same function in the 
transcriptional activation of the zebrafish cyp11a1 promoter. In agreement with the 
findings from human cyp11a1 promoter, the proximal FRE, which is situated in the 
basal promoter region, is found to be the major regulator for the core promoter activity 
in vitro whereas the function of the distal FRE in basal gene expression is less obvious 
(Hsu et al., 2004; Hu et al., 2001b). 
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 3.7 Ff1b binds to both FREs in vitro 
 
To determine whether Ff1b binds to the two FREs selectively, oligonucleotides 
containing the distal FRE (5’-GTTGACCTTGGGAAAAGTAAATG-3’) and the 
proximal FRE (5’-GTAGTTCATTGTCCTTGACCTGTG-3’) were synthesized, biotin-
labeled, and tested in electrophoretic mobility shift assay (EMSA) for their interaction 
with Ff1b proteins. Ff1b proteins were transcribed and translated in rabbit reticulocyte 
in vitro from the pcDNA3.1ff1b plasmid using the TNT® T7 quick coupled 
transcription/translation system (Promega). The identity of Ff1b, which corresponded 
to a ~50 kDa band in a SDS-PAGE, was verified by biotin-labeling and immuno-
blotting (Fig. 3.9). As expected, the ~50 kDa band did not appear in the negative 
control reaction where the pCDNA3.1 vector was used as template for the 
transcription/translation reaction in vitro. The rabbit reticulocyte containing Ff1b 
proteins was subsequently used for EMSA.  
 
Figure 3.9 Detection of Ff1b protein synthesized from in vitro 
transcription/translation. The plasmid pcDNA3.1 or pcDNA3.1Ff1b was used as 
template for in vitro transcription/translation reaction in rabbit reticulocyte using the 
TNT® T7 quick coupled transcription/translation system (Promega). Newly 
synthesized proteins were biotin-labeled with biotinylated   lysine added to the reaction 
as a precharged, ε-labeled biotinylated lysine-tRNA complex (Transcend™ tRNA; 
Promega). An aliquot (2 µl) of each reaction mixture was separated on SDS-PAGE, 
transferred to PVDF membrane, and the biotinylated proteins were visualized by 
binding Streptavidin-HRP followed by chemiluminescent detection.  
99
 As expected, no band shift was observed when the biotin-labeled 
oligonucleotides were incubated with reaction mixtures using the empty pcDNA3.1 
vector as transcription/translation template (Fig. 3.10, lane 1 and 6). Mobility 
complexes were only observed when the reaction mixtures containing Ff1b proteins 
were used (lane 2 and 7). Ff1b proteins, however, did not bind the mutated version of 
both the biotin-labeled distal and proximal FRE (lane 3 and 8). The Ff1b-FRE 
complexes were effectively competed by 200-fold molar excess of the corresponding 
unlabeled FRE (lane 4 and 9). The same complexes were, however, unaffected by 200-
fold molar excess of the unlabeled mutated FREs (lane 5 and 10). These observations 
demonstrated the specificity of Ff1b binding to both the distal and proximal FREs. 
 
Figure 3.10 Ff1b binds to both the distal and proximal FREs in the 1.7 kb 
zebrafish cyp11a1 promoter in electrophoretic mobility shift assay (EMSA). 
Biotin-labeled wild-type or mutated oligos (30bp) containing the distal (FREd) or 
proximal (FREp) were incubated with rabbit reticulocyte in which empty pcDNA 
vector (Lane 1 and 6) or ff1b overexpression plasmid pcDNA3.1ff1b (Lane 2-5 and 7-
10) was used as template for in vitro transcription and translation. In competition assay, 
~200-fold molar excess of the respective unlabeled FRE (lane 4 and 9) or mutated FRE 





Following the discovery that Ff1b binds to both the distal and proximal FREs, 
the strength of Ff1b binding to the two FREs were studied by competitive binding 
assays. Ff1b binding to biotin-labeled FREd (Fig. 3.11A) and to biotin-labeled FREp 
(Fig. 3.11B) was progressively reduced by increasing concentrations of unlabeled distal 
and proximal FRE at 10-, 50-, 100-, and 200-fold molar excesses. Overall, the binding 
of Ff1b to the FREd seemed to be slightly stronger as the Ff1b-FREd complexes were 
competed more effectively by unlabeled FREd as compared to unlabeled FREp (Fig. 
3.11A).  Similarly, the Ff1b-FREp complexes were competed more effectively by 
unlabeled FREd as compared to unlabeled FREp (Fig. 3.11B). The strength of 
competition seemed to vary slightly with different range of molar ratio. At 10-50 molar 
excess, unlabeled FREp competed more potently than unlabeled FREd. At 100-200 
molar excess, unlabeled FREd was a more potent competitor.The difference in strength 
of binding, was however, only marginal. 
 
In summary, Ff1b binds to both FREs mapped in the 1.7 kb promoter of 
zebrafish cyp11a1 as demonstrated by the EMSA data. The binding of Ff1b to the distal 
FRE seems to be slightly stronger as shown in the competitive binding assay of EMSA. 
These findings, however, have to be verified by more in vivo studies assessing the 












Figure 3.11 Competitive binding of the distal (FREd) and proximal (FREp) FREs 
in electrophoretic mobility shift assay (EMSA). Biotin-labeled FREd (A) or FREp (B) 
oligos (30bp) were incubated with rabbit reticulocyte in which ff1b overexpression 
construct pCDNAff1b was used as template for in vitro transcription and translation. In 
competition assay, ~10-, 50-, 100-, and 200-fold molar excess of the respective 




 3.8 Ff1b binds to both FREs in vivo  
 
To see whether Ff1b binds to the two FREs in vivo, the association of Ff1b with 
cyp11a1 promoter was assessed by ChIP assay. A polyclonal antibody for Ff1b was 
raised against amino acid residues 234-248 (CAYLHQEQSGRGKLE) of Ff1b, which 
corresponds to the N-terminus of ligand binding domain. This custom anti-peptide 
production was carried out in rabbits by Biogenes (Germany) and two animals (#1659 
and #1660) were immunized for each epitope chosen. The activity of the antibody 
produced was assessed by Western blot where a band corresponding to the size of Ff1b 
(~50 kDa) was detected in ovary protein extract from an adult zebrafish female. As the 
Ff1b antiserum from rabbit #1660 gave rise to a stronger signal in Western blot, the 
#1660 antiserum was subsequently used for chromatin immunoprecipitation (ChIP) 






Figure 3.12 Ff1b binds to both the distal and proximal FRE in vivo as shown by 
ChIP. Chromatin was prepared from freshly dissected zebrafish ovary and 
immunoprecipitated with Ff1b antiserum or pre-immume serum (PIS) from the same 
rabbit. DNA extracted from ChIP was analyzed by PCR using primers covering the 
nucleotide positions -1643 and -1475 for FREd, -223 and +26 for FREp, and -471 to -
255 for keratin8 promoter, which does not contain any consensus FRE. 
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 Chromatin was immunoprecipitated by Ff1b antiserum from ovary tissues 
where Ff1b is abundantly expressed (von Hofsten et al., 2005). In agreement with the 
observations in EMSA, Ff1b binds to both FREd and FREp of cyp11a1 promoter in 
vivo as shown by the enrichment of the two promoter regions in PCR analyses 
following ChIP assay (Fig. 3.12). This enrichment did not take place in samples where 
the pre-immune serum (PIS) was used instead of Ff1b antiserum. Likewise, the 
enrichment was not seen on keratin8 promoter where no consensus FRE was identified 
and thus, should not bind Ff1b. This data presented the first experimental evidence of 















 3.9 Summary 
 
A 1.7 kb 5’ upstream promoter of zebrafish cyp11a1 that was responsive to 
Ff1b transcriptional activity was isolated and studied extensively. This promoter 
fragment drived tissue-specific expression of EGFP in the zebrafish embryos and also 
the activation of luciferase gene in Y1 adrenocortical cells. This was in contrast to the 
other three gene promoters of cyp17, star, and 3β-hsd isolated concurrently despite the 
fact that cyp17 and star promoter contained at least one FRE. Truncation analysis done 
on the 1.7 kb cyp11a1 promoter demonstrated that the truncation of this promoter down 
to 1 kb did not affect the basal promoter activity significantly, indicating that losing the 
distal FRE had no effect in the basal promoter activity. In accordance with this 
observation, mutagenesis studies on the two FREs suggested that the proximal FRE 
played central role in mediating the basal promoter activity of cyp11a1. Finally, this 
study provided the first experimental evidence of Ff1b association with its endogenous 
target gene promoter cyp11a1 and also Ff1b potentiating the transcriptional activity of 
cyp11a1 promoter in vivo. The interaction of Ff1b with both the distal and proximal 
FREs in the cyp11a1 promoter was demonstrated in vitro by EMSA and in vivo by 
ChIP assay. All of the above findings have ascertained the conserved function of Ff1b 
as the transcriptional regulator of cyp11a1, and most likely also the other steroidogenic 














Our previous findings have established Ff1b as the ortholog of mammalian 
SF-1 in zebrafish. The first hint of Ff1b acting at multiple levels in endocrine 
development and function emerged from developmental analyses of its expression in 
zebrafish embryos. The expression of ff1b from the earliest stages of organogenesis in 
the interrenal and gonadal primordium (Chai and Chan, 2000) suggests a fundamental 
role in the initial differentiation of the primary steroidogenic tissues. The interrenal 
primordia expressing ff1b appear as bilateral clusters of cells located ventral to the the 
third somite at 20-22 hpf in close association to the pronephric primordium (Hsu et al., 
2003). By 28 hpf, the bilateral clusters coalesce into a discrete structure at the midline 
and the interrenal cells are capable of producing steroids, as characterized by the 
presence of key steroidogenic enzymes including cyp11a1 and 3β-hsd (Chai and Chan, 
2000; Hsu et al., 2003). In adult zebrafish, the steroidogenic interrenal cells are 
embedded in the both lobes of head kidney. Besides, ff1b is also expressed in the 
ventromedial hypothalamus (VMH), which acts as the control centre of the endocrine 
system, from about 24 hpf onwards (Chai and Chan, 2000), indicating a regulatory 
role in endocrine function. In contrast to mammalian SF-1, ff1b expression was not 
detected in the developing pituitary in zebrafish.  
Similar to SF-1, direct insights into the roles of Ff1b in zebrafish came from 
morpholino (MO) knockdown studies of ff1b. Injection of ff1bMO into embryos led 
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 to the development of late-appearing morphological defects that are indicative of 
impaired osmoregulatory functions (Chai et al., 2003; Hsu et al., 2003). In addition, 
the expression of two interrenal steroidogenic genes, cyp11a1 and 3β-hsd, were 
shown to be downregulated and the development of interrenal tissue was adversely 
affected, as judged by the complete absence of 3β-Hsd enzymatic activity. In direct 
contrast to observations from Sf-1 knockout mice, the effects of morpholino 
knockdown of ff1b in other ff1b-expressing tissues including ventral hypothalamus 
and gonads were less obvious.  
Despite the tremendous progress made in studying the expression pattern, 
knockout/knockdown, structural and chemical properties of SF-1 and Ff1b, the 
molecular mechanisms underlying their regulation and transcriptional activity remain 
largely unknown. As the interrenal of ff1b morphant disappeared at relatively early 
stages of development, it has been difficult to trace the fate of ff1b-expressing cells or 
to define the molecular basis for the loss of these cells in the downregulation of ff1b. 
For instance, it has been shown that the adrenal primordium formed but progressively 
regressed by apoptosis in SF-1 knockout mice (Luo et al., 1994). We are still not sure 
whether the same phenomenon took place when ff1b gene was knocked down by MO. 
Therefore, it will be extremely useful if a lineage tracer could be developed for cell 
lineages that express ff1b. In mouse, an SF-1/EGFP transgenic line has been generated 
using ~45 kb of SF-1 5’ flanking sequence (up to Exon2) from a BAC plasmid that 
was placed upstream to EGFP coding sequence (Stallings et al., 2002). The resulting 
transgenic mouse displayed EGFP fluorescence in SF-1-expressing tissues, including 
the ovaries, testes, adrenal cortex, and the VMH but not in corpora lutea or the 
anterior pituitary gland.   
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 In this study, we have adopted a BAC transgenesis strategy to trace the lineage 
of ff1b-expressing cells in zebrafish embryos. BAC transgenesis has emerged as a 
powerful approach to achieve copy number-dependent and position-independent 
transgenic expression (Heintz, 2000; Giraldo and Montoliu, 2001; Yang et al., 2006; 
Lakowski et al., 2007). We have taken advantage of recent improvements in the DNA 
engineering of BAC plasmid by Red/ET homologous recombination approach. This 
strategy allows any kind of modifications, including insertion, point mutation, sub-
cloning, and deletion, at any desired site within a BAC plasmid (Muyrers et al., 1999; 
Muyrers et al., 2000a; Muyrers et al., 2000b; Zhang et al., 2000). In addition to the 
characterization of the transgenic zebrafish generated by the BAC transgenesis 
approach, this chapter discusses the initial evaluation of this transgenic line as a useful 
tool for studying the embryonic development of interrenal gland in vivo. The resultant 
transgenic line had enabled us to study the early morphogenesis of VMH and 
interrenal gland in a way that would not be possible in the mammalian system.    
 
4.2 The generation of pBACff1bEx2EGFPKan by Red/ET homologous 
recombination 
 
The most straightforward way to mark ff1b-expressing cells will be the fusion 
of upstream flanking sequences of ff1b to EGFP reporter gene. Unfortunately, initial 
experiments using a plasmid construct containing up to 20 kb of ff1b upstream 
sequences and 30 bp of 5’ UTR fused upstream of EGFP did not recapitulate ff1b 
expression in zebrafish embryos. In addition, in-frame insertion of EGFP into Exon 2 
flanked by ~3.8 kb of genomic sequences on either side did not successfully 
recapitulate ff1b expression. This indicates that elements contributing to tissue-
specific regulation of ff1b expression are located distally from the transcription start 
site. Therefore, a Red/ET homologous recombination strategy was utilized to insert 
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 the EGFP coding region into Exon2 of ff1b gene locus contained in a BAC construct, 
BACff1b2, so that EGFP expression would come under the full control of ff1b gene 
regulatory elements.  
The EGFP-Kanr cassette was designed to be inserted in-frame immediately 
downstream to codon 25 of ff1b, which is located in the first coding-exon, Exon2 (Fig. 
4.1). This insertion would prevent the generation of a dominant negative mutant, as 
the resultant fusion Ff1b-EGFP protein does not contain an intact DNA binding 
domain. Red/ET homologous recombination was carried out in a DH10B bacterial 
host whereby the donor DNA fragment encompassing the EGFP-Kanr cassette flanked 
by 75 bp and 243 bp of left and right homology arms, was used to target the genomic 
sequences flanking the insertion site. As the insertion site is located prior to the 
nuclear localization signal of Ff1b (in Exon 4), the EGFP protein will remain 
cytoplasmic. The recombined BAC construct is named pBACff1bEx2EGFPKan. 
 
4.3 Assessment of transgene activity from pBACff1bEx2EGFPKan in 
zebrafish embryos by transient transgenesis 
 
Microinjection of the supercoiled pBACff1bEx2EGFPKan into zebrafish 
embryos at 1 to 2-cell stage demonstrated that the recombined DNA containing the 
EGFP marker recapitulated endogenous ff1b expression in the VMH and their 
neuronal projections, as well as that in the interrenal gland. Despite the mosaic and 
transient nature of transgenesis, an intense expression of EGFP was detected in a 
variable number of cells, estimated to be comparable to the number of native ff1b-
expressing cells. The intrinsic fluorescence of EGFP allowed a sensitive assay to 








Figure 4.1 Construction of the pBACff1bEx2EGFPKan construct by Red/ET 
homologous recombination. (A) Schematic representation of the insertion of the 
EGFP-Kanr cassette into the BACff1b2. The BACff1b2, which contains the ff1b locus, 
and pRed/ET plasmid, which encodes phage-derived proteins catalyzing homologous 
recombination, were transformed into E. coli DH10B strain. The donor DNA 
fragment, EGFP-Kanr (2.28 kb) harbouring 75 bp and 243 bp of left (pink) and right 
(red) homology sequences targeting the insertion site in Exon 2, was subsequently 
transformed into the same bacteria cell. By shifting the temperature from 30 to 37°C, 
and L-arabinose induction, homologous recombination occurs between the homology 
sequences of donor and BACff1b2. The resultant recombined BAC plasmid, 
pBACff1bEx2EGFPKan, has the EGFP under the control of endogenous ff1b locus. 
(B) The insertion site is immediately downstream of codon 25 of ff1b, and is located 
in Exon 2. Exon 2 sequences are in blue and the successfully inserted EGFP-Kanr 




 Under an UV fluorescence microscope, weak EGFP expression could first be 
observed in the microinjected zebrafish embryos from about 28-30 hpf onwards. 
Images of embryos were taken only from ~34-36 hpf onwards when the EGFP signal 
accumulated to a level easily captured by confocal microscopy. At 36 hpf, strong 
EGFP expression could be detected in the VMH, otic vesicle, interrenal, and fibre-like 
structures in the muscle (Fig. 4.2A). 
EGFP-expressing cells in the VMH appeared as one small cluster of cells 
lateral to the anterior tip of the neural tube beginning at about 28 hpf. As development 
proceeded, the number of EGFP-expressing cells increased and so did the intensity of 
fluorescence (Fig. 4.2B and C). Occasionally, the neuronal projections and neuronal 
cell body-like structures (marked by white arrow) extended from VMH were observed 
from the forebrain up to hindbrain but their appearances were highly mosaic. The 
neuronal projections from the VMH ascended dorsally to the level of tegmentum, 
where they made a sharp 90 degrees turn and continued to project caudally to the otic 
vesicle (Fig. 4.2A). 
EGFP expression was detected in the interrenal gland in 30% of the embryos 
that showed EGFP expression following microinjection. By the time interrenal cells 
expressed detectable levels of EGFP at around 32-34 hpf, they had aggregated into a 
discrete structure ventral to the third somite (Fig. 4.2D). From 48 hpf onwards, EGFP 
fluorescence proliferated within the interrenal cells and began to show signs of 
spreading (Fig. 4.2E). Daily monitoring of injected embryos up to two weeks post-
fertilization did not produce any evidence of EGFP expression in the genital ridge 
region. The regulation of ff1b expression in the genital ridge may require control 
elements that are located at great distances from the proximal promoter and are not 




















Figure 4.2 The recombined pBACFf1bEx2EGFPKan generated by Red/ET
recombination targets EGFP to specific tissues in zebrafish embryos. EGFP is 
under the control of ff1b genomic regulatory elements in the recombined BAC plasmid. 
When the supercoiled pBACFf1bEx2EGFPKan construct was microinjected into 
zebrafish embryos at 1-2 cell stage, EGFP expression can be clearly seen at the 
ventromedial hypothalamus (A-C), and their neuronal projectios (A, C, E-F); interrenal 
(A, D, E-F); otic vesicle (A, D, E); and muscle (A, F). Neuronal cell body-like 
structures that appear alongside with the neuronal projections from VMH are 
highlighted by white arrows. Images were taken with confocal microscope with whole-
mount live embryos at the corresponding developmental stages. Scale bars, 100 µm. 
Abbreviations: ir, interrenal; m, muscle; ov, otic vesicle; vh, ventral hypothalamus. 
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 presence of repressor or the insertion site of the EGFP-Kanr cassette, causing the 
expression in the genital ridge to be prohibited. 
Besides the VMH and interrenal, EGFP fluorescence was also detected in the 
otic vesicle and fibre-like structure in the muscle (Fig. 4.2A, D, E-F). As the transient 
expression of the transgene was highly mosaic, it was difficult to judge which part of 
the muscle and the otic vesicle actually expressed EGFP. It was also difficult to 
postulate whether these were due to ectopic expression coming from genomic 
sequences contained in the BAC plasmid or they were simply non-specific expression.  
Nevertheless, the transient transgenesis demonstrated that the ff1bEx2EGFP 
transgene was capable of marking tissues where ff1b gene is endogenously expressed. 
The mosaic nature of transient expression, however, hindered further molecular 
analyses. Thus, this transgene released from pBACff1bEx2EGFPKan was used to 
generate a stable germ-line transgenic zebrafish that will express EGFP in ff1b-
expressing cells.  
 
4.4 Recapitulation of ff1b endogenous expression in zebrafish embryos by 
stable transgenesis 
 
To generate a linearized transgene for stable transgenesis, 
pBACff1bEx2EGFPKan was digested with restriction enzyme Not I to release the 
~100 kb genomic DNA sequence containing the EGFP-Kanr cassette from the 
pBeloBAC11 vector backbone. The linearized and purified transgene was 
microinjected into zebrafish embryos strictly at 1-cell stage. Embryos were checked 
for EGFP fluorescence at 36-48 hpf and only those showing strong EGFP expression 
were selected and raised up to adulthood. Out of the 135 fishes that survived to 
adulthood, only one positive founder was identified (transgenesis efficiency = 0.7%) 
and the resulting transgenic line was named ff1bEx2EGFP. Indeed, another founder 
113
 was found to produce EGFP fluorescent progenies. However, the embryos produced 
by this founder showed only non-specific EGFP expression in the CNS, probably due 
to the insertion of a truncated transgene. The low efficiency of transgenesis is 
probably due to the large size of transgene. Judging from the number of F1 progeny 
that showed EGFP fluorescence, the germ-line transmission rate was ~40 – 50%. As 
expected, because of its large size, the linearized and purified transgene must be 
freshly prepared for microinjection to achieve a high percentage of fluorescent 
embryos, and subsequent stable germ-line transgenesis.  
As reported for many other transgenic lines, the homozygous transgenic 
embryos of ff1bEx2EGFP line are not viable and only heterozygous transgenic 
embryos can be used for imaging and molecular analyses. The homozygous 
transgenic embryos are easily distinguishable from the non-fluorescent (non-
transgenic) and heterozygous transgenic by their stronger EGFP fluorescence prior to 
48 hpf and the development of pericardial edema from ~48 hpf onwards. 
Subsequently, abnormal curvatures of body axes were observed in these homozygous 
transgenic embryos and they generally do not survive beyond 6-7 dpf.  
Notably, the EGFP transgene expression faithfully recapitulated the 
endogenous expression of ff1b in the VMH and interrenal. Weak EGFP signal was 
visible in the VMH and much stronger in the otic vesicle and muscle from about 20 
hpf (21-somite stage) onwards. By 22 hpf, EGFP cells in the VMH accumulated to a 
level that could be better visualized and captured by confocal microscope (Fig. 4.3A). 
On the other hand, the interrenal appeared only as a small dot just above the yolk sac 
and ventral to the third somite in this stage. From 28 hpf onwards, the interrenal 
formed a more discrete structure in the same region (Fig. 4.3B). Concurrently, the 
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Figure 4.3 EGFP transgene expression in ff1bEx2EGFP transgenic 
zebrafish embryos. The expression of EGFP transgene at different 
developmental stages of transgenic embryos was captured by confocal (A-D; 
G-H) or epifluorescence (E-F) microscope. From 22 hpf onwards, EGFP 
could be detected in the ventromedial hypothalamus, otic vesicle, interrenal, 
and muscle (A). From 28 hpf, neuronal projections that extended dorsally 
and caudally from the ventromedial hypothalamus was apparent (B). At 48 
hpf, EGFP expression from common cardiac vein appeared and the intensity 
of EGFP expression in ventromedial hypothalamus and associated neuronal 
projections, otic vesicle, interrenal, and muscle continued to increase (C, 
lateral view; D, dorsal view). By 3 dpf, the EGFP expression at the common 
cardiac vein was almost diminished and a new EGFP expression domain at 
the neuromasts emerged and are marked by red arrows (E). As development 
proceeded, EGFP expression at the ventromedial hypothalamus and 
interrenal continued to proliferate and increase in intensity while those in the 
otic vesicle and muscle became weaker (F-H). All images were captured 
from lateral view except for A and H, which were captured from dorsal view. 
Scale bars, 100 µm. Abbreviation: vh, ventromedial hypothalamus; ov, otic
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 neuronal projections extended dorsally and caudally from VMH to the midbrain, otic 
vesicle, and muscle could be clearly visualized at this stage.   
Similar to the observations in transient transgenesis (Fig. 4.2), EGFP-positive 
cells in the VMH and interrenal continued to proliferate as embryonic development 
proceeded (Fig 4.3C-H). At 48 hpf, a previously unidentified domain of transgene 
expression appeared at the position that corresponded to the common cardiac vein 
(Fig. 4.3C and D). This vein-like structure appeared bilaterally at both sides of the 
trunk and they extended from the second somite to the direction of heart but stopped 
half way through on the yolk. The expression, however, was nearly disminished by 3 
dpf (Fig. 4.3E). Interestingly, transgene expression began to show up in the 
neuromasts (marked by red arrows) of the lateral line system from about 3 dpf 
onwards (Fig. 4.3 E-H). This expression was also not noticed in transient transgenesis, 
as these random dots could have been treated as non-specific EGFP expression or 
mosaic EGFP expression coming from other tissues. By 5 dpf, the spatial domain of 
VMH and interrenal were more or less defined and did not change much thereafter 
(Fig. 4.3 F-H). Conversely, the EGFP signal in the otic vesicle and the muscle became 
weaker as development proceeded.   
In ISH, a third domain of ff1b expression appeared at 4 dpf as stripes of cells 
located along the dorsolateral peritoneal walls parallel to the eigth and ninth somite on 
either side of the trunk, and they have been proposed to correspond to the genital 
ridge which would eventually develop into gonads (Chai, 2002). However, similar to 
observations in transient transgenesis, monitoring of EGFP expression in the 
ff1bEx2EGFP larvae up to 2 weeks did not reveal any expression domain that 
corresponds to the genital ridge. This observation indicates that the gonad-specific 
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 enhancer lies outside of the transgene used in this study or that a gonad-specific 
repressor is present in the transgene.  
In contrast to the transient transgenesis, EGFP fluorescence observed in stable 
transgenesis was now at its full complement where the domain of expression and the 
fluorescence intensity increased considerably. The EGFP expression in the otic 
vesicle and muscle was unlikely to be ectopic expression that resulted from 
integration site effect, as the EGFP signal was already detected even in transient 
transgenesis studies. They may still represent genuine endogenous ff1b expression 
that could not be detected by ISH analyses previously. 
 
4.4.1 EGFP transgene expression in the ventromedial hypothalamus 
 
In the VMH of a developing zebrafish embryo, ff1b expression is initiated at 
~24 hpf as revealed by ISH analyses (Chai and Chan, 2000). The expression pattern 
of the EGFP transgene in the VMH of ff1bEx2EGFP transgenic embryos was largely 
similar to those revealed by ISH and transient transgenesis studies of 
pBACff1bEx2EGFPKan. At about 20 hpf, 2 to 3 EGFP-positive cells appeared 
bilaterally to the anterior tip of the neural tube in the developing brain (Fig. 4.4A). 
The number of EGFP-positive cells increased steadily with development and by 24 
hpf, the number of cells almost doubled at both sides and neuronal projections from 
these cells began to be visible (Fig. 4.4B). As the anterior neural axis folds, these cells 
were translocated caudally and dorsally to form two narrow strips of cells extending 
bilaterally from the midline of the rostral diencephalon by 28 hpf (Fig. 4.4C). From 
lateral view, it was noticed that the axonal-like projections from VMH ascended 
dorsally at an angle to the midbrain, where they made a sharp 90 degrees turn and 
continued to project caudally to the otic vesicle (Fig. 4.4D-E). Additional sectioning 
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Figure 4.4 EGFP transgene expression in the ventromedial hypothalamus.
Confocal images of live transgenic embryos were taken from ventral (A-C), 
lateral (D), and dorsal (E-H) view to examine the embryonic development of 
ventromedial hypothalamus from 20 hpf through 7 dpf. At 20 hpf, a few EGFP-
positive cells appeared bilaterally at the ventral hypothalamus (A). By 24 hpf, 
the number of EGFP-positive cells almost doubled and the neuronal projections 
from these cells could be clearly visualized (B). By 28 hpf, these cells formed 
two narrow strips of cells extending bilaterally from the midline of rostral 
diencephalon (C, ventral view). From lateral view, axonal-like projections from 
the ventromedial hypothalamus ascended dorsally and caudally at a sharp 90 
degree trun to the midbrain (D). Proliferation and growth of these neurons 
continued and they eventually occupied a distinct region within the ventral 
hypothalamus (E-H). In some images, otic vesicle was included for a complete 
coverage of neuronal projections. Scale bar, 100 µm. Abbreviations: vh, 
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 of the transgenic embryos would be required to determine whether these projections 
directly innervated the otic vesicle in the developing zebrafish embryos.  
Proliferation and growth of the VMH neurons continued and eventually they 
occupied a distinct region within the ventral hypothalamus (Fig. 4.4E-H). From 3 to 5 
dpf, projections from the VMH neurons became more complex. In addition to the 
posterior projection described earlier, more localized and arborized projections 
resembling dendritic projections were observed, most notably laterally within the 
hypothalamus and midbrain.  
Collectively, these data indicate that the EGFP expression not only 
recapitulated the endogenous ff1b expression but also unraveled the neuronal 
projections that were previously not detected by ISH analyses. The discrepancy could 
be largely attributed to the difference in sub-cellular domains that are revealed by ISH 
and fluorescence detection. While ISH detects mostly ff1b transcripts in the nucleus 
and perinuclear cytoplasm, fluorescence revealed the presence of EGFP proteins in 
the cytoplasm. The ability to mark the ff1b-expressing neurons and their projections 
will certainly be a valuable asset in studying the development and function of the 
VMH as the regulatory centre for the endocrine system.    
 
4.4.2 EGFP transgene expression in the interrenal gland 
 
The morphogenetic movement of interrenal primordial cells is well defined by 
in situ hybridization analyses in zebrafish embryos. At 20-22 hpf, ff1b-expressing 
interrenal cells appear in the intermediate mesoderm bilateral to the notochord and 
ventral to the third somite. By ~30 hpf, the two clusters of ff1b-expressing cells 
coalesced into a single cluster located slightly to the right of midline from dorsal view 
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 (Chai and Chan, 2000; Chai et al., 2003; Hsu et al., 2003; Liu and Guo, 2006; Liu, 
2007).   
In the ff1bEx2EGFP transgenic embryos, EGFP was weakly expressed from 
the interrenal cells at ~22 hpf (Fig 4.5A-B) but it was not discernable if observed from 
the dorsal view. There is a possibility that the EGFP expression in the interrenal 
primodia prior to this stage was masked by the stronger EGFP fluorescence from the 
otic vesicle and the muscle. At 28 hpf, the interrenal primordium was clearly visible 
from top of the embryo as the cells had aggregated into a discrete structure at the 
midline (Fig. 4.5C).   
The number of EGFP-positive cells increased significantly as the embryo 
continued to develop (Fig. 4.5D-F). Beginning from 3 dpf, dispersal of the main cell 
cluster became evident, giving rise to a few smaller clusters across the midline (Fig. 
4.5D). The shape and size of these cell clusters, however, showed slight variations 
among different individuals as development proceeded. At 5-7 dpf, the swim bladder 
began to inflate and the interrenal cells could be seen to be closely associated with the 
dorsal and anterior end of the swim bladder.  
Just like the majority of organ rudiments, the interrenal had more or less 
completed morphogenesis by 3-4 dpf and its development slowed down considerably. 
Thus, the interrenal cells continued to proliferate but at a much lower rate thereafter. 
In agreement with the observations in transient transgenesis, no direct neuronal 
connection could be observed between the EGFP-visualized neuronal tracts and the 
interrenal in any of the transgenic embryos, suggesting that the interrenal organ is not 
directly innervated by the VMH neurons. In conclusion, the ff1bEx2EGFP transgene 
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Figure 4.5 EGFP transgene expression in the interrenal gland. Confocal
images of live transgenic embryos were taken from lateral (A-B), and dorsal (C-
F) view to examine the embryonic development of interrenal from 22 hpf
through 7 dpf. The EGFP expression at the interrenal gland was first detected at 
a position ventral to the third somite at 22 hpf (A). These cells of interrenal 
primordium continued to proliferate and occupied a region that was anterior and 
dorsal to the swim bladder by 7 dpf (B-F). Otic vesicle (ov) was included to 
indicate the orientation of embryos or larvae. Interrenal cells were highlighted 
with red arrows. Scale bar, 100 µm. 
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 this transgenic line will be extremely useful in studying molecular events governing 
early morphogenesis of interrenal gland. 
 
4.4.3 EGFP transgene expression in the otic vesicle  
 
In addition to the VMH and interrenal, the otic vesicle showed unexpectedly 
high level of ff1bEx2EGFP transgene expression. The EGFP-positive cells were first 
identified in the otocyst as early as 18 hpf (17-somite). However, it was only until 
about 20 hpf (21-somite) that the fluorescence could be effectively captured by 
confocal microscopy. At this stage, the EGFP signal appeared as a semi-circle 
structure at the ventral epithelium of the otic placode, which was just formed by the 
thickening of ectoderm, from lateral view (Fig. 4.6A). By 28 hpf, the otolith seeding 
was complete and EGFP expression continued to occupy this ventrocaudal patch of 
the sensory epithelium. 
As the otic vesicle continued to develop and invaginate, the EGFP expression 
domain became restricted and shifted gradually to the posterior region of the otocyst 
lumen. At 48 hpf, it occupied a region that corresponded morphologically to the 
maculae, which is the sensory epithelium associated with the succular and utricular 
otoliths (Fig. 4.6B and F).  From 3 through 7 dpf, EGFP expression was greatly 
reduced and became restricted to the posterior crista, which is connected to the 
posterior macula and associated with the saccular otolith (Fig. 4.6C-E, G-I). The 
EGFP-expressing cells eventually appeared as two symmetrical semi-circles lining the 
posterior wall of otic vesicle. The thinning of this EGFP-expressing posterior layer 
was probably due to the thinning of epithelium as the otic vesicle organ developed.    
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Figure 4.6 EGFP transgene expression in the otic vesicle. Confocal
images of live transgenic embryos were taken from lateral (A-E), and dorsal 
(F-I) view to examine the embryonic development of otic vesicle from 20 
hpf through 7 dpf. From 20 hpf onwards, EGFP expression appeared at the 
ventral epithelium of the otic vesicle (A, B). At 48 hpf, EGFP-positive cells 
occupied the maculae associated with the succular and uricular otoliths (B, 
F). From 3 dpf through 7 dpf, the EGFP expression reduced in intensity and 
expression domain, after which they were restricted to the posterior crista 
(C-E, G-I). The orientation of embryos or larvae was kept constant with 
anterior to the left and dorsal to the top. The main sites of EGFP expression 
were highlighted with different colors in B and labeled accordingly. Scale 
bar, 100 µm. Abbreviations: am, anterior macula; pc, posterior cista; pm, 
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 4.4.4 EGFP transgene expression in the muscle 
 
While it was difficult to determine the exact site of EGFP expression in the 
skeletal muscles by transient transgenesis, the EGFP expression in stable transgenesis 
enabled us to do so. Weak transgene expression appeared in the skeletal muscle as 
early as 18 hpf (17-somite) almost coinciding with that in the otic placode. Only 
images from 22 hpf through 7 dpf are shown (Fig. 4.7). Strikingly, the EGFP 
expression in the skeletal muscles did not occupy the entire somite. Instead, they 
appeared as thick fibers in the centre of the each somite and seemed to be located 
directly lateral to the notochord (Fig. 4.7A). From the dorsal view, they appeared as 
two strips of rope-like structure flanking the midline at 28 hpf (Fig 4.7B). 
As development continued, the expression domain decreased gradually. By 3 
dpf, the thick fibers now became thin fibers organized orderly along the trunk (Fig. 
4.7C). Viewing from top of the larvae, each pair of fibers was organized 
symmetrically and laterally to the midline (Fig. 4.7D). Each muscle fiber seemed to 
originate from the notochord and extended laterally and caudally in each somite. The 
domain and intensity of EGFP expression continued to decrease and by 7 dpf, only 
weak EGFP expression could be seen (Fig. 4.7 E-F).  
To better localize the site of EGFP expression in the muscle, transverse cryo-
sections (20 μm thickness) were prepared from 36 hpf embryos. The EGFP expression 
was clearly mapped to the muscle pioneer cells that will eventually form the future 
horizontal myoseptum (indicated by red arrows in Fig. 4.7G). They remained in 
contact with the notochord and become flattened cells that extend from the notochord 
to the lateral surface of the myotome (Du et al., 1997). A saggital cryo-section of the 


















Figure 4.7 EGFP transgene expression in the skeletal muscles. Confocal and 
epifluorescent (C-D, G-H) images of transgenic embryos were taken from lateral (A, 
C, E), and dorsal (B, D, F) view to examine the EGFP transgene expression in the 
muscle from 22 hpf through 7 dpf. At 22 hpf, the EGFP expression in the muscle 
appeared as thick fibers that were located directly lateral to the notochord (A). from 
dorsal view at 28 hpf, they appeared as two strips of rope-like structure flanking the 
midline (B). From 3 dpf through 7 dpf, the EGFP expression decreased both in 
intensity and expression domain as development continued (C-F). A transverse cryo-
section of 36 hpf embryo at 20 µm thickness (G) and a saggital cryo-section of 48 hpf 
embryo at 20 µm thickness (H) indicated that the EGFP expression domain in the 
muscle corresponded to the muscle pioneer cells that will form the future horizontal 
myoseptum. The orientation of embryos or larvae was kept constant with anterior to 
the left and dorsal to the top. The location of EGFP expression in muscle pioneer cells 
bilateral to the notochord is indicated by red arrowheads. Scale bar, 100 µm. 
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 4.5 Morpholino knockdown of ff1b in ff1bEx2EGFP transgenic embryos 
 
To confirm that the ff1bEx2EGFP transgenic line fully recapitulates EGFP 
expression only in ff1b-expressing cells, the knock-down of ff1b gene function in this 
transgenic background was carried out. We were particularly interested in tracking the 
fate of ff1b-expressing cells in interrenal organogenesis in this context. Unfortunately, 
the EGFP transgene is expressed as a fusion protein, retaining the first 25 amino acids 
from Ff1b. The antisense ff1b morpholino, ff1bMO1, which has been used 
successfully for perturbing the functions of ff1b during embryogenesis, was designed 
complementary to the AUG start codon and 22 adjacent downstream ribonucleotide 
residues (Chai et al., 2003). As a result, this antisense morpholino would be able to 
knock down the EGFP transgene expression as well and hence defeating the purpose 
of lineage tracing. Therefore, new antisense morpholinos targeting different sites of 
ff1b mRNA were necessary.    
 
4.5.1 Design of new morpholino to knock-down ff1b gene function 
 
Besides blocking translation initiation in the cytosol by targeting mRNA 
sequences spanning the AUG codon, antisense morpholinos can also modify pre-
mRNA splicing in the nucleus by targeting exon/intron splice junctions (Draper et al., 
2001; Morcos, 2007; Moulton and Yan, 2008). After screening through the splice 
junctions spanning the ff1b pre-mRNA sequence, two antisense morpholino 
oligonucleotides, ff1bMO2 and ff1bMO3, which target Exon 2/Intron II and Exon 
3/Intron III splice junctions, respectively, were selected and synthesized with Gene 
Tools Inc. (USA). Both morpholinos were 25 bases in length. Their positions across 
the corresponding splice junctions and oligonucleotide sequences are depicted in 
Figure 4.8. Both morpholinos targeted the splice donor site, and could potentially lead 
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 to outcomes such as exon skipping, retainment of the downstream intron leading to a 
partial transcript, as well as, cryptic intronic or exonic splicing (http://www.gene-
tools.com/node/18). The most possible outcome would be skipping of Exon 2 or Exon 
3, respectively (Fig. 4.8C). With the Exon 2 skipping, translation might not be 
initiated properly due to a lack of AUG start codon. On the other hand, Exon 3 
skipping would result in a defective Ff1b lacking Zn finger II in its DNA binding 
domain.   
 
Figure 4.8   Positions and sequences of morpholino oligonucleotides used in study 
of in vivo functions of ff1b. (A) The relative positions of the three antisense 
morpholinos are indicated against the ff1b genomic locus. Exon regions shown in 
purple denote untranslated region (UTR) and those in blue denote coding region. 
sff1bMO, sense ff1b morpholino; ff1bMO1, antisense ff1b morpholino spanning start 
codon; ff1bMO2, antisense ff1b morpholino spanning Exon2/IntronII (E2I2) splice 
donor junction; ff1bMO3, antisense ff1b morpholino spanning Exon3/IntronIII (E3I3) 
splice donor junction. (B) Sequences of the morpholinos used and the corresponding 
sense sequences targeted by the morpholinos. The start codon is underlined. Exon and 
intron sequences are shown in upper and lower cases respectively. (C) The most 
possible outcome of ff1bMO2 and ff1bMO3 knockdown on ff1b transcript.  
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 4.5.2 Determination of optimal dosage for ff1bMO2 and ff1bMO3 
 
To determine the optimal dosage for the two newly designed morpholinos, a 
preliminary experiment was carried out to microinject 6.75, 11.25 and 22.5 μM final 
concentration of each morpholino into 1-2 cell wild type zebrafish embryos. Scoring 
of microinjected embryos for non-specific defects at 30 hpf suggests that the optimal 
working concentration for both morpholinos was 11.25 μM (Table 4.1), which is at 
the same range as ff1bMO1. Injected embryos were then screened at 30 hpf to 
determine if morpholinos caused non-specific deformation. The morphological 
defects that are indicative of non-specific toxicity effects include reduction of the 
head and eyes, an amorphous appearance of cells in the body, downward curving 
body axis and edema of the pericardial and yolk sac. At the dosage of 11.25 μM per 
embryo, less than 20% of the microinjected embryos displayed phenotypes suggestive 
of non-specific toxicity and this is within the the acceptable limit. In all subsequent 
experiments, this dosage of morpholino was used, and only embryos showing wild-
type phenotype at 30 hpf were retained for further analyses.    
 
4.5.3 Monitoring the effect of ff1b knockdown on interrenal development 
by EGFP transgene expression  
 
The ff1bMO2 and ff1bMO3 morpholinos were microinjected into 
ff1bEx2EGFP transgenic embryos at 1- to 2- cell stage to a final concentration of 
11.25 μM per embryo. The sense morpholino, sff1bMO (5’-
ATGGACTTCAGAGCAG ATGAGGATT-3’) was included as negative control. 
Prior to scoring for morphant phenotype class A to D at 7 dpf, the ff1bEx2EGFP 
embryos microinjected with 11.25 μM of ff1bMO2 and ff1bMO3 were first 
monitored closely for their EGFP expression in the interrenal primordia. As the 
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 morphant phenotype of impaired osmoregulation could be largely attributed to the 
loss of interrenal cortisol production, close examination of interrenal morphogenesis 
is of central importance. Monitoring of transgene expression commenced at ~24 hpf, 
when weak EGFP expression could be readily detected in the interrenal, and was 
continued until 10 dpf. Between 36 to 48 hpf, homozygous embryos and non-
fluorescent embryos were removed, and only hemizygous embryos were retained for 
subsequent data collection and microscopic observations. 
 










6.75 95.5 4.0 222 
11.25 83.1 16.9 231 sff1bMO 
22.5 40.5 59.5 257 
6.75 93.7 6.3 205 
11.25 80.3 19.7 223 ff1bMO1 
22.5 30.4 69.6 214 
6.75 94.3 5.7 209 
11.25 81.4 18.6 236 ff1bMO2 
22.5 33.1 66.9 254 
6.75 90.5 9.5 243 
11.25 80.1 19.9 221 ff1bMO3 
22.5 30.0 70.0 217 
 
At ~48 hpf, when the EGFP expression could be easily visualized at the 
developing interrenal, the morpholino-injected embryos were observed for their EGFP 
fluorescence at the developing interrenal gland, and eventually sorted into three 
groups. Those in Group I had their interrenal gland fluorescent at a level that is 
comparable to uninjected ff1bEx2EGFP embryos, while those in Group II had 
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 reduced EGFP fluorescence, and Group III embryos had a complete loss of EGFP 
fluorescence in their interrenal gland. The proportion of morpholino-injected embryos 
that fell into each of the three groups is summarized in Table 4.2. Based on the 
percentage of embryos that showed EGFP fluorescence at their interrenal gland at this 
stage, the ff1bMO3 seemed to work much more efficiently than ff1bMO2.  
 
Table 4.2 Proportions of morpholino-microinjected ff1bEx2EGFP embryos that show 
different degree of fluorescence in their interrenal glands at 48 hpf.  
 Percentage of embryos showing EGFP in 
interrenal (Mean ± S.D.) 
 
EGFP Fluorescence  I (Strong) II (Weak) III (Absent) n 
sff1bMO 87.8 ± 0.87 5.9 ± 0.22 6.3 ± 0.65 354 
ff1bMO2 76.6 ± 0.21 9.9 ± 1.36 13.5 ± 1.14 359 
ff1bMO3 47.8 ± 3.85 21.0 ± 1.00 31.2 ± 2.85 366 
 
Subsequent monitoring of EGFP expression in the interrenal of ff1bMO3 
morphants showed encouraging correlation between this categorization and that of 
morphant phenotype Class A to D (Table 4.3). For instance, almost all microinjected 
embryos that fell into Group I at 48 hpf developed into Class A morphants (wild-type). 
Similarly, the majority of Group II embryos developed into Class B morphants and 
those in Group III generally developed into Class C and D morphants. Intriguingly, a 
few of the Group II embryos eventually developed into Class C morphants, while 
several embryos in Group III eventually started showing weak EGFP expression at 
their interrenal and developed into Class B morphants instead. This is most likely due 
to the individual variation in transgene expression level and/or tolerance of ff1b 
knockdown. Furthermore, the amount of morpholinos that were successfully delivered 
into each embryo was likely to vary slightly among different individuals. Nonetheless, 
the strong correlation between the loss of EGFP expression and the morphant 
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 phenotype confirms that the proper development of interrenal gland is the key factor 
in determining the severity of morphological defects observed in ff1b morphants, as 
suggested previously by Chai et al. (2003).  
As the ff1bMO3 worked much more effectively than ff1bMO2, only embryos 
microinjected with ff1bMO3 were examined in detailed for their EGFP expression in 
interrenal gland using confocal microscopy. In comparison to embryos injected with 
sff1bMO, which showed EGFP fluorescence at their interrenal gland at a level 
comparable to the uninjected ff1bEx2EGFP embryos (Fig. 4.9A, C, E, G), ff1bMO3 
morphants that were categorized into Group III and eventually developed into Class D 
morphant consistently lacked fluorescent interrenal gland (Fig. 4.9B, D, F, H). This 
observation indicates that the formation of interrenal primordia was adversely 
perturbed when ff1b is knocked down.  
 
4.5.4 Efficacy of ff1bMO2 and ff1bMO3 in inducing ff1b morphant 
phenotype at 7 dpf 
  
As the phenotype of ff1b morphant derived from ff1bMO1 is well established 
(Chai et al., 2003; Hsu et al., 2003), the activity and efficacy of the two newly 
designed morpholinos were also assessed in comparison with it to determine if they 
are capable of giving rise to the same morphant phenotype in zebrafish larvae. The 
ff1bMO1 was microinjected into wild type zebrafish embryos and scored for 
morphant phenotype concurrently for comparison. The ff1bEx2EGFP embryos 
microinjected with sff1bMO, ff1bMO2, and ff1bMO3 morpholinos as well as wild-
type embryos microinjected with ff1bMO1 were scored for morphant phenotype at 7 
dpf. As reported previously, the phenotypes of the larvae could be classified into four 
different groups based on the severity of observed morphological defects (Table 4.3). 
Phenotypic changes began to appear around 5 dpf, and were fully manifested by 7 dpf. 
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Figure 4.9 Monitoring of EGFP transgene expression in the interrenal
gland of ff1bEx2EGFP transgenic embryos following morpholino
microinjections. Transgenic embryos of ff1bEx2EGFP line were microinjected 
with 11.25 μM of sense ff1b morpholino (sff1bMO) and antisense ff1b
morpholino targeting Exon3/IntronIII splice junction (ff1bMO3) at 1 to 2 cell 
stage. Images of live embryos at different developmental stages (28 hpf to 5 dpf) 
were presented. In embryos microinjected with sff1bMO, the EGFP expression 
persisted at the interrenal gland in a manner that was comparable to the 
uninjected control from 28 hpf through 5 dpf (A, C, E, G). The EGFP 
expression at the interrenal was diminished in embryos microinjected with 
ff1bMO3 from 28 hpf through 5 dpf (B, D, F, H). EGFP expression at the 
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 Larvae were scored for morphant phenotype at 7 dpf, and repeated again at 10 dpf. In 
general, the phenotypes observed at 10 dpf were essentially the same as those 
described at 7 dpf, with the exception that fluid accumulation had become more 
pronounced in some embryos and the yolk sac was completely absorbed.  
 
Table 4.3 Classification of ff1b morphant phenotype at 7 dpf (from Chai et al., 2003). 
Phenotype Class A 
(Wild-type) 
Class B Class C Class D 
Mouth protruding protruding shortened snout shortened snout 
Swim bladder inflation full none none none 
Heart beat strong slow slow slow 
Pericardial sac normal edema edema edema 
Blood flow rapid slow none none 
Yolk sac normal normal edema severe edema 
Optic sac normal normal slight edema severe edema 
Yolk absorption complete delayed delayed delayed 
Body axis straight straight curved upward curved upward 
Blood islands none none ventral tail ventral tail 
 
The proportion of larvae displaying the various classes of phenotypes at 7 dpf 
is presented in Table 4.4. Notably, ff1bMO3 knockdown of ff1b produced morphant 
phenotype at a percentage that was comparable to ff1bMO1. On the other hand, the 
efficacy of ff1bMO2 in perturbing ff1b gene function was much lower with only 
~20% of microinjected embryos displayed morphant phenotype Class B to Class D. 
The reason underlying this discrepancy is not clear at the moment but it is a well 
known fact that morpholinos targeting the same mRNA function at different efficacies. 
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  Table 4.4 Percentages of morphants exhibiting different classes of phenotypes at 7 
dpf. 
 Percentage of embryos (mean ± S.D.)  
Phenotype 
Class A B C D n 
sff1bMO 88.7 ± 0.38 4.8 ± 0.70 3.2 ± 0.73 3.3 ± 0.35 354 
ff1bMO1 47.3 ± 1.64 20.8 ± 1.45 17.1 ± 1.56 14.8 ± 1.75 398 
ff1bMO2 79.5 ± 1.67 6.7 ± 2.27 9.0 ± 0.96 4.8 ± 0.37 344 
ff1bMO3 46.5 ± 3.45 22.4 ± 1.37 17.5 ± 0.14 13.6 ± 2.21 366 
 
   
Besides scoring for morphant phenotype, the different classes of ff1bMO3 
morphants were also subjected to microscopic analyses for EGFP expression in their 
interrenal gland at 7 dpf. Notably, morphants that fell into Class C and D completely 
lacked interrenal gland at 7 dpf (Fig. 4.10E and F). Class B morphants, on the other 
hand, showed residual traces of EGFP expression at their interrenal (Fig. 4.10C and D) 
but the fluorescent intensity and domain were both much lower than that in the Class 
A morphants (Fig. 4.10A and B), which were essentially the same as uninjected or 
sff1bMO-injected embryos.  
Collectively, these findings demonstrate that the organogenesis of interrenal 
gland is adversely affected by ff1b knock-down and the severity of phenotype is 
directly correlated with both the presence and number of interrenal cells. This 
conclusion supports our hypothesis that the ff1b morphant phenotypes observed can 
be largely attributed to corticosteroid insufficiency that resulted from a reduced size 
or a complete lack of interrenal organ. Importantly, the morpholino knock-down 
experiment beautifully demonstrated the convenience offered by the ff1bEx2EGFP 
transgenic line to perform live imaging of interrenal morphogenesis without 






Class B Class B
Class C Class D
Class A
Figure 4.10 EGFP transgene expression in the interrenal gland of ff1b morphants at 
7dpf. Ff1bEx2EGFP transgenic embryos were microinjected with ff1b antisense 
morpholino ff1bMO3 and monitored for EGFP expression in the interrenal gland. Images 
of morphants Class A to D at 7 dpf were captured with confocal microscopy. While Class 
A morphants (A-B) showed EGFP expression that was comparable to the uninjected 
controls at their interrenal glands, Class B morphants (C-D) showed reduced EGFP 
expression and Class C and D morphants (E-F) completely lacked EGFP expression at 
their interrenal glands. Interrenal cells are indicated by red arrows. Scale bar, 100 µm. 
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 4.6 Treatment of ff1bEx2EGFP transgenic embryos with aminoglutethimide, a 
steroid inhibitor 
 
Excessive fluid accumulation in ff1b morphants suggests a dysregulation of 
osmoregulatory functions. Since the interrenal gland is known to be essential for 
osmoregulation in teleosts through its secretion of corticosteroids (Norris, 2006), it is 
reasonable to postulate that the osmoregulatory phenotypes observed in ff1b 
morphants could have resulted from the loss of interrenal steroidogenic functions.  
To test this possibility, an inhibitor-based method has been adopted previously 
to interfere with the steroidogenic activities of the interrenal gland in our laboratory. It 
was reported that the treatment of wild-type zebrafish embryos with the steroid 
inhibitor, aminoglutethimide (AG), resulted in late larval phenotypes that were highly 
reminiscent of ff1b morphants (Chai et al., 2003). However, the AG-treated larvae 
that displayed ff1b morphant-like phenotype were not examined histologically for the 
presence of ff1b transcripts or 3β-Hsd enzymatic activity in the interrenal gland. AG is 
a potent non-competitive inhibitor of the P450SCC enzyme (Uzgiris et al., 1977; 
Whipple et al., 1978) and it is also known to inhibit aromatase activity (Graves and 
Salhanick, 1979; Purba et al., 1994). Thus, treatment of embryos with AG would be 
expected to inhibit de novo synthesis of steroids from cholesterol in the interrenal 
gland, thereby effecting pharmacological interrenalectomy. It will be useful and 
interesting to repeat this inhibition experiment in the ff1bEx2EGFP transgenic line to 
better understand the connection between the observed phenotypes and interrenal 
morphogenesis in zebrafish.   
The transgenic embryos were treated with 1 mM of AG, starting from 8 hpf. 
Similarly, homozygous embryos and non-fluorescent embryos were removed between 
36 to 48 hpf, and only hemizygous embryos were retained for subsequent data 
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 collection and microscopic observations. The AG inhibition resulted in late larval 
phenotypes that were remarkably similar to those shown by ff1b morphants Class B to 
D. Subcutaneous edema became evident in ~70% of the larvae from around 7 dpf. At 
10 dpf, phenotype which included edema of the cranial, curvature of the body axis, 
optic, pericardial and yolk sacs, a shortened snout and protrusion of the lower maxilla 
was clearly manifested.  
Despite the similarity in the final outcome of the two lines of experiments, 
subtle differences were discernible. For instance, the penetrance of AG treatment was 
much higher than that of morpholino knockdown. Nearly 73% of treated larvae 
displayed the phenotype of impaired osmoregulatory functions, which were indicated 
by serious yolk sac edema (Table 4.5). This is probably due to the high diffusibility of 
AG. However, a large proportion of the AG-treated embryos (50%) displayed class B 
phenotype. Besides, yolk sac edema in the most severely affected AG-treated larvae 
was generally less extensive compared to Class C and D ff1b morphants. This 
probably reflects a better tolerance of zebrafish embryos to AG inhibition compared 
to ff1b knockdown. In contrast to ff1b morphants, no blood island formation was 
noted in AG-treated larvae. These differences indicate that the molecular mechanisms 
underlying ff1b knockdown and steroid inhibition could be different to certain extent 
although embryos under the two experimental strategies gave rise to similar outcome.  
 
Table 4.5 Percentages of AG-treated embryos exhibiting different classes of ff1b 
morphant phenotypes at 7 dpf. 
 Percentage of embryos (Mean ± S.D.)  
Phenotype  
Class A B C D n 
Buffer control 93.5 ± 0.70 3.0 ± 0.66 2.6 ± 0.14 1.76 ± 0.09 341 
AG-treated 26.5 ± 0.81 47.5 ± 0.81 15.9 ± 0.30 10.1 ± 0.36 407 
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 So could the morphogenesis of interrenal gland be affected in AG-treated 
embryos? The impaired osmoregulation observed in AG-treated larvae was probably 
due to the lack of glucocorticoids, as a result of AG inhibition but it should not affect 
the development of interrenal gland. However, there is still a possibility that a 
perturbation in the feedback regulation mediated by gluococorticoids may lead to a 
downregulation of ff1b and hence interrenal morphogenesis. The previous attempt of 
AG inhibition had not addressed these issues, partially due to the difficulty of 
performing ISH and immunohistochemical assays on the larvae with edema. The 
ff1bEx2EGFP embryos have certainly provided an ideal system to study the effect of 
AG inhibition on interrenal development.   
Monitoring of EGFP expression in the interrenal gland of AG-treated 
ff1bEx2EGFP embryos revealed that the interrenal development was largely 
unaffected throughout embryogenesis (Fig. 4.11). Even when they started to show 
phenotypes of ff1b morphants at 7 dpf, the interrenal gland could be detected and 
located easily (Fig. 4.11E-H). Class A larvae showed transgene expression that was 
essentially the same as buffer control. While the interrenal gland was almost 
comparable to the buffer control in terms of size and shape, larvae of Class B to Class 
D generally had their interrenal gland slightly expanded and the displaced as a result 
of the serious edema and distortion of the whole body axis (Fig. 4.11F-H).  
Taken together, these observations indicate that the morphogenesis of 
interrenal gland is not affected by steroid deficiency induced by AG. The observations 
confirm that the end product of steroidogenesis does not play a role in regulating the 
development of interrenal gland. Therefore, the similar morphological defects 
observed in ff1b morphants and AG-treated larvae could be largely attributed to the 



















Figure 4.11 Treatment of ff1bEx2EGFP transgenic embryos with steroid 
inhibitor, aminoglutethimide (AG). Transgenic ff1bEx2EGFP embryos were treated 
with 1 mM of AG in egg water containing 1.5 mM of HEPES buffer (pH 7.4) from 8 
hpf onwards. Embryos were examined for EGFP transgene expression particularly 
those in the interrenal gland, at different developmental stages using epifluorescence 
(A, D) or confocal microscopy (B, C, E-H). From 36 hpf through 5 dpf, the EGFP 
expression persisted in the interrenal gland at a level that is comparable to the 
untreated embryos (A-D). Even when the AG-treated larvae started to show 
morphological defects in reminiscent of ff1b morphant Class A to D at 7 dpf, the 
EGFP expression at their interrenal glands remained largely intact (E-H). Positions of 
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 4.7 Summary  
 
Using a BAC transgenesis strategy, we describe the first successful targeting 
of EGFP reporter to the VMH and interrenal gland using endogenous regulatory 
sequences from the zebrafish ff1b. In conjunction, EGFP expression was also 
observed in VMH-associated neuronal projections, otic vesicle, muscle pioneer cells, 
common cardiac vein, and neuromasts. Some of these expression domains might 
represent genuine ff1b expression in vivo that were not captured by ISH analyses 
previously. The novelty and versatility of the ff1bEx2EGFP transgenic platform to 
study the roles of Ff1b in endocrine development and function, particularly with 
regards to the interrenal gland in zebrafish, was well demonstrated by the injection of 
newly designed ff1bMO3 and chemical treatment with AG. Using this stable 
transgenic line, we were able to trace the the fate of ff1b-expressing cells following 
ff1b knockdown from much earlier developmental stage without the need to perform 
labourious ISH assays. Interestingly, lineage tracing of EGFP-expressing interrenal 
cells in AG-treated embryos demonstrated that the interrenal development was largely 
unaffected despite the fact that they showed similar phenotype of impaired 
osmoregulation as ff1b morphants. The ff1bEx2EGFP transgenic line will certainly 
aid in unraveling the molecular factors and mechanisms underlying the development 
and function of ff1b-expressing organs in zebrafish with much greater efficiency and 




 CHAPTER 5 
 







Ff1b is established as a master regulator of interrenal gland development in 
zebrafish (Chai and Chan, 2000; Chai et al., 2003; Hsu et al., 2003), in reminescent of 
its mammalian ortholog, SF-1. In mouse, Sf-1 is required for the differentiation and 
maintenance of the primordia for adrenals and gonads but it is dispensable for their 
early formation (Luo et al., 1994). Apparently, additional yet unknown factors are 
acting upstream of SF-1 to specify the cell fate of adrenals and gonads at initial stages 
and to induce the onset of SF-1 expression in early embryonic development. In 
zebrafish, transcriptional activation of Ff1b in various endocrine organs has not been 
carefully analyzed but there is sufficient evidence in mammals to suggest that specific 
enhancers exist for individual organ expression.  
It is noteworthy that the four zebrafish ff1 isoforms isolated have expression 
domains that overlap, from embryonic till adult stages (Kuo et al., 2005). In a 
developing zebrafish embryo, the transcripts of ff1a, ff1b, and ff1d can be detected in 
distinct VMH subdomains that partially overlap with one another (Chai and Chan, 
2000; von Hofsten et al., 2005; Kurrasch et al., 2007). Moreover, ff1d is transiently 
co-expressed with ff1b in the interrenal gland at about 30 hpf and they are both highly 
expressed in mature gonads (von Hofsten et al., 2005). The overlapping expression 
domains of ff1 genes imply that they may regulate each other’s expression. In addition, 
functional redundancy might exist among the Ff1 isoforms when they are co-
expressed in the same cell, as they bind to the same FRE. In rodents, the expression of 
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 SF-1 and LRH-1 are partially overlapped in the ovary with differential expression 
levels in different cell types (Falender et al., 2003; Hinshelwood et al., 2003). 
Although the molecular mechanisms underlying the transcriptional regulation of the 
two genes in the ovary have not been characterized, molecular switching between the 
two NRs at α-inhibin promoter has been demonstrated (Weck and Mayo, 2006).    
In contrast to detailed characterization of their expression patterns and 
functions in the endocrine tissues, the transcriptional mechanisms that direct FF1 
genes to their designated tissues remain largely undefined. Despite the identification 
of a few promoter elements, including an E box, a CCAAT box and three Sp1 binding 
sites (Daggett et al., 2000; Nomura et al., 1995; Scherrer et al., 2002; Woodson et al., 
1997) that control the basal transcription of SF-1, subsequent investigations suggested 
that these regions were unable to account for the specific temporal and spatial 
expression of the gene. Initial effort to drive expression of reporter transgenes using 
short promoter fragments from mouse Sf-1 locus failed to fully recapitulate the 
endogenous expression pattern of Sf-1 (Stallings et al., 2002; Wilhelm and Englert, 
2002; Jeays-Ward et al., 2003). As for zebrafish ff1b, the 5’ upstream promoter of ff1b 
up to 20 kb did not target GFP reporter gene to ff1b-expressing tissues in zebrafish. 
These findings collectively indicate that regulatory elements governing ff1b and Sf-1 
expression in vivo are most likely located distally from the basal promoter regions.  
An alternative strategy to determine potential upstream regulators of SF-1 is 
through the studies of gene mutations that affect SF-1 expression. By this approach, 
transcription factors such as WT1 and PBX1 have been proposed to act upstream of 
SF-1 because Sf-1 expression was markedly reduced in WT1-/- and PBX1-/- mice 
(Wilhelm and Englert, 2002; Schnabel et al., 2003). Direct evidence of the 
involvements of PBX1 in the regulation of Sf-1 transcription came from subsequent 
148
 characterization of a fetal adrenal enhancer identified in the intron IV of mouse Sf1 
gene (Zubair et al., 2006). 
As the tissue-specific enhancers of SF-1 are expected to lie distally to the 
proximal promoter region, the effort in studying the transcriptional regulation of SF-1 
has recently switched to transgenic mouse assays that utilize BAC or even yeast 
artificial chromosome (YAC) plasmid, which can accommodate the entire gene locus 
of Sf-1 (Karpova et al., 2005; Shima et al., 2005; Zubair et al., 2006). In conjunction, 
the ff1b locus from the BACff1b2 plasmid has been demonstrated to target EGFP 
reporter transgene specifically to ff1b-expressing tissues (Chapter 4). By dissecting 
the transgene activity of genomic fragments spanning distinct but overlapping regions 
of Sf-1 locus in transgenic mouse, a highly conserved VMH enhancer (~600 bp) has 
been identified in intron VI of mouse and human SF-1 loci. This enhancer is able to 
recapitulate the endogenous Sf-1 expression in fetal ventromedial diencephalons till 
adult VMH in transgenic mice studies (Shima et al., 2005). Following this study, a 
pituitary-specific enhancer of Sf-1 has also been recently identified in Intron VI 
(Shima et al., 2008). Subsequently, a BAC- and YAC- transgenic mouse approach has 
revealed a fetal adrenal enhancer (FAdE) in intron IV of mouse and human SF-1 loci 
(Zubair et al., 2006).  
 The major objective of this chapter was to characterize the genomic structure 
of ff1b gene in zebrafish and to uncover the regulatory elements that are necessary to 
specify the temporal and spatial expression of ff1b. This was done by sequencing and 
analyzing ff1b gene locus contained in the BACff1b2 plasmid. We believe that 
specific enhancer/repressor elements are located in specific regions within or flanking 
the ff1b gene locus, distally to the basal promoter region. Each of these modules of 
regulatory element will control the expression of ff1b in a specific tissue at a specific 
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 time. By combining Red/ET recombination-based deletions of specific genomic 
fragments and transient transgenesis studies in zebrafish, we managed to locate the 
cis-elements that potentially regulate the interrenal-specific expression of ff1b to 
Intron IV, which is uniquely present among all the vertebrate FF1 genes characterized 
so far. Further characterization of these regulatory regions will certainly help to 
identify the upstream cis- and trans- factors that regulate the tissue-specific 
expression of ff1b. 
 
5.2 Genomic structure of ff1b 
 
In an effort to recover genomic sequences for the entire zebrafish ff1b locus, a 
zebrafish BAC library was screened using the PCR screening approach (Genome 
Systems Inc, MO, USA). This gave rise to BACff1b2, which contains at least 20 kb of 
5’ flanking sequences and the entire ff1b gene locus (~25 kb). A 16.9 kb EcoRI 
fragment encompassing the 5’ flanking region of ff1b was isolated and completely 
sequenced using transposon-mediated tagging. Genomic sequences spanning the ff1b 
gene (Exon 1 through Exon 8) in the BACff1b2 were characterized by restriction 
enzyme subcloning and exon-containing fragments were identified by Southern blot 
hybridization of restricted BACff1b2 using a probe targeting Exon 4 (Chai and Chan, 
2000).  Large overlapping fragments were then cloned into pBluescript II SK 
(Stratagene) or pGEM11zf (Promega) vectors for sequencing. To access internal 
regions of these fragments, deletion subclones were generated by restriction enzyme 
digestion. DNA sequences were assembled using computer program Sequencher 
(version 4.8; Gene Code Corp., MI, USA). Any gaps in the contig assembly were 
completed by sequencing with primers targeting known sequences flanking the gap in 
the BACff1b2 plasmid. Notably, the entire genomic DNA insert carried by the 
BACff1b2 plasmid was not sequenced fully. Only the ff1b locus (Exon 1 to Exon 8) 
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 with ~1 kb of 3’ downstream sequences and nearly 21 kb of 5’ upstream sequences 
has been completed and the genomic sequence is provided in Appendix I.  
 
5.2.1 Exon/Intron organization of ff1b gene 
 
Analysis of the ff1b locus revealed that the 2522 bp long ff1b transcript is 
encoded by 8 exons distributed over a region of approximately 25 kb (Fig. 5.1). The 
5’ untranslated region (UTR) is transcribed almost entirely from Exon 1 as the start 
codon AUG starts at the seventh nucleotide of Exon 2. Exon 8 represents the largest 
exon in size (1305 bp) but the final 1065 nucleotide sequences are transcribed into 3’ 
UTR. Upstream to Exon 1, nearly 21 kb of 5’ flanking sequences were completed 
with an AT-rich gap at position -8473 bp that could not be sequenced using BigDye 
(Sanger) but was estimated to be ~0.8 kb in size by PCR analysis using flanking 
primers (data not shown).  
The genomic organization of zebrafish ff1b is highly conserved with that of the 
mouse (Ikeda et al., 1993; Ninomiya et al., 1995) and human SF-1 (Wong et al., 
1996), except for the presence of the additional Intron IV (Fig. 5.1). While Exon 4 in 
the other three zebrafish ff1 genes and other vertebrate FFf1 genes represents the 
largest coding exon and encodes the entire hinge domain region, the equivalent coding 
region of the zebrafish ff1b hinge domain is split into Exon 4 and Exon 5, thereby 
giving rise to the additional Intron IV. This genomic arrangement is also observed in 
invertebrate FF1 genes including, Drosophila Ftz-F1 (Fig. 5.1) and hence this intron 
may represent an ancestral characteristic of FF1 genes.  
The sizes and nucleotide sequences spanning all exon/intron junction sequences 
are presented in Table 5.1. All introns have been fully sequenced except for Intron V, 
which contains an AT-rich region that was recalcitrant to Sanger sequencing and is 
estimated to be ~1 kb in size using PCR analysis with flanking primers (data not 
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 shown). All exon/intron junctions of ff1b follow the 5’ GT—AG 3’ rule and they are 
highlighted in blue (Table 5.1). Sequences of exons and introns are shown in upper 
and lower cases respectively and amino acids encoded at each exon/intron junction 
are indicated in red. 
 
 
Figure 5.1 Genomic organization of the zebrafish ff1b gene. The exon/intron 
organization of ff1b and the corresponding protein domains encoded by the exons are 
indicated in different colors. The exon/intron organization of the other three zebrafish 
ff1 genes, namely ff1a, ff1c, and ff1d as well as human SF-1, mouse Sf1, and Ftz-F1 
from Drosophila melanogaster (DmFtz-F1) are shown in parallel for comparison.   
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 Table 5.1 Sequences spanning the exon/intron junctions of zebrafish ff1b gene. 
Exon bp Donor Intron bp Acceptor 
1 105 TTTAATATTGAGgtattactgt  I 151 
tctgtgtcagACGGTGATGGAC 
                M  D 
2 108 GAAAGTTGTAAGgtacgacaca E  S  C  K II 2129 
accatgccagGGTTTTTTCAAG 
          G  F  F  K 
3 142 AGAGACTTGAGGgtgagcaaca R  L  E  G III 5576 
gtcttctcagCTGTGCGTGCAG 
            V  R  A  D 
4 440 GATGAGGAGCAGgtatgaagca D  E  E  Q IV 3754 
gcgtgcgcagGTGAGAGGAAAG 
          V  R  G  K 
5 157 AAGGAACTAAAGgtacggctcc K  E  L  K V ~10560 
tgtgattcagGTGGGCGATCAG 
          V  G  D  Q 
6 120 ACAGGACAGGAGgtgagcgtct T  G  Q  E VI 1792 
tgtgctgcagGTGGAGCTGTCG 
          V  E  L  S 
7 145 TCTTCAACCCCAgtgagtctca F  N  P  S VII 2202 
tcttcctcagACGTGAAGCTCC 
            V  K  L  L 
8 1305 CCGTTCATACCA    
 
 
5.2.2 The 5’ putative promoter region of zebrafish ff1b 
 
By transient transfection analyses, several cis-elements that regulate the basal 
transcription of mammalian (human, rat, and mouse) SF-1 have been identified at its 
5’ proximal promoter region (Fig. 5.2). They include an E box that binds basic helix-
loop-helix (bHLH) family of transcription factors (Nomura et al., 1995; Harris and 
Mellon, 1998), a CCAAT box and Sp1 binding sites (Woodson et al., 1997). In 
addition, tissue-specific transcription factors, such as GATA4 (Tremblay and Viger, 
2001) and Sox9 (Shen and Ingraham, 2002), have also been implicated in the 
activation of SF-1 transcription. Notably, two FREs were mapped at positions -454/-
442 and +176/183 of human SF-1 and SF-1 itself has been shown to bind the FRE 
present in its first intron in rat and human genes, indicating a possibility of 
autoregulation mechanism (Nomura et al., 1996).  
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Figure 5.2 Schematic representation of cis-elements present in the 5’ proximal 
promoter of mammalian SF-1 and zebrafish ff1b genes. A summary of 
experimental findings for basal promoter of SF-1 in human, rat and mouse is 
illustrated. Equivalent region of 5’ promoter sequences (up to -500 bp) of zebrafish 
ff1b was analyzed computationally with MatInspector and the putative cis-elements 
are shown. Regulatory cis-elements are presented in different shapes and colors and 
their positions relative to the transcription start site (indicated by black arrowhead) are 
shown. Abreviations: FRE, Ftz-f1 response element; GATA, GATA protein response 
element; Sox, Sox protein binding sites; CAT, CAAT box; Sp1, Sp1 response element.  
 
 
To identify potential transcription factor binding sites (TFBSs) that might play 
a role in the transcriptional activation of ff1b, the equivalent region of 5’ proximal 
promoter of ff1b was subjected to bioinformatics analyses using the online analysis 
program MatInspector (www.genomatix.de). Encouragingly, similar binding elements 
were revealed in the basal promoter region of ff1b to those that were found in the 
human regulatory region. In close proximity to the transcription start site, motifs 
resembling the E-box element (-59/-54 and +203/+215) and CCAAT box (-285/-283) 
were found (Fig. 5.2). In addition, binding sites for trans-factors including GATA, 
Sp1 and Sox were mapped at positions -116/-104, -325/-311, and -440/-424 
respectively. Although the positions of the promoter elements varied slightly between 
mammalian SF-1 and zebrafish ff1b, the above mapping of cis-elements indicate that 
the mechanism of activating the basal promoter for Ftz-f1 genes is largely conserved 
across the various vertebrate species. 
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 5.2.3 The zebrafish ff1b is located on linkage group 8 
 
Chromosomal location of the zebrafish ff1b has been mapped to position 
LG8_139.1 cM of linkage group (LG) 8 using the Heat-Shock (HS) meiotic mapping 
panel (Woods et al., 2000; Kuo et al., 2005). The zebrafish ff1b gene is localized in 
ctg12124 together with four other genes, namely cyr61, lmo4, nr6a1, and c11orf8  
(Fig. 5.3). The tight linkage of ff1b and ff1d to nr6a1a and nr6a1b, respectively, thus 
supports the orthology of both genes to NR5A1 as well as confirming their 
relationship as gene duplicates. The ff1d locus on LG21 retains contiguous synteny of 
neighboring genes when compared to human and mouse SF-1 locus, while the ff1b 
locus on LG8 is completely different. Thus, it appears that ff1b locus has undergone 
genomic rearrangement such as inversion and deletion, to evolve to its present 
genomic context (Kuo et al., 2005). 
The zebrfish genome database at Ensembl (http://www.ensembl.org/ 
Danio_rerio/Info/Index ), however, does not give a similar syntenic arrangement of 
neighboring genes for the ff1b locus (Fig. 5.4A), and the only gene retained by both 
genomic maps is cyr61. As the current version of the zebrafish genome is still 
incomplete, particularly for this segment of the LG8, as well as the expected tight 
linkage of nr6a1a to ff1b, the ff1b chromosomal context derived from the HS mapping 
panel is likely to be the more correct version. In contrast, the genomic context 
predicted for ff1d at Ensembl genome assembly is similar to the genetic mapping 
analysis. However, the syntheny of downstream neighboring genes of ff1d is only 
maintained until nek and the next expected downstream ORF, lhx2, could not be 





Figure 5.3. Genomic context of ff1b on linkage group (LG) 8 in comparison to 
ff1d and human NR5A1 by genetic mapping. Comparison of ff1b and ff1b locus on 
zebrafish chromosome DreLG8 and DreLG21 to NR5A1 locus on human chromosome 
Hsa9 (modified from Figure 2 of Kuo et al., 2005). The ff1b and ff1d genes were 
mapped on the LN54 radiation hybrid panel, and intercalated into the map from the 





Figure 5.4 Genomic context of ff1b and ff1d on LG8 and LG21 displayed at 
Ensembl and mapping to the ff1b genomic sequences determined from BACff1b2. 
(A)Schematic representation of genome assembly predicted for ff1b and ff1d at 
Ensembl genome browser of zebrafish (Zv7). (B) Comparison of genomic sequences 
determined from BACff1b2 to that in scaffold_831 on LG8 at Ensembl genome 
browser. The genomic DNA insert in the BACff1b2 plasmid is flanked by T7 and SP6 
vector priming sites at 5’ and 3’ end, respectively. The portions of genomic sequence 
that has been determined in this study are highlighted in orange. The portions of 
genomic DNA insert that has not been sequenced are indicated in dashed line. The 
corresponding genomic regions from scaffold_831 of Ensembl database that have 
been matched to BACff1b2 sequences are displayed underneath. The extreme 5’ and 
3’ end of matching sequences between the two contigs are indicated by red arrows. 
Gaps in the genomic sequences of scaffold_831 located at the 5’ upstream region of 




The ~46 kb of genomic sequences that have been determined from the 
BACff1b2 was compared to zebrafish genome database (Ensembl; Fig. 5.4B). The 
ff1b locus spanning Exon 1 to Exon 8 was first mapped to position 46,968,420 to 
46,993,052, which was annotated as nr5a1a on the contig termed scaffold_831 on 
LG8. The genomic sequences obtained from BACff1b2 matched the database 
sequence from -16,485 to +25749 bp, which corresponded to 91% of our genomic 
sequences spanning 46,361 bp (-20,612 to +25749 bp). Also, our genomic sequences 
have resolved all the remaining gaps that were present in scaffold_831 for ff1b, which 
consisted of two gaps in Intron III and one gap each in Intron IV and Intron VII. 
Although the entire genomic DNA insert contained in the BACff1b2 plasmid 
has not been sequenced in full, the extreme 5’ and 3’ end sequences of the DNA insert 
were obtained by DNA sequencing with T7 and SP6 primers flanking the insert on 
pBeloBAC-11 vector. Notably, sequences at the 3’ end of the genomic insert 
generated from SP6 priming in BACff1b2 can be mapped in scaffold_831 but not the 
5’ end sequences generated from T7 priming. This matching eventually gave rise to 
an additional 16,520 bp of genomic sequences 3’ to where we have stopped 
sequencing in the BACff1b2 plasmid (Fig. 5.4B). Due to the presence of several 
unsequenced gaps in the 5’ upstream region of ff1b locus in scaffold_831, no 
additional 5’ upstream sequences could be matched with confidence after -16,485 bp 
of ff1b, the position where the database and the genomic DNA insert of BACff1b2 
sequences last matched. As the genomic DNA insert in BACff1b2 was estimated to be 
~100 kb, the 5’ genomic region of ff1b that was not sequenced is estimated to be ~38 
kb. When the sequences from -20,612 to -16,485 bp of our genomic sequences were 
used to perform BLAT search against the zebrafish genome, no significant matching 
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 could be obtained, indicating that the genomic sequences spanning this region have 
not been completed for the on-going zebrafish genome sequencing project.     
 
 
5.3 Deletions of targeted genomic regions from the recombined 
pBACff1bEx2EGFPAmp by Red/ET homologous recombination 
 
The transgenesis studies using pBACff1bEx2EGFPKan described in Chapter 4 
indicate that the regulatory elements that are required for ff1b temporal- and spatial-
specific expression are contained within the ff1b locus in the BAC construct. 
Furthermore, based on the findings of mouse Sf-1 (Shima et al., 2005; Zubair et al., 
2006; Shima et al., 2008), the regulatory cis-elements governing tissue-specific 
expression of ff1b were anticipated to be localized in intronic sequences. Therefore, 
we have adopted a two-step counter selection, homologous recombination-based 
strategy to remove specific introns and genomic sequences of ff1b from the 
recombined BAC plasmid. The effect of losing those genomic fragments on the EGFP 
transgene expression was subsequently assessed by microinjecting the various deleted 
BAC contructs into zebrafish embryos.  
Using the two-step counter-selection method (Section 2.8.2), specific 
sequences within the pBACff1bEx2EGFPAmp plasmid could be deleted by Red/ET 
homologous recombination. The first step of counter selection involved the insertion 
of the rpsL-neo cassette through homology arms targeting the genomic sequences to 
be deleted and the successfully recombined BAC construct was retrieved by 
kanamycin selection (Fig. 2.2). In the second step of counter-selection, the rpsL-neo 
cassette was removed and replaced by the homologous arms, thereby leading to the 
deletion of a particular genomic region and without leaving a selectable marker 
behind.  
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 With homologous arms targeting the sequenced portion of the 
pBACff1bEx2EGFPAmp plasmid, we managed to specifically delete two genomic 
fragments spanning 10 kb and 20 kb respectively from the 5’ upstream region (Fig. 
5.5A). The first 5’ deletion (5’10kbDel1) spans -21,342 to -11,397 bp while the 
second 5’ deletion (5’20kbDel2) spans longer region from -21,342 to -1,012 bp. 
Approximately 1 kb of sequences 5’ upstream to exon 1 was retained so that the basal 
promoter activity would not be affected by the deletion. Since the data from several 
transgenic mouse studies point to the presence of tissue-specific enhancer in intronic 
sequences, the remaining deletions were planned to target the intronic region. Thus, 
Intron I to Intron VII was deleted individually from the pBACff1bEx2EGFPAmp 
plasmid (Fig. 5.5B). It was anticipated that most of the regulatory elements governing 
tissue-selective expression of ff1b should reside within the 46 kb genomic region that 
has been fully sequenced in the BAC construct. Therefore, the above deletion scheme 
represents a good starting point to identify genomic regions that potentially contain 
regulatory enhancer or repressor elements of ff1b.  
 
5.4 Assessment of 5’ genomic deletions of ff1b from pBACff1bEx2EGFPAmp 
by transient transgenesis in zebrafish embryos 
 
Although transgenesis studies performed previously in our laboratory 
demonstrated that the 5’ flanking region of ff1b up to 20 kb lacked tissue-specific 
enhancer activity, there was still a possibility for the presence of repressor elements 
within this 5’ upstream sequences. Therefore, two genomic regions spanning 10 kb 
and 20 kb each were deleted from the BAC construct. To study the effect of removing 
these 5’ upstream regions, the deleted pBACff1bEx2EGFPAmp plasmids were 
microinjected into zebrafish embryos at 1 to 2 cell stage. At about 48 hpf, 
microinjected embryos were scored for EGFP expression at the expected tissues of 
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 expression, including the VMH, neuronal projections, otic vesicle, interrenal and 
muscle (Table 5.2). 
 
Figure 5.5 Schematic representation of Red/ET recombination-based deletions of 
ff1b genomic regions in pBACFf1bEx2EGFPAmp. (A) Specific genomic regions at 
the 5’ flanking region and (B) introns were deleted from the pBACff1bEx2EGFPAmp 
construct by a two-step counter selection recombination strategy. Each genomic 
fragment deleted is indicated by V-shape in dash line.   
   
As the expression pattern of EGFP transgene in transient transgenesis could be 
highly mosaic, our analyses took mainly qualitative differences into consideration. 
Thus, the effect of losing a particular genomic fragment was considered significant 
only when the EGFP expression at a particular tissue was completely lost in all the 
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 embryos examined. As expected, the EGFP expression pattern at the various expected 
sites of expression was largely unaffected when the 5’ flanking sequences of ff1b were 
removed (Table 5.2).  
 
Table 5.2 Percentage (number) of zebrafish embryos expressing EGFP at the 
respective tissues at 48 hpf following microinjections of the corresponding deleted 
pBACff1bEx2EGFPAmp constructs. Abbreviations: VMH, ventromedial 
hypothalamus; NP, neuronal projections; IR, interrenal; OV, otic vesicles ; M, muscle. 
 Percentage (No.) of embryos expressing EGFP at: 
BAC plasmids 


















15.8    
(73) 








  (94) 
19.2  
  (77) 
12.2  
 (49) 





IntronIDel 7.5      (35) 
7.0      
(33) 
10.5    
(49) 
10.6     
(50) 
10.8    
(51) 468 
IntronIIDel          17.0    (86) 
14.4     
(73) 
8.7       
(44) 
16.8      
(85) 
10.5      
(53) 506 
IntronIIIDel 
6.4      
(33) 
8.2      
(42) 
10.7     
(55) 
17.1     
(88) 
13.6     
(70) 515 
IntronIVDel 11.8     (70) 
10.1      
(60) 0 0 
13.6      
(81) 595 
IntronVDel 2.7       (14) 
2.3      
(12) 
9.7   
(50) 
11.7    
(60) 
9.7       
(50) 515 
IntronVIDel 8.9       (46) 
9.4       
(48) 
9.6      
(49) 
13.7     
(70) 
8.7       
(34) 510 
IntronVIIDel 5.0       (25) 
5.2       
(26) 
9.5       
(47) 
9.9       
(49) 
8.2       
(41) 497 
 
Intriguingly, the number of embryos displaying EGFP transgene expression at 
interrenal was dramatically reduced with the truncation of -21,342 bp to -11,397 bp 
(5’10kbDel1) but was unaffected with truncation spanning longer region from -21,342 
161
 bp to -1,012 bp (5’20kbDel2). These observations indicate the possibility of having 
positive regulatory elements for interrenal-specific expression of ff1b within the first 
10 kb of the 5’ upstream sequences. At the same time, the results could also indicate 
the presence of potential repressor elements that suppress interrenal-specific 
expression of ff1b within the second 10 kb of 5’ upstream sequences. This postulation 
remains to be tested, as the truncation did not lead to a complete loss of expression at 
the interrenal. A more extensive deletional study of the 20 kb 5’ upstream sequences 
would aid to map any potential regulatory elements that are relevant to interrenal-
specific expression of ff1b.   
 
5.5 Assessment of intronic deletions of ff1b from pBACff1bEx2EGFPAmp by 
transient transgenesis in zebrafish embryos 
 
The tissue-specific enhancers regulating the expression of mouse Sf-1 in the 
VMH, pituitary, and fetal adrenal have been identified in Intron VI and Intron IV 
respectively (Shima et al., 2005; Zubair et al., 2006; Shima et al., 2008). These 
enhancer sequences have been shown to be highly conserved in human SF-1 but we 
could not identify the equivalent regulatory region in zebrafish by computational 
analyses. However, it is still reasonable to hypothesize that the regulatory elements 
that are responsible for the tissue-specific expression of ff1b could reside in one of the 
introns in reminiscent to the mammalian SF-1 genes. Therefore, Intron I to Intron VII 
of zebrafish ff1b gene was deleted individually using the counter selection strategy. 
The effect of losing a particular intron was subsequently assessed by microinjecting 
the deleted pBACff1bEx2EGFPAmp plasmid into zebrafish embryos followed by 
monitoring of EGFP transgene expression. 
Surprisingly, the deletions of most introns produced no effect on the EGFP 
transgene expression in tissues that are known to express the transgene (Table 5.2) 
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 with the exception of Intron IV. Deletion of Intron IV led to a complete loss of EGFP 
transgene expression in the interrenal and otic vesicle, indicating that important cis-
elements controlling the expression of ff1b in these tissues are located in this intron. 
The close association of ff1b expression in the otic vesicle and interrenal gland was 
also unexpected, as a previous ISH study (Chai and Chan, 2000) has failed to localize 
ff1b expression to the otic vesicle. Interestingly, Intron IV represents the additional, 
and most probably a more ancestral intron, that is not found in the human and mouse 
SF-1 genes. Thus, the location of interrenal-specific regulatory elements present in 
this unique intron of ff1b could be distinctive from the FAdE that has been mapped in 
mouse Sf-1.   
Intriguingly, the EGFP expression in the muscle pioneer cells remained not 
affected with deletions of individual introns or 5’ upstream sequences. This indicates 
that the cis-elements that are responsible for the muscle-specific expression of 
transgene are located outside of those portions of the ff1b locus that were studied. At 
the same time, it could also point to the absence of repressor elements or gene 
boundary elements that are required to suppress the muscle-specific expression of ff1b 
in the endogenous genomic context.  
Although EGFP expression in the VMH and associated neuronal projections 
was mostly not affected, the proportions of embryos showing the presence of EGFP in 
these locations were markedly reduced when Intron V or Intron VII was deleted. This 
observation highlighted the possibility that the two introns might act synergistically to 
regulate the VMH-specific expression of ff1b gene. This finding implies that the 
organization of regulatory elements for ff1b could be more complicated than what has 
been described for mammalian SF-1. Nevertheless, further characterization of the 
TFBSs within these introns is necessary to identify potential cis-elements controlling 
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 VMH-specific expression of ff1b. For example, both Intron V and VII can be deleted 
simultaneously to see whether they are functionally related to one another.  
Taken together, our recombination-based deletion scheme of removing 
individual introns and specific genomic sequences from the 5’ flanking region, in 
combination with transient transgenesis using the zebrafish embryos, has successfully 
identified Intron IV as the candidate genomic region containing the enhancer that 
confers interrenal-specific expression to zebrafish ff1b. In addition, several other 
genomic regions that could potentially regulate tissue-specific expression of ff1b have 
also been identified (Fig. 5.6). By dissecting Intron IV computationally and 
experimentally, core cis-elements as well as the associated trans-acting factors that 
regulate interrenal-specific expression can now be identified. While candidate cis-
elements that are required for VMH-specific expression of ff1b have not been 
determined with any certainty, Intron V and Intron VII might potentially be involved 
and they are likely to contain cis-elements that are important for the transcriptional 
regulation of ff1b in the VMH.   
 
5.6 Computational analysis of Intron IV for cis-elements that potentially 
regulate interrenal-specific expression of ff1b 
 
To determine the presence of cis-elements that contribute to the interrenal-
specific expression of ff1b, the 3754 bp of intronic sequence was analyzed using the 
MatInspector program online (www.genomatix.de). Only TFBSs that were predicted 
with core similarity of >0.90 were considered significant. Not only cis-elements that 
bind factors which have been previously implicated in SF-1 expression in the adrenal 
cortex are taken into consideration, cis-elements that bind novel factors that could 
potentially modulate interrenal-specific expression of ff1b have also been highlighted. 
The positions of these putative cis-elements are summarized in Table 5.3 and a closer 
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 examination of the arrangement of these elements revealed that most of them were 
localized between 1900 and 3200 of Intron IV. Therefore, this genomic region of 
intron IV displays the highest potential in harboring a core enhancer element for 







Figure 5.6 Genomic regions that harbor potential enhancer or repressor 
elements of ff1b gene. Genomic fragments that contain potential enhancer or 
repressor elements for interrenal- (IR) and ventromedial hypothalamus- (VMH) 
specific expression of ff1b are identified by genomic deletion and transient 
transgenesis studies in zebrafish embryos. Asterisk (*) indicates an absolute 






Figure 5.6 Potential cis-elements present between position 1900 and 3200 bp of 
ff1b Intron IV. The genomic sequences of ff1b Intron IV spanning 1900 to 3200 bp 
was analyzed bioinformatically with online prediction program MatInspector. Putative 
cis-regulatory elements that could potentially regulate the interrenal-specific 
expression of ff1b are illustrated in different shapes and colors. 
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Table 5.3. Positions of cis-elements that may potentially contribute to the interrenal-
specific expression of ff1b in Intron IV, as predicted by MatInspector.  
 
No cis-element Abbrevia tion Position in Intron IV of ff1b 
1 Pbx/Hox binding site Pbx/Hox 135/151; 290/306; 761/777; 1392/1408; 1985/2001; 2502/2518 
2 Meis/Hox binding site Meis/Hox 220/234; 503/517; 805/819; 1097/1111; 1993/2007 
3 FF1 response element FRE 2383/2395; 3113/3125 
4 Wilms tumor binding site WT1 2717/2733 
5 GATA binding site GATA 
144/151; 433/445; 806/818; 
1401/1413; 2190/2202; 2456/2468; 
2792/2804 
6 cAMP response element CRE 31/51; 526/546; 2148/2168; 2681/2701; 2841/2861 
7 LEF1/TCF binding site LEF1/TCF 2058/2074; 2689/2705;  
 Brachyury binding site Brachyury 2281/2301 
8 Forkhead/Winged helix binding site Forkhead 
401/417; 838/854; 1144/1160; 
2143/2153; 2686/2696; 2959/2969; 
3066/3082 
9 SMAD protein binding site SMAD 1626/1634; 2615/2623; 2762/2770; 
 
Notably, several binding sites for Pbx/Hox and Meis/Hox complexes have 
been mapped within Intron IV of ff1b. The Pbx-Hox-Meisi1 complex has been 
recently demonstrated to bind cis-elements present in Intron IV of mouse Sf-1 and 
directly regulate Sf-1 expression in the fetal adrenal of mouse (Zubair et al., 2006). 
Two FREs have been also mapped at position 2383/2395 and 3113/3125 of Intron IV, 
implying the presence of an autoregulatory loop in reminescent to the FAdE identified 
in mouse Sf-1 locus (Zubair et al., 2006). Also, a binding site for WT1 has also been 
mapped at position 2717/2733. The expression of wt1 at the earliest stage of 
adrenogonadal precursors of both mouse and zebrafish suggested that it could act as a 
direct upstream activator of Sf-1 or ff1b and this has indeed been demonstrated in 
mouse (Wilhelm and Englert, 2002; Hsu et al., 2003). Furthermore, the ablation of 
this gene led to developmental defects in the adrenal cortex of mouse (Wilhelm and 
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 Englert, 2002) and interrenal gland of zebrafish (Hsu et al., 2003). Another class of 
transcription factors that has been implicated in the transcriptional regulation of SF-1 
(Tremblay and Viger, 2001) and adrenocortical development (Kiiveri et al., 2002) is 
GATA factors and several GATA binding sites have also been mapped within Intron 
IV.   
In addition to the above TFBSs that have been directly implicated in SF-1 
expression or adrenocortical development, a few other novel cis-elements that may 
potentially be involved in controlling ff1b expression in the interrenal have also been 
located. Several cAMP response elements (CRE) have been predicted with high 
confidence throughout Intron IV of ff1b. Considering the important role of cAMP in 
inducing the transcriptional activation of steroidogenic enzymes in adrenocortical 
cells, it has been proposed to regulate the expression of SF-1 (Val et al., 2003). Two 
binding sites for LEF1/TCF and one binding site for Brachyury, which are both 
molecular components of Wnt signaling pathway, have also been located in Intron IV. 
These cis-elements may be functional as Wnt signaling pathway is important for 
adrenocortical development and factors involved in this pathway could, therefore, 
potentially regulate the early specification of interrenal as well as the interrenal-
specific expression of ff1b (Else and Hammer, 2005; Kim et al., 2008). Besides, 
several binding sites for transcription factors belonging to the fork head/winged helix 
family are present in Intron IV. This family of transcription factors are important 
regulators of mesoderm development (El Hodiri et al., 2001; Wilm et al., 2004). Since 
the interrenal gland is derived from intermediate mesoderm, transcription factors 
regulating mesoderm development might potentially regulate early specification of 
interrenal and thus ff1b expression as well. Lastly, three binding sites for transcription 
factors of the SMAD family have also been mapped. As molecular components of 
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 transforming growth factor beta (TGFβ) signaling pathway, SMAD proteins have 
been shown to transcriptionally regulate StAR promoter in adrenocortical cells (Brand 
et al., 1998) as well as the proliferation of adrenocortical cells (Chambaz et al., 1996; 
Mesiano and Jaffe, 1997; Langlois et al., 2002). 
Taken together, the computational prediction revealed TFBSs that are likely to 
play a role in directing interrrenal-specific expression of ff1b. Based on this prediction, 
Intron IV appears as a promising candidate regulating the interrenal-specific 
expression of ff1b. As the intronic sequences spanning 3754 bp is too long, a more 
extensive deletional/subcloning study concentrating on this fragment would be 
necessary. By placing distinct but overlapping genomic fragments fromIintron IV 
downstream to a reporter gene construct with a functional basal promoter, the 
transgene activity of potential enhancer can be investigated by transient transgenesis 
in zebrafish embryos. The functionalities of the predicted cis-elements can then be 
studied following the identification of a core enhancer of interrenal, which is 
anticipated to span only a few hundred basepairs.   
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 5.7 Summary 
 
In this chapter, the genomic organization of the zebrafish ff1b gene and the 
characterization of the gene locus to identify tissue-specific regulatory elements were 
described. The genomic sequences from the BACff1b2 plasmid spanning ~20 kb of 5’ 
upstream region and ~25 kb of ff1b locus were almost fully sequenced, except for two 
AT-rich gaps in the 5’ region and in Intron V, respectively. The structure of ff1b gene 
is generally conserved among vertebrate SF-1 genes in terms of exon/intron 
organization, with the exception of the presence of the unique Intron IV in zebrafish. 
Furthermore, cis-elements that potentially regulate the basal transcription of ff1b have 
been mapped and they appear to be highly conserved to those reported for mammalian 
SF-1. However, the genome context of ff1b on LG8 does not show conserved synteny 
with human SF-1. Instead, conserved synteny to genomic arrangement of human SF-1 
is observed for ff1d locus on LG21. Using a recombination-based deletion strategy, 
specific genomic regions and introns were successfully removed from the recombined 
pBACff1bEx2EGFPAmp and the effect of each deletion was studied by transient 
transgenesis in zebrafish embryos. The preliminary findings have identified several 
potential enhancer/repressor-containing regions. Interestingly, Intron IV has been 
shown to be essential for the interrenal-specific expression of EGFP transgene, and it 
represents an intron that is normally preserved only in invertebrate FF1 genes. 
Therefore, we have identified an ancestral intronic core enhancer that regulates the 
interrenal expression of ff1b. Computational analysis of Intron IV sequences revealed 
TFBSs that have been directly implicated in the expression of mouse Sf-1 gene or 
adrenocortical development. In addition, a few novel cis-elements that may 










6.1. The zebrafish Ff1b, similarly to SF-1, plays a conserved role in the 
regulation of steroidogenesis 
 
In the interrenal primordium of zebrafish, ff1b expression precedes that of 
cyp11a1 and 3β-hsd by about 2 hr (Chai and Chan, 2000; Hsu et al., 2003). 
Furthermore, ff1b knockdown by MO led to interrenal agenesis and impaired 
osmoregulation along with downregulation of the two steroidogenic enzymes (Chai et 
al., 2003). These observations imply a conserved role of ff1b in the transcriptional 
regulation of steroidogenic enzymes and hence steroidogenesis. To define the ability 
of zebrafish Ff1b to transactivate the expression of steroidogenic enzymes, the 5’ 
putative promoter of cyp11a1 was isolated and demonstrated to be active by transient 
transfection and microinjection studies. Through a series of detailed characterization 
of the 1.7 kb promoter of zebrafish cyp11a1, we provided evidence that Ff1b binds 
directly to the distal and proximal FRE and transactivates the cyp11a1 promoter. 
 
6.1.1. Ff1 potentially regulates the transcription of genes encoding steroidogenic 
enzymes in zebrafish 
 
Strict temporal and spatial regulation of gene expression of steroidogenic 
enzymes appear to be tightly regulated by members of the NR5A subfamily of NRs. 
For instance, SF-1 is well established as a transcriptional regulator of all steroidogenic 
enzymes except for CYP11B2 (Val et al., 2002; Payne and Hales, 2004). LRH-1 has 
been reported to regulate the expression of the following steroidogenic enzymes, 
CYP11A1 (Kim et al., 2005; Hsieh et al., 2008), CYP17 (Zhou et al., 2007), CYP19 
(Mendelson and Kamat, 2007; Ohmuro-Matsuyama et al., 2007), CYP11B1 (Wang et 
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 al., 2001), and 3β-HSD (Mueller et al., 2006; Saxena et al., 2007). In Medaka, SF-1 
and LRH-1 homologs have been shown to bind and transactivate the promoter region 
of ovarian aromatase cyp19a1 (Watanabe et al., 1999) and brain cyp19a2 (Ohmuro-
Matsuyama et al., 2007) gene, respectively. The association of the FREs present in 
the promoter region of rainbow trout cyp19a promoter with an FF1 factor similar to 
SF-1 has also been demonstrated by transient transfection and EMSA assays (Kanda 
et al., 2006). Several other studies have presented the evidence of co-expression of 
Ff1s and steroidogenic enzymes in teleosts, without demonstrating a direct 
involvement of Ff1s in their transcriptional regulation (von Hofsten et al., 2002; Liu 
et al., 2004; von Hofsten and Olsson, 2005; Zhang et al., 2007). 
Except for 3β-hsd, computational analysis has revealed at least one FRE in the 
promoter regions of cyp11a1, cyp17, and star, which have been isolated by genome 
walking in this study. To determine the commonality of the presence of FREs in the 
promoter regions of steroidogenic genes, 2 kb of 5’ upstream region for all the 
currently known zebrafish genes encoding steroidogenic enzymes were isolated in 
silico from Ensembl zebrafish genome browser. The putative regions were then 
analyzed computationally using MatInspector for the prediction of FREs. Notably, at 
least one FRE can be mapped at the 5’ promoter of cyp19a1a (-129/-117), 17β--hsd1 
(-1921/-1903, -864/-852, -129/-117), 11β-hsd2 (-1647/-1635), and 11β-hsd3 (-709/-
697). The consistent presence of FREs in these promoter regions indicates that Ff1 
isoforms could potentially regulate the transcription of steroidogenic enzymes. 
Considering the restricted expression of ff1b in steroidogenic tissues, these predictions 
imply a direct involvement of Ff1b in the regulation of these genes. At the same time, 
other Ff1 isoforms could also be involved if they are co-expressed in the same cells.  
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Figure 6.1 Relative positions of Ff1 response elements (FREs) identified in the 5’ 
flanking promoter of zebrafish genes encoding steroidogenic enzymes. Two kb of 
5’ promoter sequences of all the currently annotated steroidogenic genes at Ensembl 
were isolated in silico and FREs, as incicated by the red boxes, were identified by 
online prediction program. 
 
Although cyp11a1 catalyzes the rate-limiting step in the steroidogenesis 
pathway, no previous study of this gene in zebrafish has been reported. In this study, 
the 1.7 kb zebrafish cyp11a1 promoter was shown to be active using transient 
transfections in cell lines and transient transgenesis in zebrafish embryos. The report 
of the ability of Ff1b to transactivate the 1.7 kb zebrafish cyp11a1 promoter has 
provided a good validation for the direct involvement of Ff1b in the transciptional 





 6.1.2. Regulatory cis-elements are conserved in the zebrafish cyp11a1 promoter 
 
The human CYP11A1 promoter has been very well studied and the functional 
roles of the following transcription factors, SF-1, Sp1, AP-1, TReP-132, AP-2, NF-1, 
and Ets in its transcriptional activation  have been well established (Guo et al., 2007). 
Within the first 150 bp of 5’ promoter, an AP-2 binding motif, a TreP-132 binding 
site, an FRE, and the TATA box constitutes the basal promoter. An upstream cAMP-
responsive module between -1553 and -1633 consists of an FRE, and two flanking 
AP-1/CREB-binding sites. In addition, two adrenal-selective enhancers (AdE) 
together with two Sp1-binding motifs, a NF-1 binding site, and a consensus Ets 
binding site form a regulatory module at -1845 to -1898. These cis-elements are 
defined through many transient transfection and transgenic mouse studies.  
In the zebrafish cyp11a1 promoter, two FREs, one CRE, two Sp1 and four AP-
1 binding sites have been mapped (Fig. 3.4). It is noteworthy that the presence of the 
two FREs in a highly conserved manner is consistent with the role of SF-1 acting as a 
central regulator of the transcriptional activation of steroid hydroxylases. Unlike the 
Tetraodon, human, and mouse CYP11A1 promoter, the distal FRE of zebrafish 
cyp11a1 promoter is not tightly associated with CRE. Nevertheless, the conservation 
of the two FREs, Sp1, and AP-1 transcription factor binding sites that have been 
implicated in the transcriptional activation of mammalian CYP11A1 promoter 
indicates a conserved mode of regulation across different species. Cis-elements that 
bind known coregulators of SF-1 including Sox proteins (De Santa et al., 1998) , 
GATA factors (Tremblay and Viger, 1999), and WT-1 (Shen et al., 1994) have also 
been defined, implying a possible functions of these transcription factors in regulating 
the transcription of cyp11a1 in concert with Ff1b.  
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 6.1.3. Functional discrepancy exists between the 1.7 kb cyp11a1 promoter of 
zebrafish and human despite the high degree of cis-element conservation 
 
Despite the conservation of their cis-acting elements, the 1.7 kb zebrafish and 
human cyp11a1 promoters does not appear to be functionally equivalent. In transient 
transfection studies, the 1.7 kb human promoter consistently activates the luciferase 
reporter to a higher level in all the cell lines tested including Y1, MA-10, CHO-K1, 
LβT2, HepG2, with exception for 293T (Section 3.4). Intriguingly, the 1.7 kb cyp11a1 
promoter of both human and zebrafish are capable of activating the luciferase reporter 
gene not only in cell lines of steroidogenic origins like Y1, MA-10, and CHO-K1, but 
also in cell lines of non-steroidogenic origins like 293T and LbT2. As LbT2 cells 
originate from pituitary gonadotrope, the activation of the human and zebrafish 
cyp11a1 promoter is most likely attributed to the presence of endogenous SF-1.  The 
high level of promoter activity for both human and zebrafish cyp11a1 in 293T cells 
might not be surprising, as the human CYP11A1 promoter has ben shown to be active 
in this cell line (Ben Zimra et al., 2002). This is probably due to the presence of trans-
acting factors that are capable of assuming the role of FF1s. In placental tissue that 
does not express SF-1, another transcription factor named AP-2 has been shown to 
assume the role of SF-1 to activate the transcription of human CYP11A1 (Ben Zimra 
et al., 2002).  Intriguingly, the presence of LRH-1, which belongs to the same family 
of SF-1 and binds the same FRE (Fayard et al., 2004), did not activate both promoter 
in HepG2 of liver origin (where LRH-1 is endogenously expressed). This observation 
has highlighted the potential roles of other transcription factors that interact with Ff1b 
and SF-1 in regulating the tissue-specific activity of the cyp11a1 promoter.  
While the zebrafish cyp11a1 could activate the luciferase reporter by 5.6-fold 
above the basal level, the human CYP11A1 equivalent was completely inactive when 
they were tested in zebrafish embryos. Furthermore, the promoter activity of zebrafish 
174
 cyp11a1 can be further potentiated by co-injection of ff1b overexpression construct in 
zebrafish embryos, but not the human CYP11A1 promoter. In addition, the 1.7 kb 
human promoter was unable to direct EGFP expression specifically to the interrenal 
and genital ridge when it was microinjected into zebrafish embryos. These 
observations are in disagreement with a previous study, which demonstrated that Ff1b 
was able to induce the promoter activity of the 2.3 kb human CYP11A1 promoter in 
H1299 cells (Hsu et al., 2003). The disparities between transient transfection studies 
in cell lines and in vivo transgenesis studies in zebrafish embryos have underscored 
the in vitro nature of promoter analysis in cell lines. Although studying promoter 
activity in cell lines is useful for characterization of general properties, the findings 
might not be conclusive and they may not reflect the true context of transcription 
events in vivo. In this aspect, the zebrafish has provided a useful in vivo model for 
promoter analyses, as the activity of the reporter can be easily assessed by quantitative 
(luciferase) and qualitative (EGFP) methods.   
The discrepancies between the two promoters are intriguing, considering the 
high degree of conservation in cis-elements and that the 1.7 kb human CYP11A1 
promoter of equivalent length has been able to direct lacZ expression specifically to 
the adrenals and gonads in transgenic mouse (Hu et al., 1999; Hu et al., 2001). This 
observation highlighted the complication of promoter analysis, as promoter regions 
that are sequentially conserved might not be functionally equivalent in vivo and vice 
versa. Ff1b might not bind the FREs in human promoter at an affinity that is 
equivalent to its binding in the zebrafish cyp11a1 promoter. Nevertheless, both the 
transient transfection in cell lines and transient microinjection in zebrafish embryos 
confirm that the 1.7 kb zebrafish cyp11a1 promoter is active. Most importantly, the 
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 transactivation assays with ff1b co-expression has established Ff1b as a bona fide 




6.1.4. Functional distinction of the distal and proximal FRE in the zebrafish 
cyp11a1 promoter 
 
With the identification of two highly conserved FREs in the zebrafish cyp11a1 
promoter, similar to that reported for human and mouse, it is important to understand 
why this arrangement persisted. Previous studies on the human CYP11A1 promoter 
have revealed that while the proximal FRE is responsible for the basal activity, the 
distal FRE is needed for hormonal regulation and tissue selectivity (Guo et al., 2007). 
This difference in the functionality of the two FREs is presumably due to the different 
cis-acting elements associated with each FRE. The same feature can be seen in the 
case of zebrafish cyp11a1 promoter, where the distal FRE is surrounded by a CRE 
and binding sites for AP-1 and GATA factors while the proximal FRE is surrounded 
by TATA boxes and binding sites for transcription factors such as Sp1, Sox and WT-1.   
Transfection of the zebrafish cyp11a1 promoter carrying specific mutations in 
the two FREs, individually or simultaneously, has ascertained the pivotal role of the 
proximal FRE in the basal activity of cyp11a1 promoter (Section 3.6). Thus, Ff1b 
bound to the proximal FRE could regulate the basal promoter activity by interacting 
with transcription factors in the Pol II initiation complex such as TFIIB, CBP/p300 
and AP-1 (Li et al., 1999; Monte et al., 1998). Although the distal FRE seems to be 
dispensable in the basal promoter activity, the 1.7 kb zebrafish cyp11a1 promoter only 
loses its activity completely when both the FREs are mutated, indicating that it might 
still play a role in regulating the basal activation of cyp11a1 promoter, though to a 
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 lesser extent. The importance of the distal FRE for the regulation of tissue specificity 
and cAMP responsiveness is not addressed by the current study.   
Our EMSA and ChIP assays showed that Ff1b binds to both the distal and 
proximal FREs in vitro and in vivo. This is in reminescent to the findings from the 
human and rat CYP11A1 promoter (Clemens et al., 1994; Hu et al., 2001). The 
association of SF-1 with the two FREs of human CYP11A1 promoter has been 
confirmed by EMSA (Hu et al., 2001). In the rat Cyp11a1 promoter, the distal (-79/-
71) and proximal (-51/-43) FREs are only ~30 bp apart and SF-1 binding to the 
proximal FRE was shown to be stronger than to the distal FRE in EMSA (Clemens et 
al., 1994). In the current study, the competition binding assay for the two FREs of 
zebrafish cyp11a1 promoter suggests differential binding of Ff1b to the two FREs at 
different concentration range. The binding affinity of Ff1b to the distal FRE seems to 
be slightly stronger than to the proximal FRE. The possible discrepancy in the binding 
affinity of SF-1 to the two FREs has remained largely unexplored and the significance 
of the differential binding affinity remains unresolved until more kinetics and 
biochemistry data on the SF-1-FRE interactions became available. 
 
6.2. Generation of the ff1bEx2EGFP transgenic zebrafish: a major step for the   
lineage tracing of ff1b-expressing cells 
 
Considering the importance of Ff1b in the development and maintenance of 
endocrine organs of zebrafish, a faithful lineage tracer of ff1b-expressing cells offers a 
lot of potential advantages. A fluorescent lineage tracer will enable us to fully utilize 
the advantage of zebrafish model to study the functional roles of Ff1b and other 
related factors, such as its coregulators, in vivo. However, this is not as 
straightforward as in case of many other genes where the usage of short 5’ proximal 
promoter region is normally sufficient to drive tissue-specific expression of a 
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 transgene. Similar to the observation for mouse Sf-1, the 5’ proximal promoter 
fragment containing up to 20 kb of the zebrafish ff1b genomic sequences is unable to 
target EGFP reporter to tissues that endogenously express ff1b. A recombination-
based strategy which involved the insertion of the EGFP reporter into Exon 2 of the 
zebrafish ff1b locus successfully recapitulated the endogenous expression of ff1b in 
zebrafish embryos. Despite the low efficiency of BAC transgenesis in zebrafish, a 
stable transgenic line, ff1bEx2EGFP, has been generated successfully.  
 
6.2.1. The EGFP expression parallels the endogenous expression pattern of ff1b 
in the VMH 
 
Using ISH, zebrafish ff1b transcripts can be reliably detected at ~24 hpf as two 
tight clusters lateral to the anterior tip of the neural tube in the VMH of developing 
brain (Chai and Chan, 2000). In the ff1bEx2EGFP transgenic embryos, as early as 20 
hpf, weak EGFP expression can be detected in the first few ff1b-positive neurons in 
the VMH. The subsequent EGFP expression largely recapitulates the endogenous 
expression pattern of ff1b obtained by ISH. The earlier detection of these VMH 
neurons is expected and has allowed the confirmation that Ff1b is only established in 
a small group of precursor cells at the same time as the specification of VMH. In both 
mammals and teleosts, the molecular mechanism underlying the embryonic 
development of VMH in relation to SF-1 remain poorly characterized. Previous 
findings from our laboratory have demonstrated that ff1b expression in the VMH is 
completely absent in midline patterning mutants one-eyed pinheaed (oep) and cyclos 
(cyc) (Chai and Chan, 2000). Both mutants have been reported to be defective in their 
prechordal and floor plate formation as well as the positioning of anterior-posterior 
(AP) axis (Hatta et al., 1991; Schier et al., 1997; Sampath et al., 1998). A recent study 
has reported the downregulation of ff1b expression in the VMH in smu (smo) and dtr 
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 (gli1) mutants and, also following sonic hedgehog (shh) overexpression (Bergeron et 
al., 2008). These observations suggest that the proper differentiation of ff1b-
expressing cells in the VMH relies on the optimal level of Hedgehog signaling. The 
faithful expression of EGFP in the ff1b-expressing VMH neurons would aid to define 
the molecular mechanisms underlying the above observations.     
Interestingly, the other two ff1 isoforms, ff1a and ff1d, have both been reported 
to be expressed in the VMH at a level comparable to ff1b (Chai and Chan, 2000; von 
Hofsten et al., 2005; Kurrasch et al., 2007). The co-expression of ff1 genes in the 
overlapping subdomains of VMH implies a molecular interaction and interplay 
between these genes. Nevertheless, they seem to occupy distinct but slightly 
overlapping subdomains of VMH. Notably, both ff1a and ff1d have been reported to 
be expressed in the pituitary as well (Liu et al., 1997; von Hofsten et al., 2001; von 
Hofsten et al., 2005). ff1a transcripts was reported to be present in the pituitary from 
24 hpf up to 40 hpf (Liu et al., 1997; von Hofsten et al., 2001) but the location of this 
expression domain has not been confirmed by co-staining with pituitary markers. 
Besides,the expression of ff1d has also been reported in the anterior pituitary and the 
neurons connecting the VMH and anterior pituitary cells (von Hofsten et al., 2005). 
The significance of this observation is not clear at the moment, due to the late 
appearance of ff1d expression (only at 30 dpf) and the lack of double ISH data to 
confirm the localization to the pituitary. In the ff1bEx2EGFP transgenic embryos, 
EGFP expression is also not detected in the pituitary, in reminescent to the ISH 
expression pattern of ff1b reported till date (Chai and Chan, 2000; Kuo et al., 2005; 
Kurrasch et al., 2007; von Hofsten et al., 2005). The expression profile of ff1b, as 
revealed by EGFP and ISH detection, along with the observation from MO 
knockdown of ff1b, suggest a minimal role of ff1b in the development and function of 
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 pituitary in zebrafish. As for ff1a and ff1d, the significance of their expression in the 
VMH and pituitary has to be further clarified with double ISH assays as well as 
functional studies such as MO knockdown of the two genes. The ff1bEx2EGFP 
transgenic embryos would provide an excellent experimental platform to further 
clarify the functional complexity among ff1 genes when their expression domains 
overlap with one another. 
 
6.2.2. The EGFP transgene expression parallels the endogenous expression 
pattern of ff1b in the interrenal gland 
 
In the interrenal gland, ISH reveals that the interrenal primordium appears as 
two small and bilateral clusters of non-steroidogenic cells within the pronephric 
primordia at a location ventral to the third somite at 22 hpf (Hsu et al., 2003; Liu, 
2007). The interrenal primordia proliferate in tight association with the endothelium 
as development proceeds (Liu and Guo, 2006; Liu, 2007). Before the initiation of 
steroidogenesis (by 28-30 hpf), the bilateral clusters coalesced into a single structure 
at the midline, and migrates out of the pronephric field (Chai and Chan, 2000; Hsu et 
al., 2003). In the ff1bEx2EGFP embryos, EGFP expression can be readily detected at 
the interrenal primordium by 20 hpf. By 28 hpf, the EGFP expression strongly 
reminesce of the endogenous ff1b expression.  
The morphogenetic movement of interrenal cells has been shown to be 
influenced by the endothelium. In the cloche mutant that lacks endocardium and 
endothelial cells in the major trunk (Liao et al., 1997), the convergence of the bilateral 
interrenal primordia at the midline is disrupted (Liu and Guo, 2006). As the interrenal 
gland is in close proximity to the notochord, its ontogenic development has also been 
proposed to be associated with midline signaling. In oep mutant, the interrenal 
primordia fail to fuse together and they are displaced to ectopic bilateral locations 
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 (Chai and Chan, 2000; Hsu et al., 2003). In another midline signaling flh mutant 
which lacks notochord, the interrenal primordia remain at their original locations 
without fusing together by 36 hpf (Hsu et al., 2003).  
The sonic hedgehog (SHH) signaling also represents one of the major 
signaling coming from the midline structure. In sharp contrast to an earlier report 
which demonstrated that the interrenal primordium, as revealed by cyp11a1 detection, 
remains largely intact in SHH mutants smu and syu (Hsu et al., 2003), a microarray 
study has recently established a direct involvement of SHH signaling in interrenal and 
pronephric organogenesis in zebrafish (Bergeron et al., 2008). As reported by 
Bergeron et al. (2008), the interrenal expression of ff1b was absent in SHH signaling 
mutant smu and significantly reduced in another mutant dtr, but expanded following 
shh overexpression by mRNA microinjection. The discrepancy between the two 
reports is intriguing, as it seems to suggest that ff1b is indispensable for cyp11a1 
expression in the interrenal primordium in the smu mutant. Nevertheless, it is 
important to consider that the ISH detection of the two genes was performed at 
different time frame (24 hpf for ff1b versus 36 hpf for cyp11a1). It is unlikely that the 
expression of cyp11a1 is independent of ff1b, as the MO knockdown of ff1b gene 
function has reproducibly resulted in a downregulation of cyp11a1 expression (Chai 
et al., 2003; Hsu et al., 2003). Moreover, the current study has also definitively 
established a direct involvement of Ff1b in the transcriptional regulation of cyp11a1 
in zebrafish.  
In the mammals, signaling pathways mediated by extracellular growth factors 
such as the Wnt signaling and TGFβ signaling have been implicated in the 
differentiation, proliferation and maintenance of adrenocortical tissues. The Wnt 
signaling pathway has been shown to regulate the embryonic development of a 
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 number of organs, including adrenal cortex (Grigoryan et al., 2008). The Wnt-4 KO 
mice display abnormalities in the differentiation of definitive zone in their adrenal 
gland and defects in cell migration of adrenocortical precursors (Vainio et al., 1999; 
Heikkila et al., 2002). The targeted disruption of β-catenin, as an effector of canonical 
Wnt signaling pathway, has been shown to impair the differentiation and proliferation 
of adrenocortical precursors (Kim et al., 2008). Besides, the proliferation of 
adrenocortical cells has been linked to the TGFβ signaling pathway (Mesiano and 
Jaffe, 1997; Langlois et al., 2002) though detailed molecular or genetic data have not 
been reported. While the involvement of the aforementioned signaling pathways in 
adrenocortical differentiation and maintenance is not totally unexpected, the 
molecular mechanisms underlying them remain largely uncharacterized at the moment.     
  
6.2.3. The EGFP fluorescence unravels the axonal projections of ff1b-expressing 
neurons in the VMH to the otic vesicles and telencephalon 
 
In addition to the faithful recapitulation of ff1b expression in the VMH, the 
EGFP expression in ff1bEx2EGFP transgenic embryos revealed neuronal projections 
from VMH that was previously not detectable by ISH. Apparently, 
immunolocalization of Ff1b would not reveal the cellular processes of these neurons 
as Ff1b is a nuclear targeted protein. Similarly, ISH assays only reveal ff1b transcripts 
in the nucleus and perinuclear cytoplasm. In contrast, the EGFP expression driven by 
the ff1bEx2EGFP transgene in this study resides entirely in the cytoplasm, and this 
might have contributed to the visualization of those neuronal projections. Also, the 
accumulation of the fusion Ff1b-EGFP protein could have augmented the 
fluorescence signal as compared to the chromogenic detection method employed in 
ISH. The EGFP fluorescence in the neuronal projections and additional neurons could 
also have resulted from transneuronal transfer of EGFP molecules across synaptic 
182
 contacts. For example, EGFP has been previously shown to be able to transport across 
synaptic junctions when it is put under the control of appropriate signal such as that 
from the BDNF (Kohara et al., 2001), a known target gene of SF-1. As the same 
expression pattern was observed in transient transgenesis, we can rule out the 
possibility of postional effect that could have resulted from the transgene integration 
site in the genome.  
Interestingly, some of these neuronal projections seem to directly contact the 
otic vesicle, another EGFP-expressing domain. The neuronal connections between the 
two organs required detailed histological assays. The direct innervation of inner ear by 
VMH neurons has not been previously documented for any species, including mouse. 
In mammals, direct neuronal connection between VMH and muscle through the 
lordosis reflex circuit has been described (Flanagan-Cato et al., 2001). The existence 
of similar connection between the ff1b-expressing VMH neurons and other peripheral 
tissues in zebrafish remains to be explored. The innervations from VMH to the muscle 
would need detailed histological examination of the ff1bEx2EGFP transgenic 
embryos.   
The VMH is known to regulate a broad array of behavioral and homeostatic 
functions, including digestive, affective, and sexual behaviors as well as obesity and 
energy balance (Canteras et al., 1994). The expression of mammalian SF-1 
specifically in the dorsomedial and central sub-domains of VMH is well defined and 
SF-1 is known to control the cyto-architecture of neuronal subtypes in the VMH, 
presumaly by regulating cell migration (Davis et al., 2004; McClellan et al., 2006). 
Furthermore, CNS-specific KO of SF-1 highlights its role in modulating anxiety 
behavior. However, the exact functions of SF-1-positive neurons in the mammalian 
VMH have remained undefined.  
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 In the mammals, the neuronal projections of SF-1 expressing neurons in the 
VMH remain largely uncharacterized, mainly due to the lack of a traceble marker in 
these neuronal projections. Moreover, in mammalian model, in vivo lineage tracing of 
VMH neurons is extremely difficult, especially during embryonic development, and 
the study of these neurons as well as their projections often involves laborious 
sectioning and immunohistochemistry assays that might eventually alter the original 
strutural organizations. The ability to discern axonal and dendritic projections from 
VMH neurons would be an important step in understanding their functions. By tracing 
their projections, useful insights may be gained about the targets that they innervate as 
well as major neuronal networks that they may interact with in the CNS. Such 
information will be instructive for the understanding of the physiological processes 
that they might be involved in. Thus, the ability to visualize the neuronal projections 
from ff1b-expressing cells in the ff1bEx2EGFP transgenic embryos should find wide 
applications in the study of VMH development and function.  
 
6.2.4. The unexpected sites of EGFP expression in ff1bEx2EGFP transgenic 
embryos at the otic vesicle, muscle pioneer cells, common cardiac vein, 
and neuromasts 
 
Several unexpected EGFP-expressing domains are observed in the 
ff1bEx2EGFP transgenic embryos. They include the otic vesicles, slow muscle 
pioneer cells, common cardiac vein, and neuromasts. These expression domains have 
not been detected by ff1b ISH nor have they been reported in other species. As the 
EGFP expression in the otic vesicles and muscle is observed even in transient 
transgenesis when microinjected with supercoiled pBACff1bEx2EGFPKan, the 
transgene expression is not likely to be due to integration site. Indeed, the effect of 
integration site on transgene expression is known to be a major factor for shorter 
transgenes (a few kb), but often a minor factor for transgenes derived from large DNA 
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 constructs like BAC. In transient transgenesis studies, the EGFP expression in the 
common cardiac vein and the scattered distribution of EGFP-expressing neuromasts 
could have been overlooked, as they were usually highly mosaic. The study of a 
single transgenic line of ff1bEx2EGFP in this study does not allow us to conclude 
whether the EGFP signal from the common cardiac vein and neuromasts could have 
resulted from ectopic expression caused by integration site.    
Although the EGFP expression in the muscle pioneer cells was unexpected, the 
expression domain in the muscle has indeed been described for Drosophila FF1 genes 
and all the zebrafish ff1 isoforms. In Drosophila, the betaFF1 receptor has been 
demonstrated to regulate muscle contraction events that drive the morphogenetic 
movements at the prepupal-pupal transition stage (Fortier et al., 2003). In zebrafish, 
ff1a has been shown to be expressed specifically in the adaxial and slow muscle 
precursors. A series of gene knockdown and overexpression studies have 
demonstrated a role of Ff1a in the morphogenesis of both the fast and slow myofibril 
assembly in response to Hedgehog signaling and in cooperation with Prox1 (Sheela et 
al., 2005). Strong expression of ff1c and weak expression of ff1d in the adult muscle 
tissue have been previously described (Kuo et al., 2005). Interestingly, weak 
expression of ff1b in the muscle of adult zebrafish has also been demonstrated in our 
laboratory by RT-PCR (Chai, 2002), implying a possibility of ff1b expression in the 
muscle. If the expression of ff1b in the muscle pioneer cells is genuine, it is then 
inexplicable that the strong expression in the muscle at early developmental stage, as 
revealed by the EGFP fluorescence, is undetectable by ISH.        
Analogous to the EGFP expression in the neuronal projections of VMH, a few 
of the aforementioned explanations could hold true for the unexpected expression in 
the otic vesicle and muscle pioneer cells. They could still potentially represent 
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 endogenous expression domains of ff1b and the discrepancy between fluorescence 
visualization and ISH detection is most likely due to the difference in the detection 
limit and sensitivity of the two methods. Otherwise, the additional expression 
domains could be attributed to non-specific enhancer present in the genomic insert of 
BACff1b2 plasmid. Unfortunately, we are unable to map any ORF with high 
confidence within the sequenced portion of genomic DNA insert in the BAC plasmid, 
thereby unable to extrapolate the possible influence of genes surrounding ff1b locus. It 
is noteworthy that with the exception of the interrenal gland, other EGFP expression 
domains in the ff1bEx2EGFP embryos remain largely unaffected following ff1b MO 
knockdown. This observation indicates that the continued expression of EGFP in 
these tissues is not dependent on ff1b.   
Although we have not managed to map any known ORF in the sequenced 
portion of BACff1b2 plasmid, the presence of the extreme 5’ or 3’ genomic sequences 
from the neighboring genes might still be influential on the EGFP expression pattern. 
By genetic mapping, the nearest neighbor gene of ff1b is predicted as c11orf8 (Kuo et 
al., 2005). However, the only expression data available for this gene is from a genetic 
screen that aims to identify factors responsible for breast tumor suppression (Seitz et 
al., 2006) and it could not account for the EGFP expression in the otic vesicle and 
muscle pioneer cells. The next nearest known neighbor of ff1b is predicted to be 
nr6a1a, which is commonly known as germ cell nuclear factor (gcnf). Its expression 
is predominantly found in the germ cell of gonads  (Chung and Cooney, 2001). 
Intriguingly, Gcnf  KO mice display severe defects in somitogenesis from early stage 
of development although its functional role in this aspect has not been explored 
(Chung et al., 2001). This raises the possibility of GCNF involvement and expression 
in the muscle. In zebrafish, gcnf has been cloned and characterized in terms of its 
186
 expression in the ovary and testis (Braat et al., 1999). With more detailed expression 
profiling of gcnf as well as more complete genomic sequences between gcnf and ff1b, 
we will be able to see whether any muscle-specific distal enhancer of this gene could 
be present in the BAC transgene and thereby interefere with the EGFP expression.  
All in all, the successful recapitulation of ff1b expression in the VMH and 
interrenal gland together with the unexpected transgene expression highlights the 
complexity of gene regualtion, as in many other transgenic studies. In many cases, the 
length of transgene does not necessarily correlate with the extent of recapitulating the 
endogenous expression of a gene. Recently, there are even reports suggesting 
interchromosomal regulation of gene expression. In the most complex case of gene 
regulation, the transcription modulation may involve not only the cis-elements 
(promoter, enhancer, and repressor) and corresponding trans-factors (specific 
transcription factors, nuclear proteins, and chromatin remodeling factors), but also a 
whole concert of long range and dynamic intra- or inter- chromosomal interactions at 
specific sub-nuclear compartments (Bartkuhn and Renkawitz, 2008; Kumaran et al., 
2008; Osborne and Eskiw, 2008). The transcriptional regulation of many genes and 
the interactions among individual genes in the context of whole genome is far more 
complex than previously thought (Gerstein et al., 2007; Keller and Harel, 2007). 
Nevertheless, the unexpected sites of EGFP expression in ff1bEx2EGFP embryos 
have not interfere with the usability of this transgenic line to perform lineage tracing 
studies, at least for the VMH and interrenal gland, which currently represent two 





 6.3. The ff1bEx2EGFP stable line provides a versatile transgenic platform to 
study early morphogenesis of interrenal gland 
 
The ff1bEx2EGFP transgenic embryos have undoubtedly provided a useful in 
vivo system to trace the fate of ff1b-expressing cells, particularly those in the VMH 
and interrenal gland. More importantly, the zebrafish embryos are highly amenable to 
a broad range of experimental manipulations such as gene knockdown by MO, 
overexpression and rescue, chemical treatment with small molecules, just to mention a 
few. Although the homozygous transgenic embryos are not viable, as reported for 
many other transgenic lines, the hemi-zygous embryos are reliable enough for data 
collection. The direct visualization of EGFP fluorescence in these embryos offerred a 
level of convenience that was previously unavailable, allowing for instance the fate 
tracing of ff1b-expressing cells in live embryos.   
 
6.3.1. The EGFP transgene allows the tracing of ff1b-expressing interrenal cells 
from early developmental stage 
 
The MO knockdown of ff1b resulted in late larval phenotypes that are 
indicative of impaired osmoregulation. The morphants can be classified according to 
the severity of the subcutaneous edema (Chai et al., 2003). The knockdown of ff1b 
gene function by MO has been re-examined using the ff1bEx2EGFP transgenic line in 
the current study. The EGFP expression in the ff1b morphants of ff1bEx2EGFP 
embryos has allowed for the live monitoring of the size of interrenal primordia from 
early stages of development, before the morphant phenotypes are manifested at 5-6 
dpf. It is noteworthy that the EGFP expression of the interrenal correlated strongly 
with the severity of subcutaneous edema in ff1b morphants. All embryos that showed 
no EGFP at the interrenal gland at 48 hpf developed into Class C and D morphants, 
whereas embryos that showed weak or reduced, and normal EGFP expression at the 
interrenal at 48 hpf consistently developed into Class B and Class A morphants, 
188
 respectively.  It was previously reported that a portion of ff1bMO1-injected larvae 
retained positive staining for 3β-Hsd enzymatic activity, and they eventually 
developed into Class A morphants (Chai et al., 2003). This is in contrast to the finding 
in this study, where a good 47.8% of ff1bMO3-injected embryos retain interrenal 
EGFP expression that is comparable to the uninjected controls, and almost all of them 
(46.5%) developed into Class A morphant at 7 dpf. The discrepancy is probably due 
to the higher sensitivity of EGFP detection as compared to the chromogenic 
enzymatic assays of 3β-Hsd. However, the ability of the EGFP-positive interrenal 
cells to carry out steroidogenesis has not been examined in the current study. 
Considering the normal morphology of Class A morphants at 7 dpf, it is likely that the 
EGFP-positive interrenal cells are capable of producing steroids, at least to a level that 
is sufficient to maintain the normal osmoregulatory functions in zebrafish.   
The existence of intermediate phenotypes between the wild-type and the most 
severe knockdown of ff1b has highlighted the influence of technical variations in 
microinjection as well as a potential correlation to the dosage-sensitivity of Ff1b. 
Concomitantly, compensatory functions from other ff1 isoforms, particularly ff1d that 
has been shown to be transiently expressed in the interrenal primordium (von Hofsten 
et al., 2005), may also play a role. As of any other microinjection experiments, the 
amount of ff1bMO3 delivered into the ff1bEx2EGFP embryos may vary slightly from 
one individual to another, thereby giving rise to a range of different MO dosage, and 
hence different classes of severity. We envisage that the milder morphant phenotypes, 
i.e. Class B, probably correspond to a genetic condition of haploinsufficiency while 
the most severe morphant phenotypes, i.e. Class C and D, probably correspond to a 
nearly KO genetic background. The potential correlation to the dosage-sensitive effect 
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 of Ff1b can be further ascertained with a targeted mutagenesis of ff1b gene, which is 
now technically possible in zebrafish (Meng et al., 2008; Woods and Schier, 2008).   
 It is now known that most genes do not give rise to obvious phenotype when 
their dosage is reduced by 50%, in hemizygotes, or increased by 50%, in duplication-
bearing animals (Hodgkin, 2005). Such changes in gene dosage usually do have a 
small impact on viability but the reduction in viability is not easily discernible at the 
level of a single gene. The dosage-sensitive effect of Ff1 receptors has been 
previously described. In mammals, the drastic phenotypes of heterozygous mutation 
of SF-1 imply that this receptor acts in a dosage-sensitive manner. In human, 
heterozygous G35E mutation which is located in the first zinc finger of the DBD 
causes complete sex reversal in 46XY affected individual, and major adrenal failure 
(Achermann et al., 1999). In another heterozygous R255L mutation of human SF-1 
which is located in the hinge region, bilateral adrenal agenesis was observed without a 
defect in sexual differentiation (Biason-Lauber and Schoenle, 2000). Although not as 
obvious as in humans, haploinsufficiency of SF-1 in mice induces adrenal hypoplasia 
in both male and female at E15.5 (Bland et al., 2000). Just recently, the increased 
dosage of SF-1 has been shown to trigger cell proliferation in adrenocortical cells 
through concerted modulations of cell cycle and apoptosis (Doghman et al., 2007). 
These findings collectively suggest that SF-1 works as a dosage-sensitive NR to 
ensure the proper differentiation and function of adrenal cortex in human and mouse. 
Considering the functional homology of Ff1b to SF-1 and the existence of several 
severity classes of ff1b morphants, Ff1b could potentially act in a dosage-sensitive 




 6.3.2. The interrenal primordium is completely absent in the most severe 
knockdown of ff1b gene function 
 
In SF-1 KO studies, the developmental abnormalities observed at birth are not 
apparent during precocious development. Thus, the bipotential gonad appears to be 
normal and is colonized by primordial germ cells prior to sex determination at E10.5. 
Furthermore, the adrenal and gonadal primordia subsequently separate and migrate to 
the correct positions. However, when sex determination commences at E12-E12.5, 
gonads and adrenal primordia in these mice progressively regress by apoptosis (Luo et 
al., 1994; Luo et al., 1995). These observations indicate that SF-1 is dispensable for 
the early specification of the adrenogonadal primordia but is crucial for their 
subsequent differentiation, proliferation, and maintenance. Considering the highly 
conserved function of Ff1b to mammalian SF-1, it is reasonable to ask whether Ff1b 
modulate the morphogenesis of interrenal in zebrafish in a similar manner.  
Our MO knockdown of ff1b gene function using ff1bMO3 in ff1bEx2EGFP 
transgenic embryos demonstrated that in severe case of knockdown, the interrenal 
promordia did not form at all (Section 4.5). The complete absence of the interrenal 
primordia in these Class C and Class D morphants suggests that Ff1b is important for 
both the early specification and subsequent maintenance of interrenal functions. This 
is in contrast to the phenomenon observed for SF-1 in mouse. While the lack of 
interrenal primordium could reflect a true mechanism by which Ff1b acts to regulate 
the morphogenesis of interrenal, it could also partially due to the technical inability to 
detect the weak fluorescence from the early interrenal primordium, which is deeply 
embedded underneath the third somites in whole-mount ff1bEx2EGFP embryos. The 
adoption of imaging systems of higher sensitivity and penetration, e.g. two-photon 
confocal microscopy, as well as histological sections of the morphants at early stage 
of interrenal specification (18- 20 hpf) would help to further clarify this issue.  
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6.3.3. The formation of interrenal primordium is independent of glucocorticoids 
 
The osmoregulatory defects observed in ff1b morphants are largely attributed 
to the loss of ff1b gene function and the loss of production of corticosteroids from the 
interrenal gland. In conjunction, chemical treatment of zebrafish embryos with steroid 
inhibitor aminoglutethimide (AG) has been shown to produce similar larval 
phenotypes that are indicative of impaired osmoregulation (Chai et al., 2003). While 
ff1b MO perturbs ff1b gene function and results in the downregulation of cyp11a1 
expression, the AG inhibitor disrupts the enzymatic function of Cyp11a1 and Cyp19 
directly. Although the perturbation is directed at different level of regulation, both 
experiments ultimately resulted in the dysregulation of steroid biosynthesis and, thus, 
gluococorticoid insufficiency and impaired osmoregulatory function. However, the 
presence of interrenal primordia in the AG-treated larvae has not been examined. 
Ff1bEx2EGFP transgenic embryos treated with AG showed normal development of 
the interrenal gland throughout the study period (Section 4.6). At 7 dpf, the position 
and EGFP-expressing domain of the interrenal gland appeares to be slightly displaced 
and it is most likely attributed to the distortion of the whole body axis and associated 
organs in the larvae as a result of the edema phenotype.  
  Indeed, AG inhibits only the activity of steroidogenic enzymes Cyp11a1 and 
Cyp19, resulting in glucocorticoid insufficiency, which would presumably upset the 
balance of steroidogenesis pathways as well as the feedback regulation by the end 
product of steroidogenesis (primarily costisol). The perturbation could potentially 
alter the steroidogenic activity of interrenal primordia via gluococorticoid-mediated 
regulatiory pathways. However, it does not necessarily affect the expression of ff1b 
and ff1b-regulated morphogenesis of interrenal gland. Interestingly, a glucocorticoid 
response element can be mapped at position -637/-619 bp of ff1b promoter, indicating 
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 a possibility of glucocorticoid regulation on ff1b expression. Nevertheless, the AG 
AG-treated embryos that retain their interrenal glands indicate otherwise. ISH 
detection of cyp11a1 transcripts together with ISH and enzymatic assays of 3β-hsd 
have established that the zebrafish interrenal cells are capable of producing steroids as 
early as 24 hpf although the interrenal organogenesis is not yet completed (Chai et al., 
2003; Hsu et al., 2003). The assessment of steroidogenic activity of interrenal 
primoridia that persisted in the AG-treated ff1bEx2EGFP embryos would aid to 
pinpoint whether the steroidogenic functions of the EGFP-positive interrenal cells are 
still retained.   
It is noteworthy that blood island formation was not observed in the ventral tail 
of AG-treated larvae and the yolk sac edema in the most severely affected AG-treated 
larvae was less extensive compare to Class D ff1b morphants. These disparities 
indicate that the chemical inhibition of steroidogenic enzymes is not as severe as the 
disruption of ff1b gene function, which presumably downregulates the expression of 
all steroidogenic enzymes. Nevertheless, the penetrance of AG inhibition is 
significantly higher (73%) in comparison to MO knockdown by ff1bMO3 (54%) 
though most of the AG-treated larvae displayed Class B morphant phenotypes. The 
higher penetrance of chemical treatment in comparison to microinjection is no 
unusual as the immersion of zebrafish embryos/larvae in AG-containing egg water is 
anticipated to produce less variation in delivery amount in comparison to the 
mechanical delivery of MO by microinjection. The AG inhibition experiment has 
undoubtedly demonstrated the versatility and realiability of the ff1bEx2EGFP 
transgenic line for studying the effect of small molecules on interrenal development.   
Consistent with our findings, a search through the literature revealed that 
glucocorticoids have not been reported to influence the embryonic development of 
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 adrenal cortex. Generally, the fetal adrenal produces only low amount of cortisol until 
late gestation stage (Muglia et al., 1995; Miller, 1998). Evidence from KO studies of 
gluococorticoid receptor (GR) indicate that glucocorticoids play crucial roles in 
modulating the development of lung, thymus, liver, and adrenal medulla (Cole et al., 
1995). Nevertheless, the moderately elevated level of corticosterone and sharp 
increase in ACTH level following the loss of glucocorticoids or gluococorticoid 
receptor function indicate a dysregulation of HPA axis, which is most likely attributed 
to defective feedback modulation (Schmid et al., 1995).          
 
6.4. The conserved genomic organization of ff1b 
 
To elucidate the genomic organization of zebrafish ff1b, ~46 kb of genomic 
sequences encompassing the ff1b locus has been sequenced. The genomic sequence 
obtained matched almost completely to the nr5a1a (ff1b) locus annotated in 
scaffold_831 of LG8. With the exception of an additional Intron IV, genomic 
structure of ff1b is conserved to that of human and mouse SF-1. Intriguingly, the 
intron is uniquely found in ff1b gene but not the other three zebrafish ff1 genes. The 
ff1b genomic sequences determined in this study have set a stage for the 
manipulations of genomic sequences to delineate cis-regulatory elements that 
modulate the tissue-restricted expression of ff1b in zebrafish.  
 
6.4.1. The presence of a unique Intron IV in zebrafish ff1b gene 
 
In contrast to all other vertebrate FF1 genes characterized so far, the zebrafish 
ff1b is organized into eight exons spanning a total genomic region of 25 kb. Generally, 
Exon 4 of vertebrate FF1 genes represents the largest exon and it encodes the entire 
hinge domain. In zebrafish ff1b, the presence of the unique Intron IV splits this exon 
into Exon 4 and Exon 5. The remaining ff1a (Lin et al., 2000), ff1c (Xia, 2001), and 
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 ff1d (annotated as nr5a1b in LG21 of Ensembl genome database Zv7) also lack this 
intron. An in silico examination of currently annotated nr5a1 genes in other teleosts 
including stickleback (Gasterosteus aculeatus), medaka (Oryzias latipes), fugu 
(Takifugu rubripes), and tetraodon (Tetraodon nigroviridis) at the Ensemble genome 
database (www.ensembl.org) revealed that the presence of this intron is unique to ff1b 
in the teleost lineage. In invertebrate FF1 genes of D. melanogaster (Ftz-F1) and C. 
elegans (cnhr) genes, the presence of an intron in the corresponding position is noted, 
albeit at a much smaller size.  
Although independent and repetitive gain of introns has been reported in 
several fish lineages, (Venkatesh et al., 1999; Zhaxybayeva and Gogarten, 2003) 
subsequent evolutionary analyses of more completed genomes suggest that intron loss 
is far more predominant than intron gain during the process of evolution 
(Zhaxybayeva and Gogarten, 2003; Carmel et al., 2007; Loh et al., 2008; Sharpton et 
al., 2008). Considering the presence of a similar intron in invertebrate FF1 genes and 
the absence of it in all other vertebrate FF1 genes characterized so far, the presence of 
the extra intron in zebrafish ff1b is likely to represent an ancestral feature of FF1 
genes, which was subsequently lost in most other teleost and tetrapod lineages during 
evolution.   
 
6.4.2. Conserved cis-regulatory elements in the ff1b promoter 
 
Computational analysis of the proximal promoter of ff1b reveals conserved cis-
regulatory elements that are involved in basal transcription (Section 5.2.2). Two 
putative E-box elements have been identified, with a full consensus motif located in 
Intron I (+203/+215) and a second less conserved motif (CAAGTG) located at –59/-
54. With the exception of human NR5A2, all other vertebrate FF1 gene promoters 
characterized lack a TATA box, (Zhang et al., 2001). The E-box elements are utilized 
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 instead for transcription initiation of mouse SF-1 (Ninomiya et al., 1995), rat SF-1 
(Nomura et al., 1995; Harris and Mellon, 1998), human SF-1 (Woodson et al., 1997; 
Oba et al., 2000), bovine SF-1 (Oba et al., 2000) and mouse LRH-1 (Pare et al., 2001). 
The E-box motifs that are located in close proximity to the TSS are known to be 
essential for maximal promoter activation while E-box elements located in introns are 
able to induce gene transcription. For instance, an E-box element located at the Exon 
1/Intron I junction of the human norepinephrine transporter gene regulates not only 
the transcription initiation but also the splicing of the gene (Kim et al., 2001). 
Similarly, an intronic E-box located at position +767 bp  of the acetylcholinesterase 
(AChE) gene has been shown to be functional for myogenin-induced expression 
during myogenesis (Angus et al., 2001).  
A putative FRE at position -355 to -343 of ff1b promoter indicates the 
possibility of autoregulation of ff1b transcription by Ff1b itself. For the rat SF-1 gene, 
an FRE in Intron I has been demonstrated to bind SF-1 itself and modulate the 
transcriptional activation of SF-1 gene (Nomura et al., 1996). However, studies on 
human and mouse promoter of SF-1 revealed that such autoregulatory mechanism 
does not take place (Oba et al., 2000; Woodson et al., 1997) despite the presence of 
an FRE at a corresponding region in the promoters of these genes. Recently, an FRE 
in the Intron IV of mouse Sf-1 gene has also been implicated in an autoregulatory loop 
that maintains the fetal adrenal-specific expression of SF-1 (Zubair et al., 2006). 
There might be inter-species difference in the autoregulation of SF-1 genes and more 
in vivo data would be needed to confirm the previous findings which were mostly 
derived from transient transfection studies in vitro.  
The characterization of mammalian SF-1 promoter has also revealed a Sp1 
binding site that is important for their activity in steroidogenic cell lines (Scherrer et 
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 al., 2002; Woodson et al., 1997). Furthermore, the expression of many adrenocortical-
specific genes such as CYP11A1 (Guo et al., 2003), StAR (Sugawara et al., 2000), 
CYP21B (Kagawa and Waterman, 1991), CYP17 (Borroni et al., 1997) and AKR1B7 
(Aigueperse et al., 2001) have been shown to require Sp1 binding. Hence, the 
presence of a putative Sp1 site at location -325/-311 bp of ff1b proximal promoter is 
likely to be involved in the modulation of ff1b expression in the interrenal gland. Two 
other tissue-specific transcription factors have been implicated in the transcriptional 
regulation of mammalian SF-1, namely SOX9 and GATA4 (Tremblay and Viger, 
2001). The regulation by the two transcription factors, however, seems to be confined 
to gonadal cell lineages. The presence of binding sites for the two factors in ff1b 5’ 
promoter indicates that possible functionality of these elements in modulating gonad-
specific expression of ff1b. 
 
6.4.3. Zebrafish ff1b locus does not show conserved synteny with human SF-1 
 
The genome context of zebrafish ff1 genes in terms of their conserved 
syntennies with human NR5A paralogues have been reported by Kuo et al. (2005). 
The four zerbafish ff1 genes, namely ff1a, ff1b, ff1c, and ff1d, have been mapped to 
chromosomal location LG22_40.9 cM, LG8_139.1 cM, LG3_80.3 cM and 
LG21_36.7 cM, respectively, using the HS meiotic panel (Woods et al., 2000). 
Although the expression and functional analyses have undoubtedly placed ff1b as an 
ortholog of human NR5A1, the phylogenetic and genetic mapping analyses suggests 
ff1d as the true ortholog of NR5A1. The examination of genomic context surrounding 
ff1b and ff1d indicates that ff1d, but not ff1b, shows conserved long-range syntenies 
with human NR5A1. It is likely that regulatory sequences of ff1d, as the duplicate of 
ff1b, may have been allowed more freedom to change during evolution due to the 
maintenance of its duplicate gene ff1b. The presence of an ancestral intron in 
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 zebrafish ff1b and the conserved synteny between ff1d and human NR5A1 suggests 
ff1b as the ancestral copy of the two duplicated genes (ff1b and ff1d). The ancestral 
ff1b gene was subsequently lost in the tetrapod lineages and its function has been 
retained by its duplicated gene. 
Although the genetic maps are generated with high confidence, they would 
eventually need to be verified by data from genomic sequence assembly. This proves 
to be rather difficult at the moment as the sequencing of zebrafish genome is still 
incomplete and the sequence assembly is still in a draft version. It is noteworthy that 
the genomic context displayed at the Ensembl genome assembly is quite different 
from that shown by genetic mapping and even the nr6a1a gene that is closely 
associated with ff1b cannot be located in close proximity to ff1b on LG8. Since no 
ORF could be localized in the known genomic sequences of BACff1b plasmid, the 
c11orf8 that supposedly lies 3’ downstream of ff1b is likely to reside in genomic 
region beyond the genomic DNA insert studied.   
 
6.5. A potential repressor element is present at the 5’ upstream flanking region 
of ff1b 
 
The inability of the 20 kb long fragment of ff1b 5’ flanking sequences to drive 
tissue-specific expression of EGFP in zebrafish embryos indicates not only the 
absence of tissu-specific enhancer elements within this region, but also the existence 
of potential repressor elements. This mode of regulation, however, has largely been 
overlooked for most transcription regulation studies, mainly because it is technically 
far more difficult to identify a true repressor than a true enhancer. Nevertheless, many 
complex modes of gene regulation involve modules of enhancer and repressor cis-
elements, acting in concert with their associated trans-factors, to bring upon a 
particular pattern of gene expression (Hawkins and Ren, 2006; Wallace and 
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 Felsenfeld, 2007; Bartkuhn and Renkawitz, 2008). Till date, the only study that has 
investigated the effect of repressor-like element is the assessment of a histone 
acetylation boundary present between the mouse Sf-1 and Gcnf genes (Ishihara and 
Morohashi, 2005). This study has identified an insulator element residing between the 
two genes that contains bind sites for the insulator protein CTCF and a nuclear matrix 
attachment region (MAR). Experimental evidences from ChIP and DNase I suggested 
that the chromatin architecture induced by this insulator is responsible for the the 
regulation of distinct expression patterns of Gcnf and Sf-1. Ths study, however, did 
not identify the associated trans-factors or cis-elements that specifically repress the 
expression of Sf-1 in Gcnf-expressing cells, and vice versa.  
When the 5’ flanking sequences spanning -21,342 to -11,397 bp of ff1b locus 
was deleted from the pBACff1bEx2EGFPAmp plasmid, a sharp decrease in the 
number of embryos showing EGFP at interrenal gland is noted (Section 5.4). This 
decrease was, however, relieved with longer deletion spanning -21,342 to -1,012 bp. 
These results point to the presence of a potential enhancer element in the genomic 
region spanning -21,342 and -11,397 bp, and at the same time the presence of a 
potential repressor element in the genomic region spanning -11,397 and -1,012 bp. 
Taken the previous finding on the transcriptional activity of ff1b 5’ sequences into 
account, the possibility of the presence of a repressor element seems to be higher. 
Nonetheless, it is currently difficult to map the true repressor and associated trans-
factors from the long genomic region spanning 10 kb. 
 
6.6. An intron deletion strategy using Red/ET method localizes an interrenal-
specific enhancer to Intron IV of zebrafish ff1b 
 
The realization of the enhancer for VMH, adrenal, and pituitary specific 
expression is located in the intron of mouse Sf-1 and that these enhancers are highly 
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 conserved and could be located in the human SF-1. However, this conservation does 
not seem to extend to the zebrafish ff1b. Using the Red/ET recombination strategy, 
individual intron is deleted and the ability of the remaining introns to drive the EGFP 
expression was assessed in microinjected zebrafish embryos (Section 5.5). This has 
allowed for the localization of an interrenal-specific enhancer to Intron IV of ff1b.    
 
6.6.1. Intron IV of ff1b contains regulatory elements that are essential for 
interrenal-specific expression 
 
A recent study has reported the identification of a fetal adrenal enhancer 
(FAdE), spanning 0.6 kb, in the Intron IV of mouse SF-1 gene (Zubair et al., 2006). 
The lacZ reporter gene expression driven by the FAdE enhancer is only restricted to 
the fetal stage of adrenal cortex, indicating the presence of temporal-specific enhancer 
elsewhere to modulate the adrenal-specific expression of SF-1 in the postnatal and 
adult stages. Although the enhancer was shown to be highly conserved between 
human and mouse, bioinformatics analysis suggest that the conservation does not 
seem to extend to zebrafish ff1b nor ff1d. It is likely that the high degree of sequence 
divergence between zebrafish and mouse, especially in the non-coding genomic 
regions, has hindered the idenfitication of the equivalent of FAdE enhancer by 
sequence homology. Nevertheless, similar cis-elements and corresponding trans-
factors may still be involved for the specification of interrenal-specific expression of 
ff1b considering the conserved roles of ff1b in interrenal development, as well as, the 
conserved ontogeny between mammalian adrenal and zebrafish interrenal. 
In this study, we report the identification of a putative interrenal-specific 
enhancer in Intron IV of ff1b gene following a combination of deletional analyses 
spanning ff1b locus and trasient transgenesis in zebrafish embryos. The deletion of the 
entire Intron IV (3754 bp) from the pBACff1bEx2EGFPAmp plasmid led to complete 
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 disappearance of EGFP expression in the interrenal and otic vesicle. Although the 
close association of otic vesicle-specific transgene expression to that of interrenal 
gland cannot be explained, the resulting transgene expression pattern indicates that 
Intron IV contains regulatory elements that are indispensable in mediating the 
interrenal-specific expression of ff1b. Intriguingly, the interrenal-specific enhancer 
resides in Intron IV of ff1b, which is uniquely present among all other vertebrate FF1 
genes characterized so far. Thus, Intron IV of mouse Sf-1 where the FAdE resides 
does not correspond to the Intron IV of zebrafish ff1b where the interrenal enhancer 
resides. Since the Intron IV of zebrafish ff1b represents an ancestral feature of FF1 
genes, the interrenal enhancer that has been identified in this study is likely to 
represent an ancestral enhancer in regulating the interrenal-specific expression of ff1b. 
Most probably, this intron was subsequently lost in the tetrapod lineages after which 
the enhancer was relocated to Intron IV of mouse Sf-1, which corresponds to Intron V 
of zebrafish ff1b, via a currently undefinable evolutionary mechanism.      
In the mouse FAdE, the Pbx/Prep and Pbx/Hox sites were shown to mediate 
the initiation of SF-1 transcription in the fetal adrenal while the FREs and associated 
SF-1 have been implicated in the autoregulation and maintenance of SF-1 
transcription (Zubair et al., 2006). Within position 1900 to 3200 of ff1b Intron IV, 
which harbors a high concentration of putative cis-elements, two FREs and several 
binding sites for Pbx/Hox and Pbx/Meis1 have been mapped. Prep1 and Meis1 are 
closely related factors that both belong to the TALE class of homeodomain 
transcription factors and they bind the same DNA motif (Berthelsen et al., 1998). 
While PBX1 has been repeatedly implicated in the modulation of SF-1 expression in 
the adrenal cortex in mammals (Schnabel et al., 2003; Else and Hammer, 2005; 
Hammer et al., 2005; Zubair et al., 2006; Lichtenauer et al., 2007), a collaborative 
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 study in our laboratory demonstrated that the zebrafish pbx1 is not expressed in the 
interrenal gland at embryonic stages up to 3 dpf (Dr Teoh Pick Har and Dr Alexander 
Chong Shu Chien, personal communication). However, detection of pbx1 transcripts 
in the head kidney of adult zebrafish by RT-PCR indicates that it may still play a role 
in maintaining the expression of ff1b in the interrenal gland. During embryonic stage, 
pbx1 function might be assumed by other pbx isoforms or its expression level is below 
the detection limit of ISH.  
Several other novel cis-elements that may be potentially involved in 
controlling ff1b expression in the interrenal have also been mapped. Several cAMP 
response elements have been predicted with high confidence. Although SF-1 has been 
demonstrated to regulate a number of target genes in a cAMP-dependent manner, it is 
still not established whether cAMP signaling pathway directly modulate the 
expression of SF-1. The connection of ff1b transcription to cAMP cannot be ruled out 
currently considering the important role of cAMP in inducing the expression of most 
steroidogenic enzymes in the interrenal.  
The Wnt signaling pathway has been shown to be important for adrenocortical 
development and factors involved in this pathway could potentially regulate the early 
specification of adrenal cortex as well as the adrenocortical expression of SF-1 (Else 
and Hammer, 2005; Kim et al., 2008). In Intron IV of ff1b, two binding sites for 
LEF1/TCF and one binding site for Brachyury, which are both molecular components 
of Wnt signaling pathway important for embryogenesis (Technau, 2001; Galceran et 
al., 2004), have been predicted. Also, a number of binding sites for fork head/winged 
helix family of transcription factors have been mapped within Intron IV. This family 
of transcription factors have been implicated in the modulation of mesoderm 
development (El Hodiri et al., 2001; Wilm et al., 2004) and hence may potentially 
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 regulate early events of interrenal morphogenesis and ff1b expression. Lastly, three 
binding sites for SMAD family of transcription factors have been predicted. SMAD 
proteins are components of transforming growth factor beta (TGFβ) signaling 
pathway, which has been implicated in the transcriptional regulation of StAR gene in 
adrenocortical cells (Brand et al., 1998) as well as the proliferation of adrenocortical 
cells (Chambaz et al., 1996; Mesiano and Jaffe, 1997; Langlois et al., 2002). Thus, 
they could also potentially regulate the expression of ff1b in maintaining the proper 
expansion of interrenal cell domain.       
 
6.6.2. Intron V and Intron VI may potentially regulate the VMH-specific 
expression of ff1b 
 
A 503-bp core VMH-specific enhancer has been localized to Intron VI of Sf-1 
using transgenic mouse assays (Shima et al., 2005). Mutagenesis and EMSA analyses 
revealed that the transcriptional activity of this enhancer is mediated through tight 
cooperation between an activating and a suppressive element, and the activating 
element is likely to bind homeobox protein Nkx2.1. In reminescent to the FAdE, the 
VMH enhancer has been shown to be highly conserved in Intron VI of human SF-1. 
Bioinformatic analysis has not managed to identify an equivalent region in zebrafish 
ff1b or ff1d by sequence homology. In our intron deletion studies, the number of 
embryos expressing transgene in the VMH and neuronal projections decreased 
markedly with the deletion of Intron V or Intron VII, indicating that they may 
potentially regulate the VMH-specific expression of ff1b. However, residual transgene 
expression in VMH following the deletion of Intron V or Intron VII alone indicates 
that they are not absolutely required for VMH-specific expression. Although their 
roles in regulating the expression of ff1b in the VMH cannot be properly defined at 
the moment, further studies on the two introns as well as simultaneous deletion of 
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 them would most likely lend more insights into the molecular mechanisms underlying 




This study has presented multiple approaches to study the zebrafish ff1b gene, 
particularly with regard to its functional roles in the ontogenic development of 
interrenal gland. Detailed analysis of the two FREs identified within the 1.7 kb 
zebraifsh cyp11a1 promoter and the demonstration of Ff1b transactivation activity 
and association with this promoter have established Ff1b as a bona fide transcription 
factor that is directly involved in the transactivation of cyp11a1. The presence of 
FREs in the putative promoter regions of other annotated steroidogenic genes of 
zebrafish suggest that this transcriptional regulation is likely to extend to most 
steroidogenic enzymes. These findings have further ascertained the roles of Ff1b as 
the central regulator of steroidogenesis, similar to that already described for 
mammalian SF-1, indicating a conserved mode of regulation for steroidogenesis over 
450 million years of evolution. The co-expression of the other three zebrafish ff1 
isoforms within ff1b-expressing cells remains to be established and the resolution of 
this would then fully define the extent of transcriptional influence of Ff1b. 
The sequenced portion of zebrafish ff1b locus determined in this study 
matches scaffold_831 of zebrafish LG8 (Ensembl) and when sequences from these 
two sources of BAC genomic sequences were combined, about 60 kb of genomic 
sequences encompassing zebrafish ff1b could be clearly defined and established. The 
~100 kb genomic sequences contained within the BAC construct are sufficient to 
direct expression of EGFP to all the relevant tissues that are known to express ff1b as 
previously determined by ISH. However, additional EGFP expression were seen in 
the otic vesicle, muscle pioneer cells, common cardiac vein, and neuromasts, and it is 
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 reasonable to conclude that either the upstream 5’ DNA sequences were responsible 
or the actual ff1b genomic locus contains previously undetermined cis-elements. With 
the exception of the otic vesicle, as ff1b expression also disappeared when Intron IV is 
deleted, we have specifically determined that the same enhancer located within Intron 
IV is also functional in otic vesicle. Despite the presence of broader EGFP expression 
domain in the ff1bEx2EGFP embryos, the transgene has allowed us to study the fate 
of ff1b-expressing cells in the developing VMH and interrenal gland in a manner not 
previously possible. The availability of the ff1bEx2EGFP transgenic zebrafish line 
will thus allow the upstream regulators and coregulators of ff1b to be worked out 
rapidly, which is currently difficult to perform with the mouse SF-1 lineage-tracing 
model.  
Using Red/ET recombination strategy, we have devised a novel and rapid 
strategy to specifically delete intronic enhancers, which is particularly suited for genes 
with such arrangement of core enhancers. This strategy can also be widely applicable 
to the removal of large tract of DNA, as well as, to make small deletions. Thus, when 
combined with transient microinjection assay into zebrafish embryos, we have been 
able to rapidly narrow down the required core enhancer that is responsible for 
directing ff1b expression in the interrenal and otic vesicle. 
After comparison of the various FF1 genes, we conclude that ff1b is the 
ancestral ortholog of SF-1 lineage, and that in the other vertebrate classes, this 
ancestral ortholog is lost and that only the ff1d (SF-1) lineage persisted. Indeed, LRH-
1 is derived subsequently from the SF-1 ortholog. The interrenal enhancer identified 
in ff1b should in fact be the ancestral enhancer and that the interrenal enhancer found 
in ff1d/SF-1 lineage is likely to be acquired after the initial duplication, followed by 
205
 the loss of the ancestral intron. While this remains speculative, a through 
characterization of the ff1d isoform should be able to confirm this interpretation.    
 
6.8. Future perspectives 
 
The promoter analysis of cyp11a1 has established firmly the direct 
involvement of Ff1b in the transcriptional regulation of steroidogenic enzymes. With 
the isolation and extensive characterization of the cyp11a1, an endogenous target gene 
promoter that is strictly regulated by Ff1b is now available. It is, therefore, amenable 
to a whole series of investigations with regards to the transactivation activity of 
zebrafish Ff1b. For instance, the involvement of the two FREs in cAMP 
responsiveness of the cyp11a1 promoter can be further defined by transient 
transfections with hormonal treatments (e.g. with forskolin). Most importantly, the 
cyp11a1 promoter can be used as a platform to delineate the transcriptional activity of 
Ff1b with regards to the influence of coregulators using transient transfections in cell 
lines or transactivation assay by microinjections into zebrafish embryos.  
An important reagent presented in this study is the successful generation of an 
Ff1b antibody that works efficiently in ChIP assay. It is now possible to study the in 
vivo occupancy of Ff1b with potential target gene promoters. More importantly, it will 
enable us to perform genome-wide profiling of Ff1b binding sites using strategies 
such as ChIP-on-chip (Hudson and Snyder, 2006; Tavera-Mendoza et al., 2006), 
SABE (Chen, 2006), and PET-ChIP (Hudson and Snyder, 2006). By combining the 
data from the genome-wide analysis with computational analysis to identify Ff1 target 
genes (Bowler et al., 2006), we will be able to identify novel target genes of Ff1b that 
are involved in the morphogenesis and ontogenic development of interrenal gland and 
VMH. With the ff1bEx2EGFP line, this effort would even be more meaningful as 
EGFP-positive interrenal or VMH cells can be readily isolated from early stages of 
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 embryonic development by fluorescence activated cell sorting (FACS). The 
fluorescent ff1b-expressing cells isolated by this method can also be used for other 
molecular analyses such as real-time RT-PCR, transcriptome profiling by microarray 
and SAGE, etc. This line of experiment is currently on-going in our laboratory and 
they are anticipated to greatly aid in identifying novel upstream and downstream 
factors of Ff1b that cooperatively play a role in the development of VMH and 
interrenal gland. 
Although we have not determined whether the disparities in EGFP transgene 
and endogenous expression revealed by ISH are due to the absence of regulatory 
elements or the presence of interfering regulatory elements in the transgenic construct, 
or even the integration site of the transgene, further studies could be carried out to 
determine which of these hypotheses are correct. Several experimental approaches 
could be undertaken to investigate the genomic sequences that are required for ff1b 
expression in these endocrine tissues. For instance, multiple transgenic constructs 
encompassing truncated or additional genomic sequences could be used to explore 
whether the genomic sequences 5’ or 3’ to ff1b locus are needed to activate or 
suppress the expression of the EGFP reporter. In addition, genomic sequences that 
have been shown to potentially contain regulatory cis-elements should be sub-cloned 
into a reporter vector and assessed for their ability to drive tissue-specific expression. 
By tracing the EGFP expression in ff1bEx2EGFP transgenic embryos, we can 
now perform real-time observation of morphogenetic movement of ff1b-expressing 
cells in the developing embryos without the need for subsequent ISH and 
immunohistochemistry assays, which will often alter the integrity of the embryos. 
This has opened up a whole new avenue of live imaging experiments utilizing the 
developing zebrafish embryos. For instance, one interesting experiment would be the 
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 study of migration of ff1b-expressing neurons in the developing VMH and to dissect 
the target sites of their neuronal projections. Moreover, the easy manipulations of 
zebrafish embryos has made the transgenic line an excellent in vivo system to screen 
for molecules or genetic mutations that affect the development of VMH, interrenal 
gland, or any other EGFP-expressing tissues.  
Functional studies can also be performed by crossing the ff1bEx2EGFP 
transgenic line with other mutant or transgenic lines. For example, the interrenal gland 
morphogenesis has been demonstrated to be dependent on midline signaling (Chai 
and Chan, 2000; Hsu et al., 2003). A simple cross between the ff1bEx2EGFP line and 
mutant zebrafish lines such as oep and flh (or any other signaling mutant line that 
could potentially affect interrenal development) would provide a convenient platform 
to study the molecular mechanisms underlying their connections. Besides mutant lines, 
crossing with other transgenic lines that express different fluorescent markers driven 
by genes related to ff1b would also provide useful functional data. For instance, we 
are currently generating a red fluorescent transgenic line for the tracing of prox1, 
which has been proposed as a transcriptional repressor of ff1b (Liu et al., 2003). A 
double fluorescent transgenic line of ff1b and prox1 would provide useful insights in 
to the mechanism by which the two transcription factors interact with each other to 
modulate important developmental events such as interrenal morphogenesis.  
Last but not least, the putative interrenal-specific core enhancer that has been 
localized to Intron IV of ff1b needs to be further delineated. As Intron IV spans 3754 
bp and core enhancer elements usually encompass only a few hundred bp of 
nucleotide sequences, additional fine deletion and truncation analyses need to be 
carried out. Not only should we aimed to identify the core enhancer element 
responsible for interrenal-specific expression, we should be able to simultaneously 
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 establish the upstream trans-acting factors that interact with the cis-elements located 
in the enhancer. More importantly, this core enhancer would eventually enable us to 
generate another stable transgenic line that expresses fluorescent marker specifically 
in the interrenal gland only. Besides Intron IV, other genomic regions that potentially 
contain regulatory elements responsible for directing ff1b expression to other specific 
tissues should also be further analyzed by deletions spanning shorter regions and sub-
cloning of smaller and overlapping fragments into a reporter vector. These include the 
10 kb 5’ upstream sequences that potentially contain an interrenal repressor as well as 
Intron V and Intron VI as they potentially contain VMH-specific enhancer. 
With the findings delivered from this study and the above experimental plan in 
place, we will be able to gain useful insights into the mechanisms by which Ff1b 
regulates the development of interrenal gland and VMH, particularly in terms of its 
upstream regulators and its downstream gene targets. Importantly, the zebrafish 
transgenic model serves as an excellent developmental platform to deliver new and 
reliable findings that could be hardly achieved in the mouse model. Furthermore, the 
ontogeny of the endocrine development and functions have been shown to be highly 
conserved between zebrafish and mammals, indicating that key aspects of endocrine 
function could be readily and reliably addressed using a more amenable vertebrate 
model species like the zebrafish. Together, with the active research of SF-1 and LRH-
1 in the mammalian system, and the experimental findings that have been generated 
for zebrafish Ff1s, we now have a good chance to unravel the complex molecular 
networks that use this sub-family of NR as an important transcriptional modulators of 
diverse biological processes, particularly in the maintenance of endocrine 
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